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INTRODUCTION
Osteoarthritis is a degenerative joint disease with a high and increasing prevalence. In 2011, 
the prevalence of osteoarthritis in the Netherlands was 53.8 per 1,000 men and 88.5 per 
1,000 women and it is predicted that this number will increase by approximately 140% 
between 2011 and 2030.1 The increase of osteoarthritis can be related to general demographic 
changes, increase in the incidence of overweight and obesity, and more active lifestyles of 
elderly people. Osteoarthritis can have a major effect on quality of life and social-economic 
functioning in relatively young and active patients in particular. Patients may have difficulties 
in their work and become dependent on their environment and healthcare facilities. The 
costs of osteoarthritis are estimated to be around €1.1 billion each year for a small country, 
such as the Netherlands.1 With increasing prevalence of osteoarthritis globally, this can be 
considered as a serious burden to society.
While the most commonly affected joint is the knee, the second most common form of 
osteoarthritis is osteoarthritis of the hip.1 Initial treatment regimens for osteoarthritis of the 
hip are generally conservative, but when this fails, a total hip arthroplasty is indicated in 
patients with advanced osteoarthritis. Total hip arthroplasty is a frequently performed and 
cost-effective procedure with a successful clinical outcome that improves quality of life 
and social-economic functioning of many patients.5,6 In 2014, 28,026 primary total hip 
arthroplasties were performed in the Netherlands, and the trend projection suggests an 
increase of 140% towards 2030.7-9
The success of total hip arthroplasties in older patients caused an extension of its indication 
to young- and more active patients due to good long-term results compared to hip-preserving 
treatments.11 However, young and active patients that present for total hip arthroplasties hope 
to restore their quality of life, which apparently differs from those of elderly, and typically 
includes physically demanding activities. Consequently, the long-term results in young and 
more active patients are less successful with a lower overall survival.12,13 The history of hip 
arthroplasty is still dynamic and innovations are directed at reduction of failure, especially 
in younger patients with a higher activity profile. 
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Figure 1. Smith-Peterson Vitallium® mould (cobalt–chromium–molybdenum alloy) 
arthroplasty interposed between refashioned surfaces of acetabulum and femoral 
head.3
The history of total hip arthroplasty dates back to the first half of the 20th Century. At that 
time, the first efforts were made to treat patients with osteoarthritis through interposition of 
soft tissues, such as the fascia lata, skin and mucosa of a pig bladder, all with poor results.14 
The search for an inert material that could be successfully interpositioned started in 1923. 
Since then, Smith-Peterson experimented with glass mould and other substances, as an 
interposition in the hip. However, these materials could not sustain the forces that they were 
exposed to, and broke within a matter of months after implantation. Fifteen years passed 
until Smith-Peterson introduced a new arthroplasty that used a vitallium mould to cover the 
femoral head (figure 1). While the results were still poor, they were recorded to be more 
satisfactory than an arthrodesis of the hip.15 
In the meantime, Wiles developed the first prosthetic total hip replacement. In 1938, 
he tried inserting a pre-formed acetabulum and femoral head, both made of stainless steel 
(figure 2A).2 This prosthesis can be regarded as a prototype for the modern type of total 
hip arthroplasty, and the first metal-on-metal implant. Thereafter several metal-on-metal 
implants, such as the McKee and Watson Farrar Prosthesis, were developed, but all failed 
due to poor material and failure of fixation (figure 2B).4 
Innovations in total hip arthroplasty continued, and a major advance was made in the 
1960s, when Sir John Charnley introduced a low-friction torque total hip arthroplasty (figure 
2C). He used a 22mm metal head and a polyethylene socket and fixed the components to 
the bone with a filling methacrylate bone-cement.10 The survival of this prosthesis was very 
good and has been reported to be approximately 81-85% at 25-years follow-up. Even for 
modern designs, this survival rate is high and can be considered as the golden standard.12,16 
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A B C
Figure 2. 
(A) Wiles metal-on-metal total hip arthroplasty.2 
(B) McKee-Farrar metal-on-metal total hip arthroplasty.4 
(C) Charnleys’ low friction total hip arthroplasty.10
One of the main causes of failure of the Charnleys’ total hip arthroplasty was loosening, as 
a result of mechanical failure of fixation.14 Although new materials and improved cementing 
techniques reduced the rate of loosening, loss of fixation was still seen, especially in young 
and active patients.17,18 At first, it was associated with an inflammatory response to particles 
from the bone cement, referred to as ‘cement disease’.19 New implants that used cementless 
fixation were developed. Nevertheless, lytic lesions were still reported in stable uncemented 
implants.20 Fragments of polyethylene wear were now recognised as the causative factor of 
premature loosening by periprosthetic bone-loss secondary to particle-induced osteolysis.21 
Surfaces of articulating surfaces are prone to wear, and subsequently release small particles. 
These particles are phagocytosed and initiate an inflammatory response. The process of 
particle-induced osteolysis is complex and involves the interaction of various cell types, 
cytokines, chemokines and growth factors that stimulate osteoclast differentiation and 
activation, which results in osteolysis.22 
The biologic effects of wear debris are an important factor that limits the longevity of 
total joint replacements. Nowadays, a total hip arthroplasty with a ceramic head and a 
1Introduction
13
polyethylene acetabular component is common practice in the Netherlands (54%), with 
metal-on-polyethylene arthroplasty (30%) as the second most frequently used combination.7 
Both combinations use a polyethylene acetabular component that has limited wear properties. 
This is especially important for young and active patients, in which higher stresses on the 
bearing may enhance wear and induce premature aseptical loosening. The introduction of 
highly cross-linked polyethylene and the addition of Vitamin E might have overcome the 
problem of wear of the conventional type of polyethylene, but this is still uncertain since 
long term studies are limited.23,24 The search for new, durable materials that can minimise 
wear and improve the longevity continues, as does the development of alternative surface 
bearings, including metal-on-metal bearings and more recently introduced, ceramic-on-
ceramic bearings.
The use of metal-on-metal bearings is not new and dates back to the beginning of the 
development of total hip arthroplasties.2,4 Above all, the name McKee is associated with the 
first generation metal-on-metal implants, but many others, including K.M. Sivash, P. Ring, 
J. Scales, A. Hugler, M. Müller and M. Postel, were involved.25 The first generation had a 
high rate of component loosening, which in retrospect, cannot be contributed to the wear 
of the metal-on-metal articulation, but rather unfavourable biomechanics and the role of 
the implantation technique.26 However, the promising results of the Charnley hip prosthesis 
diminished interest in metal-on-metal bearings during the 1960s and 1970s. Renewed 
interest arose in the 1980s, when premature loosening was related to polyethylene wear-
induced osteolysis. It was recognised that debris-induced osteolysis featured less frequently 
in the first metal-on-metal hips, due to a lower wear-rate compared to polyethylene. This 
initiated the introduction of the second- and third generation metal-on-metal implants that 
used alloys with a higher carbon content (0.20 - 0.30%), with a hardness that would enable 
precise manufacturing. In addition, joint movements were optimised by smoother bearing 
surfaces.25 Implant retrieval studies revealed superior wear, characteristic in the region of five 
microns a year, which is a decrease of about a 60-fold compared to polyethylene.27,28 This 
would, in fact, reduce particle-induced osteolysis, and prolong implant survival. Another 
advantage of metal is its self-polishing characteristic, and hardness, although not brittleness. 
This has created the opportunity to design prostheses with thin acetabular components and 
large femoral heads. 
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Creating a thin acetabular socket also enables the creation of a femoral bone-reserving 
option; a resurfacing hip arthroplasty. McMinn was the first to combine the experience 
with metal-on-metal implants with the hip resurfacing concept, and introduced it in the 
1990s.29 The concept of a resurfacing hip was not new. In the 1970s, the first generation of 
a resurfacing concept, the Total Hip Articular Replacement using Internal Eccentric Shells 
(THARIES) hip replacement was introduced.30 The THARIES consisted of a thin polyethylene 
acetabular component and a metal femoral cap. Failures of this hip replacement were 
primarily related to the very thin acetabular component.31 The implant was abandoned by 
the mid-1980s due to its high failure rate in comparison with total hip arthroplasties.
Figure 3. Resurfacing hip arthroplasty. Conserve plus® (Wright Medical Technology, 
Arlington, Tennessee, USA)
Although the conventional design total hip arthroplasty was favoured in clinical outcome, 
the aim for a resurfacing implant persisted. The bone- and natural anatomy preserving 
characteristics of resurfacing remains an appealing treatment option, especially for young 
and active patients. In the 1990s, the resurfacing hip arthroplasty was reintroduced and 
marketed as the latest advancement in hip arthroplasty. The theoretical advantages and 
1Introduction
15
clinical results addressed in the initial clinical studies were appealing.32-34 In addition, 
in vitro studies revealed superior wear characteristics, with up to 100-fold reduction of 
wear debris compared to metal-on-polyethylene.35 Moreover, the resurfacing technique 
preserves the bone of the proximal femur and leaves the option to perform a ‘primary’ total 
hip arthroplasty at times that the resurfacing hip arthroplasty fails. The wear characteristics 
and additional revision options are not the only factors that make the resurfacing implant 
attractive for young patients. Theoretically, the use of a larger femoral head diameter 
compared to a conventional design of hip arthroplasty also has a substantial effect on the 
stability of the hip.35,36 Pushing the hip further than the maximum arc, in which the neck 
impinges on the socket, will lift the head out of the socket. The distance before the head can 
escape the rim of the socket is called the ‘jump distance’. A larger head increases the jump 
distance and positively affects the stability of the hip, which subsequently lowers dislocation 
rates.36-38 
Based on the proposed theoretical advantages, the resurfacing hip arthroplasty was 
promoted as an attractive alternative for the conventional total hip arthroplasty. The name 
‘sports hip’, as it was called in the Netherlands, sounded appealing to patients compared 
to the conventional type of implant that was generally related to the older, inactive patient. 
In particular, young patients with hip osteoarthritis were intent on having a resurfacing 
hip implant. Globally, the increased demand led to an accelerated introduction of various 
resurfacing hip implants on the market and a rise in their use.39 However, long-term clinical 
results of these implants were lacking. The potential disadvantages, such as the more 
technical demanding procedure, the subsequent potential risk of femoral neck fractures, the 
occurrence of excessive metal ion release, and adverse reactions to metal debris (ARMD), 
were less widely specified and, in hindsight, may have been underestimated.40-44
Aim of this thesis
In a time of rapidly emerging market of resurfacing hip arthroplasties, a randomised 
clinical trial was initiated, in which the new concept of resurfacing hip arthroplasty was 
balanced against the ‘golden standard’ of an established, small-diameter head conventional 
type of total hip arthroplasty. This thesis focuses on the results of a randomised clinical 
trial that comparedring a metal-on-metal resurfacing hip arthroplasty to a metal-on-metal 
conventional type of total hip arthroplasty. The randomised clinical trial formed the base of 
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several related studies undertaken to give a better understanding of the adverse reactions 
that can be encountered related to metal-on-metal bearings and the value and interpretation 
of metal ion analysis and cross-sectional imaging. For this thesis, seven objectives were 
formulated, which are further outlined in the next paragraphs.
The objectives of this thesis were to: 
1. Determine the effect of preference bias for a specific implant on satisfaction and 
short-term clinical outcomes.
2. Obtain an objective comparison between the clinical results of a metal-on-metal 
resurfacing hip arthroplasty and a small-diameter head metal-on-metal total hip 
arthroplasty at mid-term follow-up.
3. Determine the difference in metal ion release between a resurfacing hip arthroplasty 
and a small-diameter head total hip arthroplasty.
4. Determine if metal ion concentrations in whole blood and serum can be used 
interchangeably, and if a formula can give a reliable conversion from serum to 
whole blood.
5. Define if concerns on metal ion release after metal-on-metal hip arthroplasty can 
be extrapolated to a metal-on-metal discus arthroplasty in the lumbar spine. 
6. Determine if periprosthetic lesions, as seen on Magnetic Resonance Imaging (MRI) 
scans, and classified as pseudotumours, are exclusively seen around metal-on-
metal hip implants.
7. Present a case report of a patient with a destructive pseudotumour in the absence 
of a metal-on-metal bearing.
Outline of this thesis 
Chapter 2: Determination of the effect of preference bias for a specific implant 
on satisfaction and short-term clinical outcomes.
A randomised trial is an ideal study design to obtain an objective comparison between 
a new experimental device, such as comparing a resurfacing hip implant, with a golden 
standard. However, at the time of enrolment of the randomised clinical trial that compared 
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the resurfacing hip (RHA) implant to a small-diameter head metal-on-metal total hip 
arthroplasty (MoM THA), the RHA had been considerably promoted. Patients were 
influenced by the promising stories and preferred to receive a resurfacing implant rather 
than the golden standard. The high preference for the resurfacing hip implant made it hard 
to recruit patients for the randomised trial. Since the RHA was considered an experimental 
device, patients were obliged to participate in intensive follow-up with clinical outcome 
scores, radiographs and metal ion level. As a compromise, a cohort was created that 
included patients, who insisted upon having a resurfacing implant and, as a consequence 
were not able to participate in the randomised comparison trial. The patients included 
in this cohort were considered to be biased due to their profound preference. It can be 
supposed that patients with a profound preference are more satisfied postoperative and 
score better on the subjective clinical scores. For patients included within the randomized 
trial, this can be questioned. The availability of two groups of patients - with and without a 
profound preference - enabled a study that compared the satisfaction and clinical results of 
patients, who insisted on getting a RHA and those who were simply allocated to a RHA by 
randomisation. Chapter 2 presents an analysis of whether a profound preference for a RHA 
is a confounding factor or not and if it affects the subjective clinical results and patients’ 
satisfaction in the short-term. 
Chapter 3: Obtaining an objective comparison between the clinical results of a metal-
on-metal resurfacing hip arthroplasty and a small-diameter head metal-on-metal total hip 
arthroplasty at mid-term follow-up.
And
Determination of the difference in metal ion release between a resurfacing hip arthroplasty 
and a small-diameter head total hip arthroplasty.
The RHA was promoted as an implant with a better stability and function that would enable 
patients to function on a higher activity level. Expectations of patients and their surgeons 
were high at the time of RHA introduction. However, long-term clinical results that balanced 
the RHA against a golden standard were lacking. A prospective randomised clinical trial was 
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initiated to assess the clinical scores, complication rate and survival of the RHA, compared to 
a MoM THA. Patients were followed with clinical scores, radiographs and metal ion levels in 
blood were determined at regular time intervals. In Chapter 3, the results of the randomised 
clinical trial are given at a three to five-year follow-up, including the encountered adverse 
reactions associated with the MoM bearings implants. In addition, metal ion levels in either 
the RHA or MoM THA were analysed, and an evolution in time is presented.
Chapter 4: Determining if metal ion concentrations in whole blood and serum can be used 
interchangeably, and if a formula can give a reliable conversion from serum to whole blood.
 
Metal ion concentrations in blood rise after patients obtain a metal-on-metal bearing 
implants, as presented in Chapter 3. Cobalt and chromium ions can be detected in various 
matrices, such as whole blood and serum and can be used for the evaluation of the metal 
ion concentrations. The knowledge of their interpretation and a possible superiority 
of measurements in serum over whole blood are, however, under debate. There is no 
consensus in literature as to whether serum levels are superior to whole blood levels or 
vice versa. Furthermore, cut-off points are not specified, and since metal ion levels in serum 
and whole blood are different, the outcome and interpretation of the cut off points are 
obscured. Patients, who enrolled in the randomised clinical trial, were evaluated for metal 
ion concentrations at regular intervals. The results of the prospective follow-up of cobalt and 
chromium ion levels, in both whole blood and serum, are presented in Chapters 3 and 4. 
These data could additionally be used to analyse if measurements in serum and whole blood 
can be used interchangeably (Chapter 4). A conversion formula was generated to calculate 
whole blood metal ion levels from serum levels and practical guidelines were developed for 
clinical use in the interpretation of metal ion levels.
Chapter 5: Defining if concerns on metal ion release after metal-on-metal hip arthroplasty 
can be extrapolated to a metal-on-metal discus arthroplasty in the lumbar spine. 
It became clear that metal ion levels in blood rise after implantation of a metal-on-metal hip 
arthroplasty. Due to this rise of metal ions levels in blood, concerns arose on the systemic and 
local consequences. Many consequences were and are still uncertain, but the occurrence 
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of ‘adverse reactions to metal ion debris’ (ARMD) was one that is related to excessive metal 
ion release. The term ARMD was used to cover a sequel of adverse events, such as oedema, 
osteolysis and fluid-filled or solid lesions collections surrounding the hip implants after 
implantation of a metal-on-metal device. The hazardous side effects gave rise to several 
guidelines for a close follow-up of metal-on-metal hip arthroplasties to screen for ARMD. 
By comparison, very little attention has been paid to this phenomenon in other orthopaedic 
metal-on-metal implants in other joints. For instance, in spinal surgery, a metal-on-metal 
total disc arthroplasty is used. The question has arisen as to if elevated metal ion levels can 
also be detected in patients with these metal-on-metal implants. Chapter 5 presents the 
results of a study, in which the cobalt and chromium ion concentrations in patients with a 
total disc arthroplasty were evaluated and compared to metal ion levels of patients with a 
metal-on-metal hip implant.
Chapter 6: Determining if periprosthetic lesions, as seen on MRI, and classified as 
pseudotumours are exclusively seen around metal-on-metal hip implants.
The various guidelines that were developed for follow-up of patients with a metal-on-
metal implant were recommended to screen patients using cross-sectional imaging, such 
as ultrasound, Computed Tomography (CT) and MRI. As a result, the presence of soft-tissue 
and fluid collections, muscle atrophy and oedema have been reported in relation to joint 
arthroplasties in both symptomatic and asymptomatic patients. Most depicted lesions were 
classified as pseudotumours, a form of ARMD that is used to describe solid and fluid-filled 
lesions surrounding hip arthroplasties. These pseudotumours have been generally defined as 
a serious adverse reaction, although the clinical consequence of many of these findings is 
unknown. Since pseudotumours are also seen in patients without metal-on-metal bearings, 
it can be hypothesised that identical pseudotumour-like lesions might be present in patients 
with bearings other than metal-on-metal, and that these lesions are subsequently classified 
as pseudotumours by current classification systems. Chapter 6 presents the prevalence of 
periprosthetic lesions diagnosed by metal-artefact-reducing sequence-MRI in three groups 
of patients: 1) RHA, 2) MoM THA and 3) asymptomatic patients with a small-diameter 
ceramic-on-polyethylene (CoP) THA. The depicted periprosthetic lesions are graded by three 
pseudotumour classification systems given in literature. 
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Chapter 7: A case report of a patient with a destructive pseudotumour in the absence of a 
metal-on-metal bearing
The mechanism and source of metal ion release is another point of debate. In general, 
metal ions and particles are generated by wear from the articulating surface, and corrosion. 
However, ARMD has also been reported in retrieval studies that included patients without 
excessive wear of the articulating surfaces. The role of other sources, such as the taper-head 
junction is obscure. In contrast to RHA, a THA uses a taper-head junction. This junction 
may potentially be a source of metal corrosion product and may trigger ARMD. Chapter 
7 presents a case report of a patient with a destructive pseudotumour without a metal-on-
metal articulating surface. This case is used to outline the potential sources and risk factors 
that may have initiated ARMD.
Finally, in Chapter 8, the preceding chapters are summarised and discussed.
1Introduction
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ABSTRACT
Background and purpose: Hip resurfacing arthroplasty (RHA) is done in patients 
who often have a high preference for the method. This preference can influence 
the clinical outcome and satisfaction. We evaluated the potential influence of this 
preference bias.
Patients and methods: From an ongoing randomized trial comparing RHA with 
total hip arthroplasty, 28 consecutive patients (28 hips) who had been allocated to 
an RHA were characterized as the “randomized” group. Twentytwo other patients 
(24 hips) who had refused participation and had especially requested an RHA were 
characterized as the “preference” group. Harris hip score (HHS), Oxford hip score 
(OHS), University of California at Los Angeles activity scale (UCLA), Short Form 12 
(SF-12), and visual analog scale satisfaction score (VAS) were assessed in both groups.
Results: Both groups had a high implant satisfaction score (97/100 for the 
“preference” group and 93/100 for the “randomized” group) at 12 months. The HHS, 
OHS, and UCLA were similar at baseline and also revealed a similar improvement up 
to 12 months (p < 0.001). Regarding the SF-12, the “preference” group scored lower 
on the mental subscale preoperatively (p = 0.03), and there was a greater increase 
after 12 months (p = 0.03).
Interpretation: We could not show that there was any influence of preference on 
satisfaction with the implant and early clinical outcome in patients who underwent 
RHA. The difference in mental subscale scores between groups may still indicate a 
difference in psychological profile.
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INTRODUCTION
The outcome of any surgical treatment is influenced by several factors. Apart from the surgical 
intervention itself, co-morbidities and postoperative rehabilitation—and also factors such 
as patients’ perception, confidence, and expectations—contribute to the final result and 
patient satisfaction. Nowadays, most patients have access to the internet and other sources 
of information, and are well-informed. Their conceptions will lead beliefs and expectations, 
which will in turn lead to preferences. Preference for a specific treatment can influence the 
outcome and can introduce bias into assessments of satisfaction and acceptability.1-6 This 
might be a confounding factor in a trial, and may affect the validity of the results. To obtain 
hard evidence of any possible preference effects is problematic, as it is difficult to reliably 
distinguish between simple therapeutic effects and preference effects mediated through 
psychological pathways in experiments.7
The dilemma of a possible influence of preference is frequently encountered in studies in 
orthopedic surgery. For example, the interest in resurfacing hip arthroplasty (RHA) has grown 
in the past 15 years and has received much international attention.8-10 The results reported 
regarding the short-term and long-term follow-up of RHA appear to correspond with the 
results of conventional total hip arthroplasty (THA) and the satisfaction rates reported have 
been 90–100%.11-16 Hip resurfacing surgeons generally deal with patients with a profound 
preference for this particular implant. We have not found any studies that have incorporated 
the possible influence of preference of the patient for an RHA into their results, and it can 
be speculated whether these results are influenced by this preference and perception on the 
part of the patients.
In an ongoing randomized trial comparing RHA with conventional THA, we 
encountered—as expected—some difficulty in recruiting patients for inclusion, since several 
patients had a specific demand for RHA. In this way, RHAs were performed in two groups of 
patients: (1) an unbiased “randomized” group without any preferences, willing to participate 
in the ongoing trial, and simply allocated to RHA; and (2) a “preference” group of “potentially 
biased” patients with a specific demand for RHA and who declined participation in the trial. 
We could therefore evaluate the potential role of preference bias on implant satisfaction 
and early clinical outcome. We hypothesized that patients in the “preference” group would 
be more satisfied than the patients in the “randomized” group. On the other hand, patients 
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with a high degree of preference could have such high expectations of the treatment that 
they might be difficult to fulfill, which would lead to lower satisfaction compared to patients 
without any preference.
PATIENTS AND METHODS
From April 2007 through March 2010, patients under 65 years with primary arthritis of the 
hip were evaluated for eligibility to enter the randomized controlled trial (RCT) comparing 
RHA with THA. After having given informed consent, patients with a strong preference for 
RHA (and who were therefore unwilling to be randomized) entered the prospective cohort 
study—the “preference” group. Patients with no preference were enrolled in the RCT to 
receive either an RHA or a THA. The current study included all patients in the “preference” 
group and all patients in the RCT who were allocated to RHA, with a minimum follow-up 
of 6 months.
The criteria for inclusion in both the RCT and the cohort were identical: patients 
between 35 and 65 years old, eligible for primary hip replacement because of osteoarthritis, 
congenital hip dysplasia, or posttraumatic arthritis. Patients were excluded in case of 
(previous) infection of the hip, hip fracture, avascular necrosis with collapse, osteoporotic 
bone mineral density index levels of the involved hip (t-score < 2.5), renal failure, or hip 
revision of the primary index procedure. 
All patients received a Conserve Plus RHA (Wright Medical Technology, Arlington, TN). 
The operations were performed through a standard posterolateral approach by a senior hip 
surgeon with considerable experience in RHA implants.17 Both groups received identical 
antibiotic prophylaxis, periarticular ossification prophylaxis, and thrombosis prophylaxis 
during hospital admission, and six weeks afterwards. The patients had identical rehabilitation 
protocols with unrestricted weight bearing according to individual tolerance, starting on the 
first postoperative day.
Fifty patients were included in the study, with 28 implants (28 patients) in the 
“randomized” group and 24 implants (22 patients) in the “preference” group (Figure 1 and 
Table I). All patients in the “preference” group and 22 of the 28 patients in the “randomized” 
group completed the follow-up term of 12 months. The remaining six patients had a follow-
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up of 6 months. All patients completed a questionnaire that included the Short Form 12 
(SF-12) and Oxford hip score (OHS) preoperatively, at 6 months, and at 12 months. The 
Harris hip score (HHS) and the University of California at Los Angeles activity scale (UCLA) 
were assessed by an independent member of the research staff (AH) who collected and 
registered all the forms. Satisfaction with the implant was measured on a numeric scale 
(visual analog scale satisfaction score (VAS)) of 0–100 mm, where 100 mm corresponded to 
being completely satisfied. 
Approval for the randomized clinical trial and the cohort follow-up was obtained from 
the regional ethics committee of the Radboud University Nijmegen Medical Centre, with 
issue number LTC 419-071206 and date of approval 01/02/2007. All patients agreed to sign 
an informed consent document. The EudraCT number asigned to the randomized controlled 
trial was 2006-005610-12. 
 
Figure 1. Recruitment of patients to the study
58 no preference 
RCT
28 RHA
Excluded52 RHA included this study
82 hips
30 RHA
24 denial RCT 
preference cohort
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Table I. Demographics of patients
“Preference” 
group (n = 24) 
“Randomized” 
group (n = 28)
p-value
Age
median 52 58
interquartile range 48–56 52–62 0.01
Sex: Male 15 13 0.2
Diagnosis   
Osteoarthritis 24 26 
Hip dysplasia – 1
Avascular necrosis – 1 0.5
Statistics
Variables were checked for normal distribution with the Shapiro-Wilk test. A value of < 
0.05 was defined as the absence of a normal distribution. The mean and standard deviation 
(SD) were used for normally distributed variables and the median and interquartile range 
(IQR) for variables without normal distribution. Differences between the groups were 
determined by the Student’s t-test for variables with normal distribution, the Mann-Whitney 
test for variables without normal distribution, and the Pearson Chi-square test for categorical 
variables (sex and diagnosis). Variables that were not normally distributed were: age, blood 
loss, the preoperative OHS and UCLA scores, the VAS satisfaction score at 12 months, and 
the change in satisfaction score between 6 and 12 months. These p-values are marked with 
the superscript β. Significance was defined as p-values of < 0.05. SPSS software version 15.0 
was used for statistical analysis.
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RESULTS
The characteristics of the patients are given in Table I. Both groups were similar regarding 
sex and diagnosis, but the patients in the “preference” group were younger than in 
the “randomized” group. Mean operation time (“preference” group: 81 min (SD 15); 
“randomized” group: 76 min (SD 11); p = 0.2) and median blood loss (“preference” group: 
300 (288–313) mL; “randomized” group: 300 (200–300) mL; p = 0.4β) were similar in both 
groups. Similar implants sizes were used in both groups (p = 0.7). 
The preoperative HHS, OHS, and UCLA scores were similar in both groups (Figure 2). 
The SF-12 score, however, was higher (88 (SD 14)), in the “randomized” group than in the 
“preference” group (80 (SD 12)) (p = 0.03). This difference mainly originated from inter-
group differences in the mental subscale. A mean score of 47 (SD 13) on the mental subscale 
was found in the “preference” group, as opposed to 53 (SD 10) in the “randomized” group 
(p = 0.05).
The HHS, OHS, and UCLA scores all showed a postoperative improvement at 12 months 
compared to the preoperative baseline scores for both groups (p < 0.001) (Figure 2). These 
improvements were similar between the groups (p = 0.8, p = 0.7, and p = 0.4, respectively). 
For the SF-12, however, at 12 months a better recovery was achieved from preoperative 
levels in the “preference” group than in the “randomized” group (p = 0.03). 
Patient satisfaction (VAS) was assessed at 6 and 12 months for both groups. Both groups 
had a high satisfaction score, with a median of 97 for the “preference” group and 93 for the 
“randomized” group at the 12-month follow-up (p = 0.7β). Similar scores were obtained at 
the 6-month follow-up. 
Two complications occurred in the “preference” group. One patient had a perioperative 
collum fissure with a delayed, but uneventful, recovery—and with clinical and satisfaction 
scores that matched within the interquartile range. Another patient had complaints of 
possible anterior impingement of the RHA. This patient had clinical and satisfaction scores 
that dropped below the interquartile range. With exclusion of both patients, the median 
satisfaction score remained at 97 for the “preference” group and 93 for the “randomized” 
group (p = 0.6β). With this exclusion, there were minimal changes in clinical scores, but with 
no consequences for the differences between the “preference” group and the “randomized” 
group (p = 1.0, p = 0.9, p = 0.3, and p = 0.01 for HHS, OHS, UCLA, and SF-12, respectively). 
The other 50 RHAs all had an uneventful clinical course.
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Figure 2. Clinical scores (HHS, Oxford, SF-12 and UCLA) with 95%-confidence 
interval preoperatively, at 6 and 12 months.
* In the horizontal axis of the SF-12 score represents a significant difference at baseline preoperative scores 
(p<0.05).
2N
o clear influence of preference bias on satisfaction and early functional outcom
e in resurfacing hip arthroplasty
35
DISCUSSION
In this prospective comparative study, patient satisfaction and early clinical outcome in 
“biased” patients with a high preference for resurfacing hip arthroplasty (the “preference” 
group) did not differ statistically significantly from the results in unbiased patients who were 
simply allocated to an RHA after randomization in a separate randomized controlled trial 
(the “randomized” group). There was, however, a trend toward better satisfaction in the 
“preference” group. Only for the preoperative SF-12 values, and for the mental subscale in 
particular, was any statistically significant difference between groups encountered, in favor 
of the “randomized” group. 
In spite of the fact that the potential bias from treatment preferences is a well-recognized 
phenomenon in orthopedic practice, there have only been a few studies dealing with this 
clinical dilemma. Van der Windt et al. (2000), for example, demonstrated a success rate of 
85% in patients with shoulder pain who received their preferred therapy compared to a 64% 
success for those who underwent the same treatment against their preference.6 In another 
study, any direct influence of preference for a certain therapy on shoulder pain could not be 
confirmed; however, the authors revealed that in general patients with a preference before 
randomization tended to have a better overall outcome than those with no preference.4
Randomized controlled trials are usually regarded as the gold standard in comparing two 
therapeutic treatments, as they diminish possible confounding factors. To study the potential 
influence of preference bias on the outcome of one and the same surgical procedure, 
randomization is, however, not a feasible tool for obvious reasons. Our randomized 
controlled trial on THA and RHA confirmed for us the existence of patient preference for 
RHA; it was difficult to recruit patients for the trial. Many patients had a preference for RHA 
even after being informed about the absence of any evidence in the literature of a benefit 
of RHA over a conventional THA.14,18 The presence of a cohort of patients with a clear 
preference for RHA and a group of patients allocated to RHA after randomization enabled 
us to gain some insight into the possible role of preference bias.
Our study had some limitations, however. The number of patients in both groups was 
small, eventually resulting in a power of 59% to detect a clinical significant difference of 
10 on the VAS for patient satisfaction in a post hoc power analysis. A power of 80% was 
calculated to detect a difference of 13 on the VAS for patient satisfaction. Clearly, there was 
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a small difference in outcome between the groups and a larger number of patients may 
eventually have revealed a statistically significant difference in patient satisfaction between 
the groups. On the other hand, the power in our study was substantial enough for us to 
question whether such a difference would have been of clinical importance. 
Another limitation of our study may have been the short follow-up. However, evaluated 
the Birmingham hip arthroplasty in a five to eight year follow-up and demonstrated that the 
satisfaction rate did not change substantially after the first postoperative year.12 Lingard et al. 
also showed a ceiling effect after one year.13 In addition, it is debatable whether a potential 
difference in satisfaction after one year would be influenced by preference, because 
expectations would be most manifest in the short period after the operation. 
Two patients with a bilateral prosthesis were included. One must assume that the 
outcome of two prostheses in the one patient cannot be interpreted independently. The 
result of the first prosthesis can either positively or negatively influence the outcome of the 
second, and vice versa.19 Study outcome in general may be biased by this phenomenon; 
however, the number of bilateral prostheses in our study was low and exclusion of the two 
patients with bilateral prostheses did not have any consequences for our findings (data not 
shown).
Apart from the presence or absence of a profound preference for an RHA, both groups 
matched regarding most demographic features and preoperative functional scores. The size 
of the femoral component of the implant was similar in both groups. This is important, as 
component size is known to influence the outcome of RHA.20,21
The only differences between the groups were age and preoperative SF-12 score. The 
difference in age between the groups suggests that younger patients are less willing to 
participate in a randomized clinical trial. As for the SF-12, and for the mental subscale 
in particular, patients in the “preference” group had a lower preoperative score. There 
were no outliers that could explain this difference between the groups. One could argue 
whether there is reason to believe that patients with a high preference for a certain treatment 
generally have a different psychological profile than patients who are willing to participate 
in a randomized trial. This finding has been recognized before.3
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In conclusion, we could not demonstrate any influence of preference on implant 
satisfaction and early clinical outcome in patients with an RHA. A trend towards a relatively 
higher degree of satisfaction was nevertheless established for patients with a specific request 
for RHA. The significant difference in mental subscale scores encountered between groups 
may indicate a difference in psychological profile.
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ABSTRACT
We present an update of a randomized controlled trial on 71 patients (<65 years) 
who received either a resurfacing hip arthroplasty (RHA) (n = 38) or cementless 28-
mm metal-on-metal (MoM) total hip arthroplasty (THA) (n = 33). Metal ion levels and 
functional outcome scores were analyzed with a mean follow-up of 58 months (SD 
8.1). No clear shifts in relatively good outcome was encountered between RHA and 
THA. Metal ion levels appear to equalize between groups after 3 years. Median cobalt 
and chromium remained below 1.3 μg/L throughout follow-up in both groups. Six 
revisions were performed, of which three for pseudotumour formation (one THA, two 
RHA). In conclusion there were no clinical differences between the two groups and 
metal ion levels were lower than other series remained low, however, pseudotumour 
formation was not eliminated.
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INTRODUCTION
The resurfacing hip arthroplasty (RHA) has been marketed as the latest advancement in hip 
arthroplasty and was targeted at young active patients who needed a hip that would last a 
lifetime. Based on all (theoretical) advantages RHA and metal-on-metal (MoM) bearings 
were appealing concepts to both surgeon and patients.1-8 The potential disadvantages, 
however, like the more technical demanding procedure, the subsequent potential risk 
of femoral neck fractures, the occurrence of excessive metal ion release and the adverse 
reactions to metal debris (ARMD) were less widely specified and in hind view may have 
been underestimated.2,9-12 In the rapidly emerging market of RHA, we felt that there was 
a lack of literature where this new concept was balanced against the ‘gold standard’ of 
conventional total hip arthroplasty (THA). In a period with considerable promotion for the 
use of these MoM implants we undertook a randomized clinical trial to assess the proposed 
benefits of RHA compared to an established THA (with a small-diameter MoM bearing). On 
the short term, up to 2 years, we found that all functional outcome scores improved highly 
significant for both groups.13 RHA patients scored significantly higher on UCLA, OHS and 
VAS satisfaction at some intervals, however, it may be argued whether these encountered 
differences were clinically relevant. Chromium and cobalt blood levels were significantly 
higher for RHA during the running in phase of 1 year with a tendency towards decreasing 
levels up to 2 years follow-up. No pseudotumours were encountered in either group at the 
earlier short-term follow-up report. One RHA was revised for early aseptic loosening and in 
two THA‘s a cup insert was exchanged for recurrent dislocation.13
In this RCT we questioned whether the functional results of RHA would indeed be 
superior to a conventional metal bearing THA and whether a large diameter RHA bearing 
would induce more metal ion release than a relatively small 28-mm diameter similar bearing 
in a conventional THA. Since there is an ongoing international debate on the surplus value 
of RHA against conventional THA we felt it appropriate to provide an update of a previous 
report 13 with now 3 to 5 year follow-up of a randomized trial comparing RHA with a small 
diameter metal-on-metal THA.
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PATIENTS AND METHODS
Study Design and Randomization Procedure
In the original exploratory study13 patients with osteoarthritis of the hip were randomized to 
receive either a resurfacing total hip arthroplasty (RHA) or a conventional uncemented small 
diameter MoM total hip arthroplasty (THA). The study is designed to compare the functional 
results and metal ion blood levels of patients after RHA versus THA at (the now presented) 
short and medium follow-up, and eventually the long-term interval.
From June 2007 until January 2010 eighty-two patients were randomly assigned to receive 
one of two hip implants (RHA versus THA). A computer-generated variable block schedule 
was used for randomization. An independent statistician generated the randomization list and 
the resulting treatment allocations were stored in sealed opaque envelopes. Randomization 
occurred at the outpatient consultation by the orthopaedic surgeon at the time of planning 
a hip arthroplasty. Patient and the surgeon could not be blinded for the eventual type of 
implant; neither could, however, influence the randomization outcome. The criteria for 
inclusion were patients under 65 years, who needed a primary hip arthroplasty for hip 
arthritis. Patients were excluded if they had (previous) infection of the hip or other sites, hip 
fracture, avascular necrosis with collapse, osteoporotic bone mineral density, neoplasm, or 
renal failure. Inclusion and subsequent follow-up of patients are summarized in the consort 
statement (Figure 1). A per-protocol was used in this study, because revised patients could be 
followed for metal ions. Two patients were lost to follow-up because of lack of motivation, 
one in each group (RHA after 12 months, THA after 24 months). Two patients deceased in 
the THA group, of conditions not related to the implantation of the THA. Ten patients also 
had a metal-on-metal implant on the contralateral side and thus their metal ion blood levels 
were evaluated separately. The revision cases are described in detail in the results section. 
Approval from the regional ethics committee from the Radboud University Nijmegen 
Medical Centre was obtained, with issue number LTC 419–071206, Committee Human 
Research number (CCMO) 2007/015 and date of approval 01/02/2007. All patients agreed 
to sign an informed consent. This study was performed in compliance with the Helsinki 
declaration. The EudraCT trial register number consigned to this study was 2006-005610-12.
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Figure 1. Consort statement
Assessed for eligibility
n=107
Excluded (n=25)
n=15 Not meeting inclusion criteria
n=10 Refused to participate
Baseline Assessment & randomization
82 Patients
Allocated to RHA (n=42)
Received allocated intervention (n=38)
Did not receive allocated intervention (n=4)
n=2 Co-morbidity while on waiting list
n=2 Peroperative exclusion because of 
 posttraumatic anatomical deformities
Allocated to THA (n=40)
Received allocated intervention (n=33)
Did not receive allocated intervention (n=7)
n=3 Co-morbidity while on waiting list
n=4 Refused to participate after allocation 
 to THA, choose further treatment
 elsewhere
Follow-up (n=38)
Discontinued follow-up (n=4)
n=1 Lack of motivation (bilateral)  
 after 12 mo
n=3 Revision: 1 femoral necrosis after  
 24 mo, 2 pseudotumor after 36 mo
Follow-up (n=33)
Discontinued follow-up (n=5)
n=1 Lack of motivation after 24 mo
n=3 Revision: 1 pseudotumor after  
 36 mo, 2 recurrent luxation (only 1  
 discontinued follow-up after 12 mo)
n=2 Deceased (1 unilat, 1 bilat)  
 after 24 mo
Metal ion and functional scores analyzed
32 unilateral patients
6 bilateral patients
Metal ion and functional scores analyzed
29 unilateral patients
4 bilateral patients
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Surgical Technique
The surgical technique, after-treatment and rehabilitation protocol have been described 
inthe previous report on this study.13 In the RHA group a resurfacing prosthesis was 
implanted with both components made of a cast, heat-treated solution-annealed Co–Cr 
alloy (Conserve plus; Wright Medical Technology, Arlington, Tennessee, USA). In the THA 
group, an uncemented tapered stem and threaded titanium cup with a polyethylene insert 
with a metal liner were placed (Zweymuller Classic) together with a metal 28-mm head 
(Metasul) (Zimmer Orthopaedics, Warsaw, Indiana, USA).
Clinical Evaluation 
Questionnaires that included the SF-12, Oxford Hip Score (OHS) and VAS implant 
satisfaction were taken pre-operatively and at 6, 12, 24, 36 and 60 months. An independent 
(not blinded) research staff member (AH) assessed the Harris Hip Score (HHS) and the 
University of California at Los Angeles (UCLA) Activity Score. 
Cup inclination was measured on standardized postoperative anterior–posterior (AP) 
pelvic radiographs. 
Cobalt and Chromium Blood Levels
Whole blood samples were collected pre-operatively and at 3, 6, 12, 24, 36 and 60 months 
post-operatively and assessed on cobalt and chromium concentrations. Blood samples were 
collected in metal-free vacutainers, the first 5 mL blood was discarded to eliminate any 
form of metal contamination from the needle. Tubes were stored at 2–8 °C and sent to the 
laboratory of Toxicology of the University Hospital Ghent (Belgium) for analysis. The metal 
ion levels were determined using an inductively-coupled plasma mass spectrometer (ICP-
MS) on a Perkin Elmer Elan DRC-e, equipped with a standard cross-flow nebulizer and a 
Dynamic Reaction Cell (Perkin Elmer SCIEX, Canada). Since ten patients with a bilateral 
metal-on-metal implant had a double exposure to wear and thus tend to have higher metal 
ion blood levels, these data are presented separately from unilateral implants. Extracted data 
from the unilateral group were considered to represent the metal ion concentration curves 
after RHA versus THA most reliably. Following the recommendations of Daniel et al we only 
report on metal ion levels in whole blood.14
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Statistical Analysis
Metal ion data distributions were asymmetric and are expressed as a group median with 95% 
confidence interval, Friedman‘s ANOVA, was used for analysis. To determine the between-
time differences within the groups the non-parametric Wilcoxon signed-rank test was 
performed, to protect for a type-1 error a Bonferroni correction was applied. To determine 
differences between the two groups and between functional results the Mann–Whitney U 
test was used. Symmetrical data are represented by a mean and standard deviation (SD), 
the tests used for significance are expressed in the legend of Table I. In the boxplots the 
outliers are represented by a dot (•), extreme outliers (more than three times deviation of the 
interquartile range from the upper quartile) are characterized by an asterisk (*). Differences 
were considered statistically significant at P < 0.05. Lacking information about metal ion 
levels and functional results in a randomized setting after a discontinued intervention in some 
cases, the small number of patients and multiple endpoints make this anexploratory trial. 
The results should therefore be read as hypotheses. Because of the exploratory character of 
the study, formal adjustment for multiplicity between endpoints was not made.All statistical 
analyses were performed using SPSS software (Version 21.0, SPSS Inc. Chicago, IL).
Table I. Patient Characteristics of the Study Population.
RHA (n = 38) THA (n = 33) P-Value
Median age in years (IQR) 57.5 (50–61) 59.2 (51–61) 0.407a
Mean body mass index (SD) 26.1 (3.1) 28.0 (5.1) 0.069b
Gender (men/women) 21/17 21/12 0.629c
Uni- or bilateral MoM prosthesis 32/6 29/4 0.633c
Diagnosis (OA/AVN/CHD)d 35/1/2 31/0/2 0.785e
Charnley category (A/B) 24/14 23/10 0.649c
Mean operating time in min(SD) 77.3 (11.2) 55.6 (11.8) <0.001b
Median blood loss in mL (IQR) 300 (100–300) 250 (100–300) 0.993a
Cup inclination (range) 45 (30.2-61.6) 48 (31.0-62.3) 0.360b
a Mann–Whitney U test.
b Student‘s t-test.
c Fisher‘s exact probability test. 
d OA, osteoarthritis; AVN, avascular necrosis; CHD, congenital hip dysplasia.
e Kruskall–Wallis test.
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RESULTS
Patient characteristics are described in Table I. Mean follow-up was 58 months (SD 8.1). 
Mean RHA femoral head size was 48.7 mm (SD 3.5). All patients (excluding revised, LTFU 
and deceased patients) reached the 36 month follow-up point, and approximately 50% of 
the patient had their 5-year follow-up available; available number of patients at each time 
interval is indicated in Table II.
Table II. Clinical Scores and VAS Satisfaction.
HHS UCLA 
Activity
SF-12 OHS VAS 
Satisfaction
RHA
Preoperative (n = 38) 57 54–60 5a 4–7 88.2a 85–94 34 30–36
6 months (n = 38) 96a 93–98 7a 7–8 107.4 99–110 16a 14–18 89 82–98
12 months (n = 38) 98 96–100 8a 7–9 107.0 101–110 13 12–16 92a 88–96
24 months (n = 37) 98 96–100 7 7–8 107.5 103–112 13a 12–14 94a 88–98
36 months (n = 36) 98 98–100 7 7–8 108.8 100–112 13a 12–15 92 85–98
60 months (n = 14) 96 93–98 7 6–7 108.7 89–116 14 13–17 83 66–99
THA
Preoperative (n = 33) 53 44–59 4a 4–4 79.8a 74–83 37 34–38
6 months (n = 33) 93a 85–94 7a 5–7 100.6 85–110 18a 16–23 81.5 75–93
12 months (n = 33) 96 91–98 7a 6–7 106.0 80–110 15 14–17 86a 79–91
24 months (n = 33) 96 93–100 7 6–8 107.7 99–112 15a 14–18 88a 78–92
36 months (n = 30) 96 95–100 7 6–8 103.3 99–110 15a 13–17 87.5 80–94
60 months (n = 12) 98 72–100 6 4–10 100.0 85–116 14 12–16 94 79–100
All values are given as the median (95% CI).
a Significant difference between RHA and THA (P ≤ 0.05).
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Clinical Evaluation
The clinical scores are summarized in Table II and Figure 2. In spite of the fact that we 
performed a randomized trial the preoperative values of UCLA activity score and SF-12 
appeared to be significantly lower in the THA group (P = 0.042, r = −0.24 and P = 0.007, 
r = −0.32 respectively). The HHS, OHS, UCLA activity score and SF-12 all improved 
significantly after surgery for both groups (P < 0.001).This improvement in clinical scores 
remained stable throughout the available follow-up. At 6, 24 and 36 months a significantly 
better OHS for the RHA patients was found (P = 0.023, r = −0.27; P = 0.023, r = −0.27; P 
= 0.033, r = −0.26) as compared to THA patients. The HHS at 6 months was higher for the 
RHA patients (P = 0.021, r = −0.27).
The median UCLA activity score was significantly better for the RHA patients at 6 and 12 
months with medium effect size (P = 0.10, r = −0.30; P = 0.002, r = −0.37). RHA patients 
were significantly more satisfied after 12 months (P = 0.025, r = −0.27) and 24 months (P 
= 0.019, r = −0.28) compared to THA patients, this significant difference disappeared at 36 
months. Acetabular component positioning, calculated as the mean cup inclination, did 
not differ between both groups: RHA 45° (range; 30.2–61.6) and in the THA 48° (range; 
31.0–62.3)(P = 0.36). 
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Figure 2. 
(A) Boxplot HHS. 
(B) Boxplot UCLA activity score. 
(C) Boxplot SF-12. 
(D) Boxplot OHS.
A B
C D
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Cobalt and Chromium Blood Levels
The concentrations of chromium and cobalt in whole blood for RHA versus THA for each 
time interval are summarized in Table III and Figure 3. Baseline preoperative chromium 
and cobalt concentrations were, as expected, below the reference level of 1.0 μg/L for both 
groups with a unilateral implant (Mayo Medical Laboratories 2010). Cobalt and chromium 
blood levels increased significantly (P < 0.001) for both RHA and THA after surgery until 
6 months postoperatively, with stabilizing concentrations thereafter. Cobalt concentrations 
were significantly higher for RHA compared to THA at 3 (P < 0.001, r = −0.50), 6 (P = 0.006, 
r = −0.35), 24 (P = 0.009, r = −0.34) and 36 months (P = 0.019, r = −0.31).
At 12 and 60 months the difference was no longer significant (P = 0.148, P = 0.126), however 
since the median cobalt level did not really change this absence of significant difference 
may well be explained by the incomplete 5 year follow-up data. Chromium concentrations 
were also significantly higher for the RHA group, however this time at all postoperative time 
intervals until 60 months (3 months P < 0.001, r = −0.57; 6 months P < 0.001, r = −0.47; 
12 months P < 0.001, r = −0.54; 24 months P < 0.001, r = −0.52; 36 months P = 0.012, r = 
−0.33; 60 months P = 0.036, r = −0.46).
Cobalt and chromium levels were higher in the subgroup of bilateral MoM implants, yet, 
did not reveal significantly higher metal ion concentrations as compared to the unilateral 
group. However, it has to be noted that the bilateral subgroup is small (Table III). 
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A
B
Figure 3. 
(A) Errorplot of cobalt concentrations with median (95% CI) in μg/L for RHA (blue) 
and THA (green) for each time interval. 
(B) Errorplot of chromium concentrations with median (95% CI) in μg/L for RHA (blue) 
and THA (green) for each time interval.
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Complications and Revisions
In the conventional THA group three patients with a recurrent dislocation were encountered 
for which two patients had an early reintervention with cup insert and head exchange, 
which solved the problem. Follow-up was discontinued in one after 12 months and the 
other continued the follow-up because of a Metasul inlay. Metal ion levels 1 year after 
revision stayed below the median cobalt and chromium levels for this group, excluding 
profound bias on the results from the introduction of a potential new running-in phase in 
this patient. Another revision in the MoM THA group occurred at 36 months for unclassified 
pain, which appeared to come from a profound pseudotumour on MRI with the typical 
aspect of an adverse reaction to metal debris (ARMD) during revision surgery .15 Whole 
blood metal ion concentrations in this female patient were relatively low at 36 months 
(chromium 0.9 μg/L, cobalt 1.0 μg/L). As for the RHA group, three revisions were also 
encountered. One revision at 24 months, an early aseptic loosening from avascular necrosis 
of the femoral head mandated a conversion to an intramedullary stem with a large femoral 
head. The original acetabular component and thus the MoM bearing was maintained since 
the patient had been pain free for 2 years and cobalt whole blood levels were 2.3 μg/L 
prior to revision. Two other revisions in female patients occurred after 36 months because 
of pseudotumour formation on MRI and confirmed during surgery, one with relatively low 
metal ions at 36 months (chromium 2.4 μg/L, cobalt 1.8 μg/L) and the other with high metal 
ion concentrations (chromium 10.50 μg/L, cobalt 19.40 μg/L). Figure 4 shows the Kaplan 
Meier survival curve of both groups, there is no significant difference (log rank P = 0.912) 
between RHA (survival 89.5%) and THA (survival 90.9%) at a mean follow-up of 58 months. 
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Figure 4. Kaplan Meier with revisions for any reason.
DISCUSSION
The most important finding of this 3 to 5 year follow-up of a randomized controlled trial 
comparing RHA and conventional THA is that no major shifts in metal ion concentrations, 
good clinical outcome for both groups and revisions had occurred. The majority of patients 
in both groups remained well functioning and highly satisfied. The numbers of revisions are 
comparable between groups, where pseudotumour formation was the predominant cause 
for revision in the RHA group (n = 2) and recurrent dislocation in the THA group (n = 2). 
Unexpectedly, a profound pseudotumour (n = 1) as a result of ARMD was also encountered 
in the 28-mm MoM THA group at time of revision for unclassified pain. Median cobalt and 
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chromium levels increased after implantation of both type of MoM implants with somewhat 
higher levels for RHA. Overall median levels stabilized after the running in phase and 
remained well below 2 μg/L, which is commonly recognized to be the safe zone.16 These 
median cobalt and chromium levels are relatively low as compared to several other reports 
in the literature.17,18
The functional results tested by validated functional scales showed a highly significant 
improvement 5 years postoperatively for both RHA and THA, which corresponds with 
other recent mid-term follow-up studies.19-24 Some functional outcome scores revealed a 
significant difference in favor of the RHA group at certain time intervals. For example, VAS 
satisfaction at 12 and 24 months was in favor of the RHA group, however, this difference 
resolved at further follow up. The OHS scored significantly better in the RHA group at 6, 
24 and 36 months. The significant difference in UCLA activity score in favor of RHA, which 
was also preoperatively higher for RHA despite randomization, resolved at 24 months. 
In general, it seems that RHA patients perform slightly better than THA the first 2 years 
after surgery, but after 3 years no major differences in functional outcome can be found. In 
addition, for some encountered statistically different outcomes, like two points difference 
in OHS, one can argue whether the minimal clinically important difference is met. These 
findings correspond with earlier studies. Stulberg et al report from their large retrospective 
comparative study an initial advantage in HHS for RHA at 6 and 12 months, however after 
24 months the results were comparable.23 There is only one other RCT comparing RHA with 
a conventional THA.25 These authors also describe initial UCLA activity scores in favor of 
the RHA, no differences at the 3 to 6 year and again a significant difference at 8 years. In 
accordance to Vendittoli et al, we found a significant difference at the early term and a not 
significant difference in UCLA activity score at mid-term.21,24
Metal ion evaluation is increasingly common after metal-on-metal arthroplasties and 
some articles state it serves as an indicator of bearing performance and device safety.26 
However, others question the sensitivity and specificity and state that it is not sufficient 
as screening measure.27,28 Furthermore, thresholds of save zones of metal ion levels differ 
between studies and countries and vary between the 2.0 and the 7.0 μg/L, making it hard 
in decision making when to remove an implant.16,29,30 In our study both RHA and THA 
groups revealed a chronological curve of cobalt and chromium blood levels representing 
an increase during the running-in phase of 1 year and stabilizing (cobalt) or decreasing 
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(chromium) levels afterwards. Regardless the implant group median metal ion levels 
remained well below the safety cut-off level of 2.0 μg/L for cobalt and chromium given 
by the Dutch Orthopaedic Society and far below the limits given by the Medicines and 
Healthcare products Regulatory Agency (cobalt 119 nmol/L = 7.0 μg/L; chromium 134.5 
nmol/L = 7.0 μg/L).16,30 Within this safety zone below 2.0 μg/L, overall cobalt and chromium 
levels were significantly higher for the RHA group, however this difference tended to fade 
at 5-year follow-up. Especially for chromium a gradual decrease with longer follow-up in 
both groups was observed.
The number of patients in this study and certainly the number of revisions for a 
pseudotumour is too small to draw any conclusion on a possible correlation between 
metal ion levels and pseudotumour formation. It can be noted however, that in two out 
of three revisions for a pseudotumour (one THA and two RHA patients) metal ion levels 
were relatively low (<2.0 μg/L), which supports Malek et al 28 and Macnair et al27 in their 
conclusion that that metal ion levels cannot be counted on as screening measure.
At our 2-year follow-up we reported no revisions for pseudotumour formation, we 
feared a peak of revisions at 2.9 years for RHA as indicated by earlier reports in literature.13,31 
Fortunately we did not find a major shift in revision numbers so far. At 5-year follow-up six 
patients have had a re-operation, indicating that the mid-term revision percentage for any 
reason was 8% in both groups. As already described, at the 2-year follow-up study, two 
THA patients underwent a relatively simple insert exchange for recurrent dislocation and 
one RHA patient had a femoral component revision because of early aseptic loosening from 
avascular necrosis. Around the 3-year followup moment in three patients (one THA and two 
RHA patients) a symptomatic pseudotumour was encountered, which mandated revision 
to an alternative bearing. Interestingly one of these three pseudotumours was encountered 
in the conventional THA group, which indicated that this complication was not reserved 
for RHA only. These results are in accordance with the RCT of Vendittoli et al as they also 
found no significant differences in revision rates and functional results between RHA and 
a 28 mm MoM THA.21 The adverse reactions to metal debris (ARMD) after a 28-mm MoM 
bearing as was encountered in our study are not commonly described in literature and have 
a lower prevalence then after large diameter MoM bearings. However, recent literature, 
has also recognized a 0.5–1.8% revision rate because of ARMD after 28-mm MoM hip 
arthroplasties, up to 10 years of follow-up.32-34
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In spite of the strength of a true prospective randomized comparison of clinical outcome 
and metal ion levels between conventional THA and RHA, our study also had limitations. 
Since patients tended to have a profound preference for a RHA at the time of study start-
up patient inclusion for randomization proved to be extremely difficult and therefore 
the available number of patients limited.35 For this reason, we feel the results should be 
interpreted as an exploratory trial only. In addition, this profound preference might be a 
reason for the preoperative differences in SF-12 and UCLA activity score. On the other hand, 
a true randomized comparison between RHA and conventional THA is scarce and still 
valuable in the current debate about whether RHA should be abandoned or maintained. In 
addition, our results reflect rather successful results for RHA as compared to more disturbing 
reports in the recent literature.15,36 Design features may have played a role. Another limitation 
is the absence of cross sectional imaging on all patients. Current insights show that metal 
ion concentrations and functional outcome seem to underestimate the prevalence of (silent) 
pseudotumours.37-39 This may also be true for our study and therefore, MRI on all study 
patients is currently performed in a separate study protocol.
In conclusion, we feel that the absence of a clinically relevant benefit of RHA over 
conventional THA in this study versus the well-established concern from potential MoM 
bearing related adverse events does not support general use of RHA in relatively young 
patients. On the other hand mid-term results against THA are reassuring and for selected 
cases it remains a validated treatment option, in particular from its proven relatively stable 
concept. Patients should then be well informed preoperatively about the current concern for 
potential metal toxicity and be monitored accordingly, postoperatively.
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ABSTRACT
Metal ions generated from joint replacements are a cause for concern. There is no 
consensus on the best surrogate measure of metal ion exposure, and both serum 
and whole blood measurements are used in clinical practice. This study provides a 
guideline for interpretation of metal ion analysis in clinical practice. 
In a prospective trial comparing resurfacing hip arthroplasty (RHA) with a 
conventional metal-on-metal (MoM) total hip arthroplasty (THA) cobalt and 
chromium levels were determined for whole blood and serum in 343 paired samples 
at regular intervals up to 24 months postoperatively. 
Cobalt whole blood and serum levels increased significantly after both procedures. 
Cobalt concentrations were significantly higher for the RHA group compared to the 
THA group, at 3, 6 and 12 months, for whole blood and serum. At 24 months cobalt 
levels decreased and differences between RHA and THA were no longer significant. 
In contrast, chromium whole blood levels remained significantly higher for RHA until 
24 months. 
Whole blood and serum levels could not be used interchangeably. The mean 
differences for cobalt and chromium between blood and serum values were +0.13 
μg/L and -0.91 μg/L respectively. Regression analysis provided a formula for conversion 
from serum to blood of 0.34+[0.88*Co serum] for cobalt and 0.14+[0.58*Cr serum] 
for chromium, with an acceptable prediction error below ±1.0 μg/L. Cobalt and 
chromium levels were significantly higher for RHA versus THA, especially during the 
run-in phase of one year. Overall, the metal ion levels were well below 5 μg/L. We 
cannot recommend the use of whole blood over serum measurements or vice versa. 
The provided conversion formula between whole blood and serum in combination 
with the presented practical guidelines may be useful for clinical practice. 
4M
etal ion interpretation in resurfacing versus conventional hip arthroplasty  
and in whole blood versus serum
. How should we interpret m
etal ion data? 
65
INTRODUCTION
Resurfacing hip arthroplasty (RHA) has been re-introduced as an attractive bone preserving 
treatment option for young patients with osteoarthritis. In addition, ‘in vitro’ studies on 
the metal-on-metal (MoM) articulation revealed a 20-fold reduction of volumetric wear in 
comparison with metal-on-polyethylene.1,2 The relatively small size of these metal particles 
(6-834nm) accounts for this decrease in volumetric wear, since the total number of particles 
is higher.3 Liberated metal ions may bind to proteins and cells and can be transported 
elsewhere, resulting in elevated levels in blood, serum and urine.2,4-7 These elevated systemic 
metal ion levels are a cause for concern. Reports of hypersensitivity reactions 8,9, osteolysis 
9,10 and the growth of liquid or solid soft tissue reactions 11,12 are available. There is increasing 
evidence that elevated levels of metal ions (especially cobalt) may have adverse long term 
systemic effects including polyneuropathy, cardiomyopathy and hypothyroidism.13,14 The 
uncertainty about the consequences of these elevated metal ion levels has raised concerns 
and diminished the use and acceptance of MoM bearings. In the United Kingdom, the 
Medicines and Healthcare Products Regulatory Agency (MHRA) has produced guidelines 
regarding the monitoring of systemic ion levels, and assay is recommended in cases 
with pain, adverse radiological abnormalities and small component head size. Metal ion 
measurements and a knowledge of their interpretation have thus become important. 
Various matrices, such as whole blood (WB), serum (SE) and urine can be used. Analyses 
in whole blood or serum is preferable, since urine requires a 24-hour collection and the 
levels seem to be more variable due to variation in hydration of the patient.15 Metal ion 
levels after different MoM hip implants have been reported.16,19 However, most studies 
report on either metal ion concentrations in whole blood or serum, and data on repeated 
measurements over time are scarce, resulting in a lack of knowledge of how levels evolve 
over time. There may be superiority of serum over whole blood measurements, but whether 
these two levels can be correlated is not fully understood. 
The aim of our study was to present prospective follow-up of cobalt and chromium levels 
in both whole blood and serum in a group of patients with a RHA versus a conventional 
MoM total hip arthroplasty (THA). In addition, a conversion formula was generated to 
calculate serum from whole blood metal ion levels and practical guidelines were developed 
for clinical use in the interpretation of metal ion levels.
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PATIENTS AND METHODS
Between May 2007 and April 2010 97 patients were prospectively followed in either a 
randomised controlled trial (RCT) comparing a RHA to a conventional MoM THA, or they 
participated in the cohort of RHA patients. Approval for both RCT and cohort was obtained 
from the regional ethics committee of the Radboud University Nijmegen Medical Centre 
(LTC 419-071206). All patients agreed to sign an informed consent.
All patients under the age of 65 were asked to participate in the ongoing RCT. Patients 
who preferred not to participate but who requested RHA were followed in a separate cohort. 
Cobalt and chromium levels were prospectively analysed in both whole blood and serum 
at consecutive time intervals. In the RHA group a resurfacing prosthesis was implanted with 
both components made of a cast, heat treated solution-annealed Co-Cr alloy (Conserve 
plus®; Wright Medical Technology, Arlington, Tennessee, USA). 
Mean resurfacing femoral head size was 48 mm (range 42-54). In the THA group, an 
uncemented tapered stem and a threaded titanium cup with a polyethylene insert with 
a metal liner was inserted (Zweymuller Classic; Zimmer Orthopaedics, Warsaw, Indiana, 
USA) together with a metal 28-mm head (Metasul®; Zimmer Orthopaedics, Warsaw, 
Indiana, USA). A total of 343 paired whole blood and serum specimen were collected pre-
operatively and at 3, 6, 12 and 24 months in 97 patients. Ninetytwo patients had a follow-
up of more than 3 months. Metal ion levels below the detection limit of 0.5 μg/L were 
excluded in the statistical evaluation of the correlation between whole blood and serum 
levels and in generating a conversion formula. After exclusion of these baseline levels below 
the detection limit 213 cobalt specimens and 191 chromium specimens remained in 79 and 
72 patients respectively. Demographic data of the study population and specimens are given 
in Table I and II.
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Table I. Demographic data of the study population
RHA (N=60) THA (N=32) p-value
Gender (men/women) 36/24 20/12 1.000 a
Median age in years (range) 55.3 (25-65) 59.1 (36-65) 0.106 b
Mean body mass index in Kg/m2 (SD) 26.6 (4.8) 27.9 (5.2) 0.243 c
Preoperative diagnosis (OA/AVN/CHD) 57/1/2 30/0/2 0.786 d
Charnley category (A/B1/B2) 36/14/10 23/5/4 0.285 d
Mean operating time in minutes (SD) 78.1 (12.9) 55.5 (12.0) <0.001 c
Median blood loss in mL (range) 300 (100-600) 275 (100-900) 0.653 b
OA: Osteoarthritis, AVN: Vascular necrosis, CHD: Congenital hip dysplasia
a Fisher’s exact probability test, b Mann-Whitney U test, c Student’s t-test. d Kruskall-Wallis test
Table II. Demographic data of specimens
Cobalt (N=79) Chromium (N=72)
Gender (men/women) (p-value) 48/31 (0.056) 39/33 (0.480)
Median femoral component size of 
RHA (range) 48 (42-54) 48 (42-54)
Total number of specimen 343 343
Number of specimen included 213 191
Below detection limit 130 152
Conserve/Metasul/Bilateral/No 
prosthesis 149/58/53/6 147/40/45/4
Cobalt and chromium blood levels
Blood samples were collected in metal-free vacutainers, the first 5 ml blood being discarded 
to eliminate metal contamination from the needle. A 6 ml BD ‘EDTA’ and a 5 ml ‘SST 
II Advance’ vacutainer system (Franklin Lakes, New Jersey, USA) was used for blood 
collection. After blood collection the tube with clot activator was set at rest for a minimum 
of 30 minutes and was then centrifuged at 3600 rpm for ten minutes. Both tubes were stored 
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at a maximum of 4°C and sent within 7 days to the laboratory of Toxicology of the University 
Hospital Ghent (Belgium) for analysis. The metal ion levels in serum and whole blood were 
determined using an inductively-coupled plasma mass spectrometer (ICP-MS) on a Perkin 
Elmer Elan DRCe, equipped with a standard cross-flow nebuliser and a Dynamic Reaction 
Cell (Perkin Elmer SCIEX, Canada). 
Statistical analysis
Since metal ion data are not normally distributed they are represented by the median, and 
a non-parametric test (Mann-Whitney U) was used for analysis. The agreement between 
whole blood and serum levels was assessed with mean difference, regression analysis and 
the Blandand-Altman limits-of-agreement between methods of measurement with multiple 
observations per individual, as is proposed by Bland-and-Altman.20 In this study several 
measurements in the same patients were used. Therefore we used the modification from 
Bland-Altman with adjustment for the repeated measurements.21 
The multiple observations per individual can have influence on the regression analysis. 
Therefore prior to this analysis a mixed model analysis was used to analyse the influence 
of the repeated measurements on the linear regression. The Null Model Likelihood Ratio 
Test showed a p-value of > 0.05 for all tests, indicating that there is no significant difference 
between a regression with ignorance of the repeated measurements and the regression with 
adjustment for the repeated measurements. As a result the simple linear regression with the 
equation ‘whole blood level = α+β*serum level’ was used for all analyses in this study. To 
validate our regression equation we randomly split the database into two. The patients in 
the first section were used to calculate a regression equation which could be tested on the 
second section. The data was processed in SPSS (Version 15.0 SPSS Inc. Chicago, IL) and 
analysed for statistical differences. Statistical significance was set at p ≤ 0.05.
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RESULTS
RHA versus THA metal ion levels 
Patient characteristics are described in Table I. The mean operating time was longer for RHA 
(p < 0.001), but median blood loss was equal between the two groups. The concentrations 
of cobalt and chromium in whole blood and serum for RHA versus THA for each time 
interval are summarised in Table III and Figures 1a and 1b. Baseline preoperative cobalt and 
chromium concentrations were, as expected, below the detection level of 0.5 μg/L for both 
groups. Cobalt whole blood and serum levels increased after implantation of a RHA (p < 
0.001) and a THA (p = 0.015 (WB) and p = 0.002 (SE)).
Cobalt concentrations were higher for RHA compared to THA at 3, 6 and 12 months for 
whole blood (p < 0.001, p = 0.001, p = 0.026) and serum (p < 0.001, p <0.001, p = 0.007). 
At 24 months cobalt levels stabilised and the initially statistically significant difference 
between RHA and THA could no longer be detected for whole blood (p = 0.082) and serum 
(p = 0.530). Postoperative chromium levels of RHA patients increased compared to the 
preoperative levels for whole blood and serum (p < 0.001). The THA patients showed a 
solitary increase for serum (p < 0.001), while whole blood concentrations remained stable 
(p = 0.243). Chromium concentrations were higher for RHA at 3, 6 and 24 months for whole 
blood (p < 0.001, p < 0.001, p = 0.021), and at all follow-up intervals for serum (p < 0.001).
Whole blood versus serum
Demographics of specimen-specific patient data are given in Table II. The mean difference 
between serum and whole blood was +0.13 μg/L for cobalt (95%-CI:0.03;0.22) and -0.91 
µg/L for chromium (95%-CI:-1.05;-0.77). There was a statistically significant difference 
between whole blood and serum levels for cobalt (p = 0.01) and chromium (p < 0.001). 
Despite this difference, cobalt and chromium levels in whole blood and serum were highly 
correlated: cobalt R = 0.936 (p < 0.001) and chromium R = 0.937 (p < 0.001). A Bland-
Altman analysis showed limits-of-agreement of +1.5 μg/L and -1.25 μg/L with a mean 
difference of +0.13 μg/L for cobalt (Figure 2a). This means that cobalt levels in whole blood 
are on average +0.13 μg/L higher compared to serum and that 95% of these differences 
between blood and serum levels appeared to be between +1.5 μg/L and -1.25 μg/L. For 
chromium the correlation between whole blood and serum levels was obscured by an 
470
increase in difference at higher mean concentrations. There was a mean difference between 
whole blood and serum of -0.91 μg/L with relatively wide limits-of-agreement between 
+0.95 μg/L and -2.85 μg/L. The tendency of an increase in difference between whole blood 
and serum at higher mean concentrations is visualised by a diagonal trend in the Bland-
Altman plot (Figure 2b). We calculated a conversion formula for serum metal ion levels into 
whole blood metal ion levels by regression analysis. The following formula was established 
for Cobalt (Co) and chromium (Cr):
Co whole blood = 0.34+[0.88*Co serum]
Cr whole blood = 0.14+[0.58*Cr serum]
Validation of prediction model blood versus serum
In order to validate the conversion formula, we randomly divided our database in two. A 
similar regression analysis on half of the database provided a conversion formula which 
was subsequently tested on the second half of the database. The newly obtained conversion 
formulae were Co whole blood = 0.29+[0.89*Co serum] and Cr whole blood = 0.21+[0.54*Cr 
serum]. Serum levels from the second half of the database were used to predict whole blood 
levels, and compared to the actual measured values. The Bland-Altman test was computed 
as the difference between the measured and predicted value (Figure 3a and b). The mean 
difference between measured and predicted values of cobalt and chromium was 0.0 μg/L. 
Limits-of-agreement for the difference between predicted and measured cobalt whole blood 
levels were +0.77 μg/L and -0.84 μg/L. In relation to chromium these limits were +0.92 μg/L 
and -0.98 μg/L. There was no difference between predicted and actual measured whole 
blood values of cobalt (p = 0.411) and chromium (p=0.561).
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Figure 1.
(A) Error-plot (median and IQR) cobalt concentrations in whole blood and in serum in 
µg/L. 
(B) Error-plot (median and IQR) chromium concentrations in whole blood and serum 
in µg/L.
A
B
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Figure 2.
(A) Cobalt standard Bland-Altman plot 
(B) Chromicum standard Bland-Altman plot. In both graphs the black line illustrates 
the mean difference between metal ion levels in serum and whole blood and the two 
gray parallel lines illustrate the 1.96 standard deviation of this difference or ‘limits-of-
agreement’.
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Figure 3.
(A) Predicted cobalt levels compared to the actual blood levels 
(B) Predicted chromium levels compared to the actual blood levels. In both graphs the 
black line illustrates the mean difference between predicted and real metal ion levels 
in serum and whole blood and the two gray parallel lines illustrate the 1.96 standard 
deviation of this difference or ‘limits-of-agreement’.
A
B
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DISCUSSION 
The evaluation of metal ion levels is becoming increasingly important after a MoM hip 
arthroplasty and serves as an indicator of bearing performance and device safety.19 In this 
study, RHA revealed a higher initial increase in cobalt and chromium concentrations than 
a conventional MoM 28-mm THA. After a run-in phase, this difference in cobalt levels 
between the two groups resolved, but chromium levels were still higher for the RHA group. 
Because cobalt is known to be a relatively toxic ion 13,22, it is important to note that cobalt 
levels decrease after a run-in phase of 12 months. It is clear from our observations that 
increased metal ion levels are not exclusively seen in RHA patients, and over time metal ion 
levels after RHA may approach values following a MoM THA. These findings are consistent 
with previous reports; which suggest that after 5 years there is no difference in metal ion 
concentrations following large-diameter resurfacing and a small-diameter MoM THA.17 
Unlike some reports following the use of a variety of RHA devices, the metal ion levels 
following both RHA and THA used in our study appeared to be rather low.16,17,19 Implant-
related differences are present in metal ion release and this should be taken into account as 
one of the confounding factors in the interpretation of our results. Furthermore, it has to be 
recognised that the mechanism and source of metal debris may also be different for RHA 
compared to MoM THA. In general metal ions and particles are generated both by wear 
from the articulation and by corrosion. In addition to metal ion release from the bearings, 
a THA may create metal debris from the taper junction with the head. This may thus have 
influenced metal ion concentrations in peripheral blood in the THA group However, the 
source of metal ion release should not influence the relationship between metal ion levels 
in serum versus whole blood as evaluated in our study. Metal ion levels may be influenced 
by renal excretion, protein binding and transport, and extremely high levels of cobalt may 
occur in patients with renal dysfunction, and therefore MoM bearings are contraindicated 
in these patients.23 High levels can also be related to other sources of metal ion release, 
such as mechanical heart valves, orthodontic implants, medical or nutritional supplements 
containing metal ion ‘equivalents’ or environmental and/or occupational sources of metal 
contamination. All patients in our study were carefully monitored for the potential presence 
of these other sources of metal ions. These confounding factors should always be taken into 
consideration when confronted by high metal ion levels, and remain an obstacle in the 
interpretation of metal ion levels. 
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Regarding the differences between serum and whole blood, cobalt serum levels were 
slightly lower or equivalent to whole blood, which was represented by a mean difference 
of only +0.13 μg/L. For chromium, serum levels were relatively high compared to whole 
blood, indicated by a mean difference of -0.91 μg/L. Our results correspond with earlier data 
from Walter et al, who found little difference between whole blood and serum for cobalt, 
but higher serum levels compared to whole blood for chromium.6 Studies that examine the 
difference between metal traces in whole blood and serum are rare. Daniel et al 7 studied 
the suitability of whole blood and serum for measurement of ion levels, but the limits-
of-agreement between whole blood and serum for cobalt and chromium were relatively 
wide as compared to our data with +3.8 μg/L; -2.2 μg/L for cobalt and +8.4 μg/L; -4.2 μg/L 
for chromium. This finding may be explained by differences in collection and processing 
of the samples, and the fact that Daniel et al studied a group of miscellaneous types of 
resurfacing implants each with unique metallurgy.24,25 Daniel et al suggested whole blood 
as a superior matrix over serum metal ion measurements 7, but from our data we cannot 
recommend whole blood over serum or ‘vice versa’. From a practical point of view, the use 
of whole blood may be preferred, since whole blood can be sent to the laboratory without 
separation of serum, a step which can introduce pollution to the sample. The option of a 
conversion formula to extrapolate serum to whole blood metal ion levels is attractive for 
obvious reasons. Based on the wide limits-of-agreement of the Bland-Altman plot we do 
not believe that the two blood fractions can be used interchangeably. However, conversion 
between whole blood and serum remains possible. The conversion formulae, as provided in 
this study, can be used with limits-of-agreement that are within acceptable range (Figure 3a 
and b). For both metal ions the whole blood and serum levels could be predicted from one 
another with a prediction error below 1.0 μg/L. The prediction error is obtained from testing 
on a homogeneous group of patients, and verification on a heterogeneous group might be 
helpful. The conversion formula is best used for the lower boundary of metal ion levels 
and may offer reassurance to the clinician in interpreting metal ion levels. The provided 
levels can subsequently be balanced to the upper acceptable limits. Higher values cannot 
be predicted without accepting a greater prediction error, but we believe that prediction of 
these values from serum to whole blood is of less clinical significance since the values are 
usually already in the pathological range, and indicative of malfunctioning of the implant. 
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There are some weaknesses in our study. The number of available samples at 24 months 
was limited, which may have contributed to the observed non-significant difference in 
cobalt levels between both implants. Further follow-up of these patients will eventually 
resolve this. Cobalt has a smaller variability compared to chromium, but is recognised to 
be more toxic both in particle and ion form. It is therefore important to follow cobalt ion 
levels closely. We also recognise some limitations in the conversion formulae presented. The 
conversion formula is particularly valuable for the concentrations in the range of 2-5 μg/L, 
both because its prediction error is lowest in the lower range and because the lower values 
are of clinical importance for the evaluation of implant performance. Since the vast majority 
of metal ions should be below 5 μg/L it may not be clinically relevant to be able to predict a 
serum or whole blood level knowing that it is already in the higher range. The formulae can 
be used for reassurance in clinical practice. A low serum level, for example, will never be 
correlated with a high whole blood level. Only one clinical sample (either whole blood or 
serum) can be used to conform to safety guidelines referring to serum or whole blood levels.
It is extremely important in clinical practice to know the upper acceptable levels for metal 
ions. The best-defined reference values are the “exposure equivalent of carcinogenic 
substances” (EKA values) 26 for industrial workers and the Mayo Medical Laboratories 
interpretive handbook.27 The upper limits are defined for cobalt at 5 µg/L in whole blood and 
for chromium at 17 μg/L in erythrocytes (no whole blood upper limits reported).26 In addition 
to these reference values, De Smet et al analysed metal ion levels in patients with a well 
functioning versus a malfunctioning RHA and proposed that serum cobalt and chromium 
levels up to respectively 4.4 μg/L (odds ratio for revision 6.0) and 5.1 μg/L (odds ratio for 
revision 4.3) are acceptable as upper limits.28 Metal ion levels higher than twice these upper 
limits are very likely to be associated with poor clinical outcome.28 The median ion levels 
of our study are well below this limit, although a few outliers were still encountered. The 
North Tees group (UK) state that patients with cobalt values between 2 and 5 μg/L have to 
be followed clinically and patients with cobalt values above 5 μg/L have to be evaluated 
with cross-sectional imaging.29 In patients with clearly elevated levels, revision should be 
considered or anticipated. 
We have summarised our results together with data from the literature in an attempt 
to produce some guidelines (Tab. IV) which may help the orthopedic surgeon regarding 
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the use and interpretation of metal ion levels in patients with a MoM hip arthroplasty. It 
is important to emphasise again that these guidelines can only be seen as an aid to the 
clinician in decision making and certainly not as an absolute reference tool. Numerous 
limitations exist, but since the topic of the interpretation of metal ion levels is becoming 
increasingly important we believe our study may help the clinician towards understanding 
of this difficult topic.
Table IV. Practical guidelines fort he interpretation of metal ion levels in patients with 
a MoM hip arthroplasty.
Type of Analysis No superiority of whole blood or serum; whole blood 
may be favored for practical reasons depending on local 
preference.
 Inductively-coupled plasma mass spectrometer (ICP-MS) 
method of first choice.
Resurfacing (RHA) versus Conventional (THA)1 Metal ion levels are significantly higher for RHA versus 
THA. This difference decreases after the run-in phase, in 
particular for cobalt.
Metal ions measurement Serum ≠ whole blood
Toxicity: Cobalt > Chromium
Cobalt Serum > and < whole blood 
Co blood = Co serum + 0.13 µg/L (95%-CI:0.03;0.22) 
Conversion formula (prediction error <1 µg/L): 
Co whole blood = 0.34+[0.88*Co serum]
Chromium Serum (in general) > whole blood 
Cr blood = Cr serum - 0.91 µg/L (95%-CI:-1.05;-0.77).
Conversion formula (prediction error <1 µg/L): 
Cr whole blood = 0.14+[0.58*Cr serum]
Confounding Factors Renal impairment
‘Contamination’ by nutritional supplements, medication, 
other metal implants
Implant type and positioning
High levels Associated with an increased risk of a malfunctioning 
implant. Close monitoring is indicated with levels : 
Cobalt serum concentration >4.4 µg/L
Chromium serum concentration >5.1 µg/L
1 This conclusion applies for the implants used in this study and may differ for other implants.
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CHAPTER 5
Metal ion levels in patients with a lumbar 
metal-on-metal total disc replacement. 
Should we be concerned?
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ABSTRACT
The purpose of this study was to evaluate whether concerns about the release of metal 
ions in metal-on-metal total hip arthroplasty (THA) should be extended to patients 
with metalbearing total disc replacements (TDR).
Cobalt and chromium levels in whole blood and serum were measured in ten 
patients with a single-level TDR after a mean follow-up of 34.5 months (13 to 61) 
using inductively-coupled plasma mass spectrometry. These metal ion levels were 
compared with preoperative control levels in 81 patients and with metal ion levels 12 
months after metal-on-metal THA (n = 21) and resurfacing hip replacement (n = 36). 
Flexion-extension radiographs were used to verify movement of the TDR.
Cobalt levels in whole blood and serum were significantly lower in the TDR group 
than in either the THA (p = 0.007) or the hip resurfacing group (p < 0.001). Both 
chromium levels were also significantly lower after TDR versus hip resurfacing (p < 
0.001), whereas compared with THA this difference was only significant for serum 
levels (p = 0.008). All metal ion levels in the THA and hip resurfacing groups were 
significantly higher than in the control group (p < 0.001). In the TDR group only 
cobalt in whole blood appeared to be significantly higher (p < 0.001). The median 
range of movement of the TDR was 15.5° (10° to 22°).
These results suggest that there is minimal cause for concern about high metal 
ion concentrations after TDR, as the levels appear to be only moderately elevated. 
However, spinal surgeons using a metal-on-metal TDR should still be aware of 
concerns expressed in the hip replacement literature about toxicity from elevated 
metal ion levels, and inform their patients appropriately.
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INTRODUCTION
Total disc replacement (TDR) is one surgical procedure used to treat degenerative disc 
disease. The theoretical advantage of TDR over spinal fusion is that movement is preserved 
at the involved level and accelerated degeneration of the adjacent segment is prevented.1-3 
As found in any joint replacement, the bearing surfaces of the implant might wear and 
release particles. Ideally, any volumetric wear should be as low as possible: metal-on-
metal (MoM) articulations were introduced in an attempt to achieve this goal. At the hip, 
despite the relatively low volumetric wear of well-positioned MoM articulations compared 
with polyethylene bearings, the total number of particles released is much higher.4,5 These 
particles measure between 6 nm and 834 nm in diameter4 and are transported throughout 
the body, resulting in elevated levels of cobalt and chromium ions in blood and urine.6-11
There is increasing concern in the literature on MoM hip replacement about the 
potentially hazardous side-effects of these elevated metal ion levels. Numerous studies, 
especially on MoM hip resurfacings, have reported serious adverse events, including 
implant-induced hypersensitivity reactions,12-14 osteolysis,13,15 pseudotumour formation16,17 
and focal periprosthetic soft tissue necrosis.13,17,18 Such adverse events frequently demand 
relatively early revision. In the United Kingdom these studies have led to an official alert 
from the Medicines and Healthcare products Regulatory Agency (MHRA), which suggests 
that metal ion levels should be measured in patients with a MoM hip replacement if they 
have features which place them at risk of an adverse reaction or pain.19 
By comparison, very little attention has been paid to this phenomenon in spinal surgery. 
A search of the literature revealed only two single-centre studies on increased metal ion 
levels after an MoM TDR20,21 They concluded that metal ion levels in patients with an MoM 
TDR are similar to those found after MoM hip replacement, which is a cause for concern 
given the official alert regarding MoM hip replacement. Accordingly, further evaluation of 
metal ion levels in patients with a TDR are required.
In this study we evaluated cobalt (Co) and chromium (Cr) ion levels in whole blood 
and serum of patients with an MoM TDR and compared these with levels from an ongoing 
trial comparing metal ion levels after hip resurfacing versus conventional MoM total hip 
arthroplasty (THA).
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Table I. Demographic data of the control, total disc replacement (TDR), hip 
resurfacing and total hip replacement (THA) subgroups (median, range)
Control  
(n = 81)
TDR  
(n = 10)
Hip resurfacing  
(n = 36)
THA  
(n = 21) p-value
*
Median age (yrs) 57 (34 to 64) 43 (25 to 49) 55 (24 to 64) 59 (42 to 64) < 0.001
Median follow-up (mths) n/a† 34.5 (13 to 61) 12 (12 to 12) 12 (12 to 12) < 0.001
Gender
Male 47 1 21 13 0.188‡
Female 34 9 15 8
Median body mass index 26 (20 to 41) 24 (20 to 28) 26 (21 to 32) 27 (20 to 41) 0.133
Median blood loss (cc) n/a 200 (53 to 1100) 300 (0 to 600) 300 (0 to 900) 0.522
Median duration operation (mins) n/a 90 (76 to 110) 79 (58 to 122) 60 (37 to 76) < 0.001
* Kruskal-Wallis test, unless otherwise stated
†  n/a, not available
‡  Pearson chi-squared test
PATIENTS AND METHODS 
Between January 2004 and June 2010, cobalt and chromium ion levels in whole blood 
and serum were prospectively assessed in an ongoing randomised controlled trial (RCT) 
comparing hip resurfacing with conventional MoM THA, and in a prospective cohort of 
patients with a hip resurfacing arthroplasty of the hip.22,23 Patients received either a Conserve 
Plus resurfacing (Wright Medical Technology, Arlington, Tennessee) with a median femoral 
head diameter of 49 mm (42 to 54) or an uncemented metal-bearing Zweymuller THA 
(Zimmer Orthopaedics, Warsaw, Indiana) with a 28-mm Metasul head. Metal ion levels 
in patients from these two cohorts were available at several intervals. For this study the 
12-month data from patients with a unilateral hip replacement were used, as the metal ion 
levels are known to be elevated during a running-in phase of approximately 6 to 12 months, 
after which they stabilise.5,8,21,24 The baseline metal ion levels of all these patients were 
assessed preoperatively and regarded as controls.
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The cobalt and chromium ion levels were also determined in ten consecutive patients 
with a single-level MoM Maverick TDR (Medtronic Sofamor Danek GmbH, Köln, Germany), 
undertaken between December 2009 and August 2010, at their routine yearly follow-up. 
Given the phenomenon of the running-in phase in MoM hip replacements, a minimum 
follow-up of one year was also chosen for TDR patients. The median follow-up for the 
TDR patients was 34.5 months (13 to 61). The median follow-up for patients with a hip 
replacement was exactly 12 months, as they had all been recalled for blood samples one 
year after implantation as part of the study protocol.
Regional ethics committee approval had been granted for the study of all the hip patients 
but no approval was required for the TDR patients, as the evaluation was considered part of 
their routine care. Informed consent was still obtained in all cases.
Study population 
A total of ten patients with a single-level TDR, 36 with a unilateral hip resurfacing and 21 with 
a unilateral THA were included in the study and were tested for cobalt and chromium ion 
levels in whole blood and serum. The pre-operative baseline metal ion levels of 81 patients 
in the hip replacement trials were used as controls. The number of control patients exceeds 
the sum of the patients with a hip resurfacing or THA, as only hip replacement patients with 
a follow-up of at least one year were included. None of these had been exposed to cobalt 
or chromium, either environmentally or medically, according to a standardised screening 
questionnaire.
All patients who underwent a TDR had suffered from discogenic back pain that failed 
to respond to conservative treatment over a period of at least 12 months; they had single-
level disc degeneration on MRI; no spondylolisthesis or congenital abnormality; a body 
mass index (BMI) < 30; no previous back operations; and were aged between 25 and 55 
years. Failed conservative treatment included antiinflammatory drugs, physiotherapy, pain 
treatment and modification of activity.
Maverick TDR plates come in small, medium and large sizes and vary in height between 
9 mm and 14 mm. None of the patients included in this study had a small implant, three 
had a medium implant and seven a large implant; their median height was 10 mm (9 to 11). 
The TDR was at L4-5 in eight cases and at L5-S1 in two. Additional demographic data are 
summarised in Table I.
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Figure 1. Anteroposterior (left) and lateral (right) radiographs showing a Maverick 
metal-on-metal total disc replacement, with a ball-and-socket articulation.
The percentage deviation of the prosthesis from the midline of the vertebral body on the anteroposterior view 
was defined as the difference between the midline of the body (yellow line C) and the midline of the prosthesis 
(dotted red line D) divided by the distance between points A and B. On the lateral view an adequate position 
was defined as implant position within 5 mm of the posterior boundary of the endplate (distance between lines 
A and C).
Clinical scoring, TDR positioning and TDR range of move-
ment 
A visual analogue scale (VAS)25 for low back pain and an Oswestry Disability Index (ODI)26 
were obtained pre-operatively and at regular intervals post-operatively in the TDR group. 
The range of movement of the TDR was also routinely measured by an author (DJZ): this 
was defined as the angle between the caudal endplate of the upper vertebral body and the 
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cranial endplate of the lower vertebral body in the sagittal plane on conventional flexion-
extension radiographs.
Because malpositioning of the implant is known to elevate metal ion levels after THA,27,28 
satisfactory placement of each TDR was confirmed on anteroposterior (AP) and lateral 
radiographs. On the AP view the centre of the implant was compared with the midline of 
the vertebrae and any deviation was expressed as a percentage of the width of the superior 
endplate of the inferior vertebra (Figure 1). Central positioning with < 5% deviation was 
considered satisfactory. On the lateral view, a satisfactory position was registered if the 
implant was sited within 5 mm of the posterior border of the endplate.
Blood collection 
Blood samples were collected in three metal-free vacutainers, a 6 ml BD ‘EDTA’ and a 5 ml 
BD ‘SST II Advance’ system (both Becton Dickinson, Franklin Lakes, New Jersey). The first 
5 ml were discarded to eliminate any form of metal contamination from the needle. After 
blood collection the tube with clot activator was set to rest for at least 30 minutes and was 
then centrifuged at 3600 rpm for ten minutes. Both tubes were stored at 2°C to 8°C and 
forwarded to the Laboratory of Toxicology at the University Hospital, Ghent, Belgium, for 
analysis. The metal ion levels were determined using an inductively-coupled plasma mass 
spectrometer (ICP-MS) on a Perkin Elmer Elan DRC-e equipped with a standard cross-flow 
nebuliser and a dynamic reaction cell (Perkin Elmer SCIEX Instruments, Ontario, Canada). 
Results were quantitatively reported if concentrations exceeded the detection threshold of 
0.5 μg/l; all values below the detection limit were registered as 0.1 μg/l for statistical analysis.
Statistical analysis 
The data were processed using SPSS 15.0 (SPSS Inc., Chicago, Illinois) and analysed 
for statistical differences. Variables were controlled for their normal distribution with 
the Kolmogorov-Smirnov test. A value of < 0.05 was defined as an absence of normal 
distribution. Median, range and non-parametric tests (Mann-Whitney U, Wilcoxon signed-
rank and Kruskal-Wallis tests) were used for all parameters owing to the absence of normal 
distribution and the small number of patients in the TDR group. Pearson‘s chi-squared test 
was used for categorical variables (gender). Statistical significance was defined as a p-value 
< 0.05.
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RESULTS
The characteristics of all implant subgroups are presented in Table I. The clinical scores, 
range of movement and metal ion levels of each of the TDR patients are shown in Table II. 
The VAS for low back pain and the ODI both improved significantly after surgery (both p = 
0.005, Wilcoxon signed-rank test). At the latest follow-up the VAS pain score had decreased 
by a median of seven points out of ten (4 to 8) against pre-operative levels. The ODI revealed 
an median post-operative decrease of 39% (24% to 80%).
All TDRs remained mobile at the median follow-up of 34.5 months (Table II) when the 
median range of movement was 15.5° (10° to 22°).
Regarding the position of the implants, the median deviation of the centre of the TDR 
from the midline of the vertebra was 2.4% (0% to 4.8%) on the AP view. On the lateral 
view all TDRs were placed within 5 mm of the posterior border of the adjacent endplate. 
Accordingly, all ten TDRs could be classified as being appropriately sited on both AP and 
lateral views.
Cobalt and chromium levels in whole blood and serum 
The median cobalt and chromium levels in whole blood and serum for each subgroup of 
implants are given in Table III and the relationship between them is shown in Figure 2.
TDR versus THA and hip resurfacing 
Cobalt and chromium levels in whole blood and serum were significantly lower in the 
TDR group than in both the hip resurfacing and the THA groups, particularly in the hip 
resurfacing group (p < 0.001, Mann-Whitney U test; Table III). The difference between the 
THA subgroup and the TDR patients was less pronounced, but with significantly higher 
cobalt levels in both whole blood and serum and chromium levels in serum for the THA 
group (p = 0.004, p = 0.007 and p = 0.008, respectively, Mann-Whitney U test). Chromium 
levels in whole blood were also relatively high in the THA group, but this difference was not 
statistically significant (p = 0.053, Mann-Whitney U test).
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Table III. Median metal ion levels in μg/l (range) in the different prosthesis groups 
(TDR, total disc replacement; THA, total hip replacement)
Control  
(n = 81)
TDR 
(n = 10)
Hip resurfacing 
(n = 36)
p-value* THA 
(n = 21)
p-value†
Cobalt whole blood 0.1 (0.1 to 0.8) 0.6 (0.1 to 1.2) 1.3 (0.6 to 11.5) < 0.001 1.1 (0.1 to 2.2) 0.004
Cobalt serum 0.1 (0.1 to 2.6) 0.1 (0.1 to 1.1) 1.1 (0.1 to 7.7) < 0.001 0.8 (0.1 to 1.9) 0.007
Chromium whole 
blood 0.1 (0.1 to 1.2) 0.1 (0.1 to 1.1) 1.0 (0.1 to 6.0) < 0.001 0.5 (0.1 to 1.9) 0.053
Chromium serum 0.1 (0.1 to 2.9) 0.2 (0.1 to 0.9) 1.8 (0.1 to 10.2) < 0.001 0.9 (0.1 to 2.9) 0.008
* comparison between TDR and hip resurfacing (Mann-Whitney U test), 
† comparison between TDR and THA (Mann-Whitney U test)
TDR versus control 
Compared with the metal ion levels in the control group, the cobalt and chromium ion levels 
in whole blood and serum were all significantly higher (p < 0.001, Mann-Whitney U test) 
after both hip resurfacing and THA. For the TDR patients, however, the cobalt levels in serum 
and the chromium levels in both whole blood and serum did not differ statistically from 
those in the control group (Figure 2). The only metal trace that appeared to be significantly 
higher after TDR was cobalt in whole blood (p < 0.001, Mann-Whitney U test).
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Figure 2. Box plot showing the cobalt and chromium metal ion levels in the total disc 
replacement (TDR) group in proportion to the other prostheses and the control group.
The horizontal thick black line represents the median, the shaded area the interquartile range and the whiskers 
the minimum and maximum values. The remainder are outliers (circles) and extreme outliers (asterisks). The 
‘α’ under the whiskers indicates a statistical difference (all p < 0.001, Mann-Whitney U test) in metal ion level 
compared with the control group. Two extreme outliers in the hip resurfacing group lie outside the range 
displayed: cobalt whole blood at 11.5 µg/l and chromium serum at 10.2 µg/l (THA, total hip replacement).
DISCUSSION
In this study, patients with a well-functioning single-level TDR appeared to have cobalt and 
chromium levels that were in most cases similar to those measured preoperatively in control 
patients without any form of MoM implant. Only cobalt levels in whole blood showed a 
significant median increase (to 0.6 µg/l) after a TDR; this is just above the detection limit 
of 0.5 µg/l. Metal ion levels in the TDR group were also significantly lower than those after 
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hip resurfacing or THA, particularly after hip resurfacing. These results are at odds with 
those of the two other single-centre studies in the literature.20,21 In these studies of mono- 
and bisegmental TDR the authors reported a median cobalt serum level of 4.97 μg/l and a 
chromium serum level of 1.78 μg/l at a median follow-up of 14.8 months. At 36.7 months 
these median values of cobalt decreased to 1.64 μg/l and chromium increased to 2.50 μg/l, 
respectively.21 These figures are much higher than we found in our study, where serum levels 
of both cobalt and chromium remained below the detection limit at a median follow-up of 
34.5 months. Cobalt levels of 4.97 μg/l should cause concern, as they approach levels of 
toxicity equivalent to the ‘exposure equivalent of carcinogenic substances’ (EKA values)29 
for industrial workers and the references of the Mayo Medical Laboratories interpretive 
handbook.30 In these references, the upper limit of cobalt is defined at 5 µg/l in whole blood. 
In addition to these reference values, De Smet et al6 analysed metal ion levels in patients 
with well- and poorly functioning hip resurfacings and proposed that serum cobalt and 
chromium levels of 4.4 μg/l (odds ratio (OR) for revision 6.0) and 5.1 μg/l (OR for revision 
4.3), respectively, should be the upper limits of acceptability.
We do not have a clear explanation for the differences in metal ion levels found between 
our study and the earlier studies of Zeh et al.20,21 Both were performed on patients with the 
same type of TDR (Maverick TDR). In the studies of Zeh et al,20,21 patients with both single- 
and two-level TDRs were included, whereas we only included patients with a single-level 
replacement. However, the previous studies state that there was no statistically significant 
difference in metal ion levels after TDR at one or two levels.20,21
From the literature on hip replacement we know that an optimal implant position is 
mandatory to ensure low friction and subsequently low metal ion levels.27 Adequate 
positioning of the TDR is also a prerequisite for normal spine kinematics,1,2,31 and it seems 
reasonable to assume that appropriate positioning of the TDR has an influence on low metal 
ion release as it does for hip replacement.
The range of movement of the device may also influence the amount of metal ion 
release, as loss of movement would inevitably lead to a decrease in wear. All TDRs appeared 
to have maintained a substantial range of movement on flexion-extension radiographs, with 
a median of 15.5° (10° to 22°) at final follow-up. Therefore we can conclude that the low 
metal ion levels cannot simply be explained by an absence of movement of the implants. 
No information on implant position and range of movement is given in the studies of Zeh 
et al.20,21
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The differences we found are probably related to differences in the protocols we used 
for blood collection and processing. Adequate and reliable measurement of ultra-low 
levels of metal ions is a delicate process and vulnerable to potential contamination, such 
as traces of metal from the needle. In our protocol the first 5 ml of blood were discarded to 
avoid potential contamination. In addition, we used ICP-MS on a Perkin Elmer Elan DRC-e 
equipped with a standard cross-flow nebuliser and a dynamic reaction cell (Perkin Elmer 
SCIEX), which is currently considered the optimal processing technique.32
Another advantage of our study is that we were able to correlate the metal ion levels 
found after TDR with control levels and levels after hip resurfacing and THA. Samples from 
all these subgroups were evaluated at the same laboratory using the same rigid protocol.
In our study both cobalt and chromium levels in the TDR group were significantly lower 
than after THA (p = 0.053) and hip resurfacing (p < 0.001). Given the current concern 
about the serious adverse events that have occurred after MoM hip replacements, and in 
particular after hip resurfacing, this is an important finding. We conclude that the chances 
of a significant increase in metal ion levels in both whole blood and serum after TDR are 
substantially lower than after THA or hip resurfacing. Apparently the amount of wear debris 
from a well-positioned TDR is relatively low. This corresponds with an earlier study where 
wear debris from a Maverick TDR was estimated to be between 0.38 mm3 and 0.44 mm3 
per year, compared with 1 mm3 to 5 mm3 for a MoM hip replacement.9,33 This difference in 
wear is almost certainly due to the fact that the kinematics of a TDR, such as loading, shear 
forces, contact area and range of movement, are profoundly different from those of any hip 
replacement. The range of movement in a TDR is relatively limited and the shear forces are 
rather low, owing to the contained position of the device. This will result in lower friction of 
the articulating surfaces and reduced wear.
There are limitations to our study. No pre-operative metal ion levels were assessed in the 
TDR group, which made it impossible to determine the actual increase in metal ion levels 
after surgery. As cobalt levels in serum and chromium levels in both whole blood and serum 
remained generally below the detection limit of 0.5 μg/l at a median of 34.5 months after a 
TDR, one can argue whether this limitation is truly relevant. We believe that the available 
dataset of 81 control patients from an ongoing hip trial provides an appropriate surrogate 
value.
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In addition, it should be noticed that there is a difference in follow-up between the 
different implant groups. Patients in the TDR group had a longer median follow-up (34.5 
months) than the hip resurfacing and THA groups (12 months), but we do not believe that 
this difference is a major confounding factor, as the metal ion levels of the TDR are certainly 
beyond their running-in phase and must have stabilised. These levels are also lower than the 
longterm figures for MoM THA and hip resurfacings given in the literature.7,8,24
The TDR group was small. A larger population would, however, probably not have 
shown any greater difference between the TDR and the control group, as all values were in 
a limited range and almost always below the limit of detection.
In conclusion, we believe that there is only limited cause for concern, as in this study 
the post-operative metal ion levels were significantly lower after TDR than after THA and 
hip resurfacing, and were generally comparable to those in the general population. These 
findings are more reassuring than those previously published.20,21 Local soft-tissue necrosis 
or pseudotumour formation as a result of metal ion debris reaching toxic release levels, 
as has been described after MoM hip replacement, would seem unlikely to occur after an 
MoM lumbar TDR. However, the exact pathology of pseudotumour formation is far from 
fully understood, and as well as a toxic reaction to an abundant volume of metal particles, 
a delayed hypersensitivity reaction to these particles has also been described as a causative 
factor.34 With a hypersensitivity reaction metal ions do not have to be elevated beyond toxic 
levels in order to cause a soft-tissue reaction. So far, only two case reports are available in 
the literature after a TDR,14,16 where the authors describe a soft-tissue mass posterior to the 
implant encroaching on the spinal cord. Revision surgery was performed and histology 
showed a lymphocyte-dominated response in the tissue similar to those reported in patients 
with an MOM hip prosthesis.13 These case reports and other similar unpublished reports still 
justify caution when using TDRs. We encourage spinal surgeons using MoM TDR to follow 
their patients at regular intervals, particularly if they complain of increasing pain, when 
investigation should include measurement of metal ion levels.
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CHAPTER 6
Similar incidence of periprosthetic fluid 
collections after ceramic-on-polyethylene 
total hip arthroplasties and metal-on-metal 
resurfacing arthroplasties
Results of a screening metal artefact 
reduction sequence-MRI study
P. Bisseling, B. W. K. de Wit, A. M. Hol, M. J. van Gorp, 
A van Kampen, J. L. C. van Susante
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ABSTRACT
Patients from a randomised trial on resurfacing hip arthroplasty (RHA) (n = 36, 19 
males; median age 57 years, 24 to 65) comparing a conventional 28-mm metal-on-
metal total hip arthroplasty (MoM THA) (n = 28, 17 males; median age 59 years, 37 
to 65) and a matched control group of asymptomatic patients with a 32 mm ceramic-
on-polyethylene (CoP) THA (n = 33, 18 males; median age 63 years, 38 to 71) were 
cross-sectionally screened with metal artefact reducing sequence-MRI (MARS-MRI) 
for pseudotumour formation at a median of 55 months (23 to 72) post-operatively. 
MRIs were scored by consensus according to three different classification systems for 
pseudotumour formation. 
Clinical scores were available for all patients and metal ion levels for MoM 
bearing patients. 
Periprosthetic lesions with a median volume of 16 ml (1.5 to 35.9) were diagnosed 
in six patients in the RHA group (17%), one in the MoM THA group (4%) and six in the 
CoP group (18%). The classification systems revealed no clear differences between 
the groups. Solid lesions (n = 3) were exclusively encountered in the RHA group. Two 
patients in the RHA group and one in the MoM THA group underwent a revision for 
pseudotumour formation. There was no statistically significant relationship between 
clinical scoring, metal ion levels and periprosthetic lesions in any of the groups. 
Periprosthetic fluid collections are seen on MARS-MRI after conventional CoP 
THA and RHA and may reflect a soft-tissue collection or effusion. 
Currently available MRI classification systems seem to score these collections 
as pseudotumours, causing an overestimatation of the incidence of pseudotumours.
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INTRODUCTION
In recent years several studies1-3 have reported pseudotumour formation after metal-on-metal 
(MoM) total hip arthroplasty (THA). These studies raised concerns about the hazardous side-
effects of these bearings and resulted in official safety alerts and market withdrawal of some 
designs of resurfacing hip arthroplasty (RHA).4-6 These alerts included recommendations to 
screen patients with MoM bearings, using cross-sectional imaging such as ultrasound, CT 
and MRI. As a consequence, the presence of soft-tissue and fluid collections, muscle atrophy 
and oedema have been reported in relation to joint arthroplasties, which were not previously 
seen on conventional imaging.7-9 These lesions have subsequently also been described in 
asymptomatic MoM arthroplasties.1,7,10,11 The incidence of pseudotumour formation varies 
from 0.1% to 67%, and latterly it has increased.1-3,9-13 Various classification systems have 
been introduced to evaluate and quantify these lesions but their ability to differentiate 
between benign and pathological lesions is unknown.1,12,14,15 There is no consensus on the 
true incidence and clinical significance of many of the MRI findings which are generally 
referred to as pseudotumours. 
Studies on the incidence of pseudotumours using CT or MRI in arthroplasties of the hip 
other than those with MoM bearings are scarce.2,7 It could be hypothesised that identical 
periprosthetic lesions might be present on MRI in patients with bearings other than MoM 
and that these lesions could also be classified as pseudotumours by current classification 
systems. 
Our objective was to determine the incidence of periprosthetic lesions diagnosed by 
´metal artefact reducing sequence´-MRI (MARS-MRI) in patients from a closed randomised 
trial on RHA versus a 28-mm MoM THA, and to compare the findings with the incidence of 
periprosthetic lesions in a matched control group of asymptomatic patients with a ceramic-
on-polyethylene (CoP) conventional THA. Periprosthetic lesions were graded by three 
classification systems for pseudotumour given in literature.
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PATIENTS AND METHODS
For this study, all patients included in a closed randomised controlled trial (RCT) comparing 
RHA (n = 36) with a 28-mm conventional MoM uncemented THA (MoM THA) (n = 28)16 
were cross-sectionally analysed with MARS-MRI during follow-up. These patients were 
compared with a matched control group of patients with a CoP THA (n = 33). 
Patients enrolled in the RCT between June 2007 and April 2010 were randomly assigned 
by a computer-generated variable block to receive either a RHA or a MoM THA. This study 
was designed to compare the functional results and metal ion blood levels of patients after 
RHA versus MoM THA. One criterion for inclusion in the RCT was age < 65 years. Further 
details are given in the previous paper.16
As part of this study, all patients included in the RCT who had not undergone revision 
during the follow-up period were invited to complete questionnaires and undergo MARS-
MRI scans. They were matched by computer to asymptomatic patients with a primary CoP 
THA, without a prior infection, from a database of patients who underwent this procedure 
between June 2007 and April 2010 in the same hospital. Matching was performed on 
period of follow-up within a margin of three months and gender using a computer program 
(Mathlab 2012A, The MathWorks Inc, Natick, Massachusetts). 
Of the patients included in the RCT, six had required revision during follow-up. For 
these patients the prerevision MRI, when available (two of six), was analysed and scored 
according to an identical protocol by two radiologists (BW, MG) who were blinded to 
the cause of revision. The operation note of the revision surgery (four of six) was used for 
patients without an available MRI to determine whether a pseudotumour was considered 
to be present macroscopically. All revisions were performed by the senior author (JS) with a 
broad clinical experience in adverse reactions to metal debris. A summary of the inclusion 
and subsequent follow-up of patients in the RCT is given in the Consolidated Standards of 
Reporting Trials statement (Figure 1). 
Approval from the regional ethics committee from the Radboud University Nijmegen 
Medical Centre for the RCT was obtained (number LTC 419-071206, Committee Human 
Research number (CCMO) 2007/015; EudraCT trial register number 2006-005610-120). The 
original study did not include cross-sectional MRI screening or a matched control group. 
This was addressed with additional ethical approval (number LTC 939/190713, Committee 
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Human Research number NL 44703.091.13, registration number 2013/221). All patients 
provided informed consent. This study was performed in compliance with the Helsinki 
Declaration of 2008.17 
Figure 1. Consolidated Standards of Reporting Trials statement. 
RCT, randomised controlled trial; RHA, resurfacing hip arthroplasty; MoM, metal-on-metal; CoP, ceramic-on-
polyethylene; THA, total hip arthroplasty.
Invited for MRI (n = 34)
Refused to participate (n = 1)
Follow-up MoM THA (n = 33)
Discontinued follow-up (n = 5)
• Deceased (n = 2, one bilateral). No CT or 
MRI available.
• Revision (n = 3). Pre-operative MRI 
available in n = 0
Follow-up RHA (n = 38)
Discontinued follow-up (n = 4)
• Lack of motivation (n = 1, bilateral).   
No CT or MRI available.
• Revision (n = 3). Pre-operative MRI  
available in n = 2
Invited for MRI (n = 28)
Refused to participate (n = 3)
Imaging available MoM THA (n = 25)
• 24 MRI
• 1 CT due to contra-indication MRI (n = 1)
• 0 MRI before revision 
Additionally 3 operative reports
Total n = 28
Imaging available RHA (n = 35)
• 32 MRI
• 1 CT due to contra-indication MRI 
• 2 MRI before revision 
Additionally 1 operative report 
Total n = 36
Matched conventional CoP THA (n = 60). Matched variables: follow-up period and gender
 Refused to participate n = 10   Unable to trace n = 3 
 Contra-indication MRI n = 5   Unable to visit clinic n = 9
33 patients received MRI
Patients enrolled in a closed RCT comparing RHA with MoM THA
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All operations were performed through a posterolateral approach by an experienced 
surgeon (JS) who undertook > 100 THAs annually. The surgical details have been described 
previously.16 In the RHA group, a cobalt-chromium (CoCr) alloy RHA was implanted 
(Conserve Plus; Wright Medical Technology, Arlington, Tennessee) with a median femoral 
head diameter of 49 mm (42 to 54). In the MoM THA group, an uncemented tapered stem 
and a threaded titanium acetabular shell with a polyethylene insert and an integral metal 
liner was implanted (Zweymuller Alloclassic stem and Zweymuller Alloclassic CSF cup; 
Zimmer Orthopaedics, Warsaw, Indiana) together with a metal (CoCr) 28-mm head (Metasul; 
Zimmer Orthopaedics). The CoP THA group received an identical femoral component and 
acetabular shell but the latter was lined with a polyethylene insert and articulated with a 
ceramic 32-mm modular head (Biolox Delta, Zimmer Orthopaedics). All groups received 
identical antibiotic, thrombosis prophylaxis and rehabilitation programmes. 
Imaging studies were performed using a 1.5-T MR scanner (Philips, Best, Netherlands) 
and a 16-channel body coil. A standard MARS protocol was used with four sequences, 
transverse T1-weighted images, transverse T2-weighted images, coronal short tau inversion 
recovery images and coronal T2-weighted images. 
MRI was contraindicated in two patients. One in the RHA group had a neurostimulation 
device and one in the MoM THA group had a cochlear implant. These patients underwent 
CT scanning with a standard protocol on a 40-slice CT scanner (Brillance 40, Philips, Best, 
The Netherlands).
MRI and CT scans were interpreted by consensus between a musculoskeletal radiologist 
(MG) with ten years of experience and a radiologist with three years of experience (BW), both 
blinded to patient data and symptoms. Periprosthetic lesions were scored according to three 
classification systems; the Anderson score,12 the system of Hart et al1 and a system described 
by Boomsma et al13 (Table I). Lesions were considered to be a pseudotumour if the criteria of 
at least one of these systems was met: an Anderson score ‘C’,12 a Boomsma grade > III13 and 
every lesion that satisfied the criteria of Hart et al.1 The volume of the pseudotumour was 
calculated using post-processing software in our Picture Archive Communication System 
(Sectra, Linköping, Sweden) by outlining the circumference of the lesion on each slice. The 
inclination angle of the acetabular component was measured with reference to the inter-
teardrop line on standardised anteroposterior pelvic radiographs.
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All patients completed a Short Form-12 (SF-12), Oxford hip score questionnaire and 
a visual analogue scale (VAS) satisfaction score of 0 to 100 (worst to best). The Harris hip 
score18 and the University of California at Los Angeles activity scale19 were assessed by two 
members of the research staff (AH, PB) who collected and registered all the forms at the time 
of the MARS-MRI. Identical clinical outcome measurements were available pre-operatively 
and at six, 12, 24, 36 and 60 months for patients enrolled in the RCT. The latest available 
scores were used in those patients who underwent revision during follow-up. 
CoCr serum levels were available for the patients enrolled in the RCT, including the latest 
metal ion levels of all patients who underwent revision during follow-up. Blood samples 
were collected pre-operatively and at three, six, 12, 24, 36 and 60 months post-operatively. 
The latest available metal ion level was used. Samples were collected according to a strict 
protocol to eliminate any form of metal contamination and analysis was undertaken using an 
inductively-coupled plasma mass spectrometer. The details have been reported previously.16 
The results were quantitatively reported if concentrations exceeded the detection threshold 
of 0.5 μg/l. All values below the limit of detection were registered as 0.1 μg/l for the purposes 
of statistical analysis. 
Statistical analysis
The variables were tested for normal distribution using the Shapiro–Wilk test. Owing to a 
relatively small number of patients and an even smaller number of those with a pseudotumour, 
none of the variables had a normal distribution. Therefore, the median and range were 
used for all variables and non-parametric tests were used. Differences between two groups 
were determined by the Mann–Whitney U test and the Kruskal–Wallis test for analysis of 
more than two groups. A sub-analysis was performed on the relation between periprosthetic 
lesions on MRI and clinical scores. For this sub-analysis, the whole study population was 
split into a group with lesions graded as ‘pseudotumour’ by one of the classification systems 
and those without a periprosthetic lesion. Secondly, the same relationship was analysed for 
each type of arthroplasty separately. Differences were considered statistically significant 
with a p-value < 0.05. IBM-SPSS Statistics version 20.0 (IBM Corp., Armonk, New York) was 
used for statistical analysis. No power analysis was performed owing to the fact that the 
number of patients included in the RCT determined the total number of patients.
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Table I. Used classification systems by Anderson et al12, Hart et al1 and  
Boomsma et al13
Grade Description Criteria
Anderson et al grading system
A Normal or acceptable Normal post-operative appearances including seromas and small 
hematomas
B Infection Fluid-filled cavity with high signal T2 wall; inflammatory changes in soft-
tissue; ± bone marrow oedema
C1 Mild MoM disease Periprosthetic soft-tissue mass with no hyperintense T2W fluid signal or 
fluidfilled peri-prosthetic cavity; either less than 5 cm maximum diameter.
C2 Moderate MoM 
disease
Peri-prosthetic soft-tissue mass/fluid-filled cavity greater than 5 cm 
diameter or C1 lesion with either of following: (1) muscle atrophy or 
oedema in any muscle other than short external rotators or (2) bone 
marrow oedema: hyperintense on STIR
C3 Severe MoM disease Any one of the following: (1) fluid-filled cavity extending through deep fasci, 
(2) a tendon avulsion, (3) intermediate T1W soft-tissue cortical or marrow 
signal, (4) fracture
Hart et al grading system
1 Thin-walled Content: Fluid-like; hypointense on T1,hyperintense on T2. Shape: flat, with 
walls mainly in apposition
2a Thick-walled or 
irregular
Content: Fluid-like: hypointense on T1,hyperintense on T2. Shape: not flat, 
with > 50% of the walls not in apposition
2b Thick-walled or 
irregular
Content: atypical fluid: hyperintense on T1, variable on T2. Shape: any 
shape
3 Solid throughout Content: mixed signal. Shape: any shape
Boomsma grading system
I Normal or acceptable Thickening of capsule up to 4 mm to 6 mm
II Reactive Thickening of capsule of > 6 mm, but not more than the neck of the 
prosthesis, with or without bulging and without eccentric enlargement with 
respect to the capsule
III Mild MoM disease Consists of a bulging capsule both anteriorly and posteriorly
IV Moderate MoM 
disease
Represents eccentric bulging or enlargement of the capsule, which is often 
seen inferomedially to the prosthetic head
V Severe MoM disease Represents the so-called bursitis mimicker, often extending posterolaterally 
with extensive filling of the subtrochanteric bursa, or anteriorly by filling of 
the iliopectineal bursa, which can extend into the abdominal compartment
MoM, metal-on-metal; STIR, short tau inversion recovery
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RESULTS
The demographic data are summarised in Table II. Patients in the CoP THA group were 
significantly older than those in the RCT (p = 0.001, Kuskal–Wallis test).
 
Lesions classified as ‘pseudotumour’ or ‘MoM disease’ by any of the three MRI scoring 
systems were seen in six patients in the RHA group (17%), in one in the MoM THA 
group (4%) and in six in the CoP THA group (18%) (Figure 2). These differences were not 
statistically significant (p = 0.19, Kruskal–Wallis test). From the relatively small number of 
patients in each group, the statistical power of these findings is, however, limited. For that 
reason detailed information on all patients with a periprosthetic lesion, including clinical 
scores, acetabular component inclination, metal ion levels and the grading of the three MRI 
classification systems, is given in Table III.
Generally there were no differences in the grade of periprosthetic lesions between 
the three groups, as is shown in Table III. Relatively high grade ‘pseudotumours’ were 
encountered irrespective of the group and classification system. Two patients had a lesion 
that was not scored as a ‘pseudotumour’ or ‘MoM disease’ by all three classification systems. 
One patient in the RHA group and one in the CoP THA group was classified as having a 
Boomsma grade II lesion,13 which represented a reactive lesion. Solid lesions (n = 3) graded 
as a Hart et al1 grade 3, were exclusively seen in the RHA group.
The median volume of the lesions was 16 ml (1.5 to 35.9) with no statistical difference 
in volume between groups (p = 0.2, Kruskal-Wallis test). Lesions were seen in nine men and 
four women, but this gender difference was not significant (p = 0.29, Mann-Whitney U test). 
The median inclination angle of the acetabular component of patients with a lesion was 
44° (33° to 57°). Again no significant difference in this angle could be established between 
patients with or without a lesion on MRI (p = 0.20, Mann- Whitney U test).
Overall good clinical scores were seen without significant differences between the three 
groups (Table II). The only significant difference was in the median VAS satisfaction scores; 
this was significantly lower for the MoM THA group with a score of 85 (18 to 100) compared 
with 91 (0 to 100) and 95 (23 to 100) for the RHA and CoP THA groups respectively (p = 
0.045, Kruskal–Wallis test). More detailed information on the clinical scores at different time 
intervals for the patients in the RCT has previously been reported.16
6110
Figure 2. MRIs showing the compilation of typical lesions (indicated by arrow) graded 
as pseudotumour on the selected classification systems. 
Images a) and b) show a resurfacing hip arthroplasty graded Anderson C2, Hart 3 and Boomsma IV; and 
images c) and d) show a ceramic-on-polyethylene total hip arthroplasty graded Anderson C3, Hart 2a and 
Boomsma V.
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No statistically significant difference was encountered between the clinical scores and 
characteristics of the periprosthetic lesions overall (p ≥ 0.13, Mann–Whitney U test) and in 
the different prosthesis groups separately (p ≥ 0.07, Mann– Whitney U test). However, it is 
acknowledged that the groups are relatively small for statistical sub-analysis.
Revision because of a destructive pseudotumour occurred in two patients in the RHA 
group (5%) and in one in the MoM THA group (3%); all three at 36 months postoperatively. 
The remaining revisions were related to osteonecrosis of the femoral head in one patient in 
the RHA group and two with recurrent dislocation in the MoM THA group. MRI scans before 
revision for pseudotumour formation were available in both patients in the RHA group and 
were used for retrospective grading. Of the remaining four patients with a revision, one large 
destructive pseudotumour in a MoM THA patient was described in the operation notes as 
an unanticipated finding. This was the only pseudotumour encountered in the MoM THA 
group.
Median serum cobalt levels, including the levels in the six patients who underwent a 
revision for RHA and MoM THA, after a median of 55 months (36 to 72) and 56 months 
(23 to 69) were 1.3 ng/mL (0.1 to 22.1) and 0.8 ng/ mL (0.1 to 2.4), respectively. In contrast 
to cobalt, the difference in median serum levels of chromium was significant with 1.8 (0.1 
to 29.9) for the RHA group and 0.5 (0.1 to 2.6) for the MoM THA group (p < 0.001). No 
statistically significant difference was encountered between metal ion levels in patients with 
periprosthetic lesions and those without (Cobalt p = 0.06; Chromium p = 0.068, Mann–
Whitney U test). 
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Table II. Demographic data presented as medians with ranges RHA. 
RHA (n=36) THA MoM (n=28) THA CoP (n=33) p-value
Gender (males) 19 17 18 0.809
Age* (yrs) 57 (24.1 to 64.8) 59 (37.0 to 64.7) 63 (38.6 to 70.5) 0.001
Follow-up (mths) 55 (36 to 72) 56 (23 to 69) 54 (40 to 72) 0.861
Pseudotumour 6 1 6 0.194
HHS 98 (62 to 100) 100 (59 to 100) 97 (64 to 100) 0.616
OHS 14 (12 to 34) 14 (12 to 43) 13 (12 to 27) 0.426
VAS satisfaction* 91 (0 to 100) 85 (18 to 100) 95 (23 to 100) 0.045
UCLA 8 (3 to 10) 7 (4 to 10) 7 (4 to 10) 0.294
SF-12 physical component 100 (0 to 100) 100 (25 to 100) 75 (0 to 100) 0.244
SF-12 mental component 80 (50 to 100) 80 (30 to 100) 80 (40 to 100) 0.850
Cobalt serum (ng/L) 1.3 (0.1 to 22.10) 0.8 (0.1 to 2.4) NA 0.087
Chromium serum + (ng/L) 1.8 (0.1 to 29.9) 0.5 (0.1 to 2.6) NA <0.001
Cup angle (̊) 45 (30 to 62) 48 (31 to 62) 46 (31 to 60) 0.223
resurfacing hip arthroplasty; 
THA, total hip arthroplasty; 
MoM, metal-on-metal; 
CoP, ceramic-on-polyethylene; 
HHS, Harris hip score; 
OHS, Oxford hip score; 
VAS, visual analogue scale; 
UCLA, University of California at Los Angeles; 
SF-12, Short-Form 12; 
NA, not applicable
† Significant difference between the groups, Mann–Whitney U test
* Significant difference between the groups, Kruskal–Wallis test
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DISCUSSION
This study illustrates that periprosthetic lesions seen on MARS-MRI and classified as 
‘pseudotumours’ by currently available scoring systems, are not exclusively seen in 
MoM hip arthroplasties. We found the incidence of periprosthetic lesions to be equally 
distributed between the RHA (17%) and CoP THA (18%) groups, whereas these lesions 
were less commonly identified in the MoM THA group (4%). Solid periprosthetic lesions 
were exclusively seen in the RHA group, while all other lesions were bulging periprosthetic 
fluid collections. Nevertheless, the three classification systems graded most lesions as a 
‘pseudotumour’ or ‘MoM disease’. 
In recent years, numerous cross-sectional studies have described solid masses and fluid 
collections in patients with MoM implants. The masses and fluid collections were mainly 
classified as adverse reaction to metal debris, pseudotumour or MoM disease and have been 
reported in symptomatic and asymptomatic patients.1,2,7-10 Cross-sectional imaging studies 
on non-MoM bearings are, however, rare. Thus there remains some uncertainty about the 
clinical relevance of these findings. 
In 2011, Williams et al2 reported on pseudotumour formation in asymptomatic patients 
with either a RHA (n = 20), MoM THA (n = 31) or metal-on-polyethylene (MoP) THA (n = 
24) screened by ultrasound. In their study, 4% of the patients with a MoP THA had a cystic 
mass and 8% had an isolated fluid collection. This incidence was lower than that for MoM 
RHA (30%) and large head MoM THA (42%). 
Mistry et al7 reporting on ten patients with an asymptomatic MoP and 12 patients with 
a MoM bearing, who were screened with MARS-MRI at a mean follow-up of 46 and 70 
months, respectively, found eight periprosthetic fluid collections, of which one occurred in 
the MoP group. 
Periprosthetic lesions, quantified as pseudotumour or MoM disease using currently 
available MARS-MRI scoring systems were encountered in our study. The incidence and 
grades of these lesions were similar in RHA and the CoP THA, at 17% and 18% respectively. 
The lesions seen in our study were graded as ‘pseudotumour’ or ‘MoM disease’ when 
they met the criteria of at least one of the three classification systems. Every lesion was 
scored as an Anderson grade ‘C’12 varying from mild to severe MoM disease. Additionally, 
every lesion could be classified by the score of Hart et al1. One lesion in the RHA group 
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and one in the CoP group was scored as a Boomsma grade II lesion.13 These were the 
only two patients who were not graded as pseudotumour by all three scores. In an earlier 
study of Bisschop et al,10 only Boomsma grade IV and V lesions were considered to be 
clinically relevant. Applying a similar restriction to our study population, an incidence of 
pseudotumour of 11% in the RHA group and 12% in the CoP group would still have been 
encountered, once again resulting in similar incidences of pseudotumour. Obviously, the 
only solid lesions met were in the RHA group. However, perhaps only lesions scored as a 
Hart et al grade 3 are really clinically relevant. 
Owing to the similar incidence of periprosthetic lesions in the RHA and CoP groups, the 
question of whether all periprosthetic lesions which are identified are ‘real’ pseudotumours 
arises. Some fluid collection is normal after any kind of THA without any destructive 
characteristics and without signs of infection in patients with good function and without 
pain. This is illustrated by the fact that in spite of the high grading on the different MRI 
classification systems, nine of 13 periprosthetic lesions were small (< 25 ml) fluid collections, 
in the presence of good clinical results and low metal ion levels. Therefore, we feel that there 
is a need for better MRI classification systems to reflect clinically relevant pseudotumours 
where a high grade actually corresponds with pathological and clinically relevant lesions. 
The presence of solid lesions, muscle damage and thickened capsule should be emphasised 
in seeking to define clinically relevant pseudotumours, as has been previously suggested.20,21
There remains no consensus on the most appropriate way of following up patients who 
have undergone a MoM arthroplasty and the indications for cross-sectional imagining 
remain unclear. Concerning the form of imaging, ultrasound, CT and MRI are used. Garbuz 
et al22 showed that ultrasound and MARS-MRI performed equally well, with no significant 
difference in sensitivity or specificity between them. In addition to the uncertainty of which 
method of imaging should be adopted and the indications for cross-sectional imaging, the 
interpretation of the findings is also a matter of debate. Furthermore, the size of periprosthetic 
lesions changes over the course of time.23,24 Serial MRI may have an important role in 
differentiating benign from pathological lesions.
We acknowledge the limitations of our study. Revisions were included in the two 
randomised MoM implant groups to maximise the follow-up for possible pseudotumour 
formation. In contrast, the matched control group of CoP THA patients originated from a 
series without complications which may have resulted in some bias towards a better clinical 
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outcome in this group. However, the absence of major differences in clinical outcome 
between the groups suggests that this did not have a great influence.
Secondly, patients in the control group were significantly (p < 0.001) older than those 
in the RCT (Table II). Initially patients were matched on three parameters: follow-up, gender 
and age. However, because of the relatively young age of the patients included in the RCT 
and a limited number of patients in our database, we had difficulty matching on all three 
parameters. Nevertheless, the mean age was only five years greater in the CoP group than in 
the RHA group. In our opinion the length of follow-up is the most important parameter, since 
pseudotumours tend to develop over time. Accordingly, matching by age was relegated to 
the last criterion. 
Thirdly, grading the pseudotumours was performed by consensus without inter- or intra-
observer reliability scoring. We accept the possibility that the junior radiologist might have 
deferred to the judgement of the senior radiologist. Nevertheless, we note that clinically 
relevant studies on this topic have almost exclusively been performed using a consensus.1,10,25 
In addition, Chang et al26 found that there was only a moderate agreement (kappa 0.439) 
between two readers using the Anderson score.12 
Fourthly, the number of periprosthetic lesions encountered in each group was relatively 
low for statistical testing. Owing to the low numbers, no conclusions can be drawn on 
clinical scores and grade of the lesions between the different prostheses groups.
Finally, no histological matching of aseptic lymphocyte-dominated vasculitis-associated 
lesion scores with the imaging findings was available in the patients who underwent 
a revision. The combination of MRI and histology would probably have given a better 
reflection of the true incidence but with only six revisions in our series, no true correlation 
between MRI findings and histology would have been possible. 
We conclude that periprosthetic lesions can be identified in some arthroplasties of the 
hip with both MoM and CoP bearings when screened by MARS-MRI. A similar number 
of lesions in the RHA and CoP groups were graded as ‘pseudotumour’ or ‘MoM disease’ 
by three currently used systems of classification for pseudotumour. However, a substantial 
proportion of these lesions appear to reflect a benign collection of fluid or effusion without 
clinical significance. Despite the fact that pseudotumour formation after MoM arthroplasty 
of the hip remains a serious concern, currently available MRI scoring systems probably 
overestimate the incidence of clinically relevant pseudotumours post-operatively.
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CHAPTER 7
The absence of a metal-on-metal bearing 
does not preclude the formation of a 
destructive pseudotumour in the hip 
- a case report
Pepijn Bisseling, Timothy Tan, Zhen Lu, 
Pat A Campbell, Job L C Susante
Acta Orthop. 2013; 84 (4): 437–441.
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CASE
In 2009, a 62-year-old woman with rheumatoid arthritis and a total hip arthroplasty (THA) 
on the right (uncemented Ti-6AL7Nb stem combined with a Ti threaded cup, polyethylene 
inlay, and a 28-mm ceramic head; Zweymuller Alloclassic; Zimmer Orthopaedics, Warsaw, 
IN) implanted in 2006 presented with a left femoral neck fracture. A THA with a double-
mobility acetabular system (Avantage Double-Mobility Acetabular System; Biomet, 
Warsaw, IN) was implanted. An uncemented titanium-niobium (Ti-6Al-7Nb) stem was used 
(Zweymuller Alloclassic; Zimmer) with a 12/14 mm trunnion combined with an XXL (+10.5 
mm) 28-mm cobalt-chromium head with a 12/14 mm tapered bore (Biomet). The femoral 
head was introduced into the highly cross-linked, vitamin E-stabilized polyethylene bearing 
using a bearing press. An uncemented Ti HA-coated 52-mm acetabular shell was press-fitted 
in the socket and the large polyethylene femoral head was reduced into the metal articular 
surface. Postoperative recovery was uneventful, with normal wound healing. 
Two years after implantation, the patient was referred to our center by her rheumatologist, 
since a soft tissue mass adjacent to the left THA had been diagnosed by ultrasound. A 
standard AP pelvic radiograph revealed adequate positioning of both hip implants without 
any signs of wear or osteolysis. Subsequent MARS-MRI scanning confirmed the presence 
of a 6 × 9 cm soft tissue mass at the posterolateral aspect of the left greater trochanter 
(Figure 1). There were no signs of any soft tissue reaction around the contralateral THA. 
Figure 1. Standard AP radiograph (panel A) and MARS-MRI scan (panel B) 2 years 
after implantation of the left THA with a double-mobility acetabular component. 
Note the adequate implant positioning and fixation (A) and a 6 × 9 cm soft tissue mass (B) at the posterolateral 
side of the left femoral component. On the right, there were no signs of periprosthetic soft tissue reaction.
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CRP was 68 mg/L and ESR was 53 mm/h; both were elevated, but this was possibly 
related to her rheumatoid arthritis. An inductively-coupled plasma mass spectrometer (ICP-
MS) was used for evaluation of metal ion levels. Serum levels of chromium were below the 
detection level of 0.5μg/L, whereas cobalt serum levels were 5.7 μg/L. An aspirate of the hip 
joint was negative for bacterial or fungal growth. 
The patient was diagnosed as having a severe and early “adverse local tissue reaction” 
(ALTR) after a metal-on-polyethylene bearing THA with the taper as the potential source of 
the metal ion release. Two and a half years after implantation, a debulking procedure of 
the pseudotumour in combination with a one-stage revision of the femoral component was 
performed. 
Perioperatively, extensive tissue necrosis and partial destruction of the abductor 
mechanism were found in the absence of any macroscopic signs of infection. The acetabular 
component was well fixed. Both the femoral trunnion and bore of the head showed signs 
of black debris (Figure 2). The femoral component was revised to a cemented polished 
straight stem (Exeter; Stryker, Allendale, NJ) with a ceramic 28-mm head (also Stryker) and 
a new double-mobility liner (Avantage Double-Mobility Acetabular System; Biomet). At 
the revision operation, six tissue samples were taken for bacterial culture according to our 
protocol. All six samples were negative for bacterial growth.
The revision procedure was complicated by a deep infection that was unresponsive to 
lavage and prolonged antibiotic treatment. Two months after revision, all components had 
to be removed, resulting in a (temporary) Girdlestone situation.
The components were sent for retrieval analysis. Multiple samples of the periprosthetic 
tissues were processed in paraffin for routine histology. The histopathology of tissue samples 
revealed extensively necrotic material with only a focal cellular area of inflammatory cells 
containing macrophages, plasma cells, occasional foci of eosinophils, and several small 
perivascular lymphocytic aggregates (Figure 3). No polarizable materials or metallic debris 
were present in several tissue samples. The ALVAL score1 was 3 + 3 + (= 8/10, moderate). 
Overall, the histological profile was consistent with an adverse immunological reaction in 
the absence of visible wear debris.
The profile of the ball taper was measured using a coordinate measuring machine (Legex 
322; Mitotoyo, Aurora, IL). The dimensions of a perfect taper based on 6726 CMM points 
with a point spacing of 0.3 mm were determined using a least-squares method. The taper 
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had an angle of 5 degrees, 47 min, and 34 s. A contour map was generated using the 
deviations of the CMM points from the fitting taper (Figure 4). The CMM results indicated 
uneven areas of contact, but the amount of material that had been removed through wear or 
corrosion could not be determined without knowing the initial form of the parts. However, 
in combination with the microanalysis described below, it appears that the small degree of 
texture and color changes was consistent with mild corrosion. 
Figure 2.
A) Extensive necrosis at the greater trochanter area and destruction of the abductor 
mechanism.
B) Debulking of large amounts of necrotic and fibrotic tissue from the periprosthetic 
region. 
C and D) Macroscopic signs of corrosion products at the bore of the Co-Cr head 
(panel C) and at the trunnion of the femoral component (panel D). 
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Figure 3. 
A) Histological view of the soft tissue mass at the interface between the necrotic 
material (on the joint side) and inflammatory cells. Hematoxylin and eosin (HE), 40×. 
B) Enlargement of A with inflammatory cells consisting mainly of macrophages and 
lymphocytes along with plasma cells and eosinophils. HE, 200×. Several lymphocytic 
aggregates were observed at low magnification (panel C; HE, 40×) and at high 
magnification (panel D; HE, 200×).
The area of the stem trunnion that appeared discolored was examined by scanning 
electron microscopy (SEM) and energy-dispersive analysis of X-rays (EDAX) to identify the 
elements present. Organic material containing chromium and/or molybdenum consistent 
with corrosion products was identified within the machined grooves and in the deposited 
dark material outside the trunnion (Figure 5). Similar analysis performed on deparaffinized 
soft tissue sections failed to demonstrate any wear or corrosion products.
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Figure 4. 
A) 2-dimensional graphical representation of the same profile. The outer diameter of 
the CMM map is the portion of the taper closest to the stem (labeled Rim) and the inner 
diameter of the CMM image corresponds to the inner surface (labeled Bottom). Areas 
with differences in color intensity may be related to wear or corrosion from the original 
dimensions.
B) 3-dimensional map with the portion closest to the stem labeled Rim and the deepest 
portion of the taper closest to the bearing surface labeled Bottom. Note the uneven 
distribution of color, corresponding to differences in contact with the trunnion.
Figure 5. Material present on the trunnion of the femoral component (panel A) was 
investigated by EDAX, revealing chromium (Cr), molybdenum (Mo), and oxygen (O) 
peaks consistent with corrosion products (panel B). The organic material within the 
grooves containing chromium oxides is shown at approx. 30× (panel C) and 500× 
magnification (panel D).
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DISCUSSION
We describe a patient with a rapidly forming, large and destructive pseudotumour as a 
form of ALTR after a THA with a double-mobility metal-on-polyethylene bearing. The exact 
pathogenesis of periprosthetic adverse reactions is still unknown, but a frequently suggested 
hypothesis is the contribution of wear particles and ions from corrosion, particularly 
from articulating surfaces of MoM hip implants.1-4 However, any MoM connection in a 
total hip arthroplasty could theoretically be a source of metal debris and ions. These MoM 
connections are diverse, with increasing modular options. The exact origin of the metal debris 
is often obscure, with the combined use of modular MoM junctions and MoM articulating 
bearings in the same implant.5,6 Numerous authors have reported higher metal ion levels 
and incidences of ALTR after largediameter MoM total hip arthroplasty (THA) than after 
resurfacing hip arthroplasty (RHA) using identical articulation characteristics.6,7 The latter 
lacks any modular MoM junctions, which may explain the difference encountered. To date, 
there is very little literature available to explain the extent to which the taper contributes to 
the release of metal particles, corrosion products including ions, and ALTR.4,5,8-11
Our case is interesting, as the ALTR could only have been triggered by metal ion release 
from the head-neck taper junction since no other MoM articulating surface was used. ALTR 
can also be associated with polyethylene wear.12 However, in this case polyethylene wear 
was not a likely cause of the massive pseudotumour since the hip arthroplasty was only 
2 years in situ, which is a short time for abundant polyethylene wear to occur, and this is 
consistent with the lack of polyethylene debris in the tissues. 
Furthermore, the SEM and EDAX analysis showed corrosion products on the trunnion. 
Corrosion and wear at this modular head-neck junction can occur when a passive protective 
oxide film on the metallic surfaces is constantly disrupted by fretting and micromotion.13,14 
The extent of the corrosion process is affected by a number of factors, including the amount 
and quality of metallic junctions and forces that are projected on the junctions.14-17 In our 
case, several factors may have contributed to the release of metal corrosion products from 
the head-neck junction together with the rapid formation of a massive pseudotumour. First, 
the quality of the tapered head-neck junction may have been impaired by a subtle mismatch 
between components from different manufacturers. Both the head and neck had a 12/14 
taper, which indicates a gradual decrease in diameter from 14 mm to 12 mm. In contrast 
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to what is commonly believed, a 12/14 taper is not standard and can reveal subtle inter- 
and intra-manufacturer differences between components. In fact, it is the angle by which 
the taper goes from 14 to 12 mm that truly determines its profile. This angle is expressed 
in degrees, minutes, and seconds where 1 degree is made up of 60 minutes and 1 minute 
has 60 seconds. In our case, according to manufacturer-derived data, the implanted stem 
trunnion had a 12/14 taper with a 5-degree, 38-min, and 0-s taper, and the head had a 
5-degree, 42-min, and 30-s taper. The amount of manufacturing tolerance of these parts is 
not known but the ball taper was demonstrated by CMM to be 5 degrees, 47 min, and 34 s, 
which may reflect the allowable tolerance, the effect of wear or corrosion, or a combination 
of the two. Even a subtle angular mismatch between the trunnion and taper may have led 
to an incongruence of the head-neck junction, leading to increased wear and corrosion. 
The release of metal debris from a modular junction due to a mismatch of components from 
different manufacturers has recently been addressed by Chana et al.18 However, reports 
on release of metal debris from the head-neck junction are also available with the use of 
components from the same manufacturer.9 This may be related to the fact that for a given 
taper from one manufacturer, the angle may also differ by a few minutes of a degree within 
the accepted range of tolerance. This tolerance is generally higher for ceramic heads than 
for metallic ones as used in this case.19
Secondly, the corrosion may partly be explained by increased mechanical stresses on 
the head-neck junction. In a sense, the double-mobility acetabular system mimics the 
configuration of a large-diameter femoral head. An increase in head diameter may cause the 
frictional force between the articulating surfaces to produce a greater frictional torque at the 
head-neck interface and may facilitate mechanically assisted fretting corrosion. Similarly, 
when the articulating surface is medialized with a large-diameter head, the frictional torque 
may be increased on the taper junction due to the greater length of arm. Forces on the 
taper may be even further increased when longer necks are used. Brown et al. found a 
correlation between corrosion and the length of neck extensions.15 They concluded that 
longer head-neck extensions may be more susceptible to fretting and crevice corrosion 
because of instability at the interface. This was also confirmed in a study by Lavigne et al., 
where higher cobalt ion levels were seen in patients with longer sleeve lengths than in those 
with shorter lengths at 12 months of follow-up.20 In our case, the double-mobility system 
may have led to greater stresses on the taper junction according to the same principle that 
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applies to large-diameter head THAs. A +10.5-mm (XXL) extended head increased the lever 
arm and applied even greater forces to the taper junction. Although contact stress may 
account for the contour irregularities observed (Figure 4), corrosion may have occurred 
without the presence of contact stress, which makes it difficult to definitively attribute the 
contour irregularities to contact stress alone.
Apart from the relatively increased lever arm and the possible taper mismatch, important 
patient factors may also have had a role in the formation of this destructive pseudotumour. 
Unknown patient susceptibility factors or metal hypersensitivity could explain pseudotumour 
formation.1,21-23 In a study by Matthies et al., pseudotumours were common in patients 
with well-positioned prostheses and were not necessarily associated with high wear 
or high metal ion levels.22 Moreover, Hart et al. found that a considerable proportion of 
unexplained hip pain could not be related to either excessive wear or elevated metal ion 
levels.21 They proposed that a patient susceptibility factor caused at least a proportion of the 
hip arthroplasty failures. Our patient may have been more vulnerable to developing ALTR 
due to her history of rheumatoid arthritis. In addition, corrosion at the trunnion from her 
earlier contralateral THA may have alerted her immune system to the metal debris released 
at the pseudotumour side. The rapid formation of the mass, the impressive surgical and 
histological findings in the surprising absence of substantial wear, and only moderate levels 
of ions may be explained by heightened sensitivity. The histological evaluation was based 
on only a small area of viable tissue but the features were comparable to several other cases 
with low wear-related pseudotumours attributed to metal allergy.1 Although rheumatoid 
arthritis and metal hypersensitivity share lymphocytic predominance as a characteristic 
immunohistological feature, no studies have supported the association between rheumatoid 
arthritis and ALTR. However, given the profound immune response in rheumatoid arthritis, it 
is conceivable that rheumatoid arthritis may enhance the development of ALTR. 
Finally, an Alloclassic uncemented titanium-niobium (Ti6A/7Nb) stem was combined 
with a cobalt-chromium (Co-Cr) articulating prosthetic head. Differences in electrical 
potential may cause galvanic corrosion when two different metals are in contact in an 
electrolyte solution.14 There is evidence that mixed-alloy combinations are associated 
with a higher corrosion incidence than similaralloy combinations.8,16,17 However, the role 
of galvanic corrosion in the latter is still debated, whereas the electrochemical gradient 
between Co-Cr and Ti alloys is said to be small.24 In our patient, the fact that there were 
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relatively low chromium ion levels (0.5 μg/L) relative to cobalt levels in serum (5.7 μg/L) 
makes it likely that there was corrosion. 
In conclusion, we believe that several factors have had a role in the development of 
a severe ALTR in our patient. It is most likely that we were confronted with a profound 
patient-related immunological response to a moderate amount of metal debris and 
corrosion products from the mismatched head-neck junction. One should be aware that, 
with or without a MoM articular bearing, the head-neck junction may also be a source of 
metal debris and corrosion products and can then trigger the development of ALTR. In spite 
of the fact that there are also subtle taper mismatches between components from the same 
company, mixing components from different companies should be avoided if possible.
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CHAPTER 8
Summary and general discussion
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SUMMARY AND GENERAL DISCUSSION
The objective of this thesis was to focus on the clinical results of a prospective randomised 
clinical trial that compared a metal-on-metal (MoM) resurfacing hip arthroplasty (RHA) to 
a MoM small-diameter head conventional type of total hip arthroplasty (MOM THA). In 
addition, it aimed to enhance understanding on the potential adverse reactions related to 
MoM bearings, together with the evaluation and interpretation of both metal ion analysis 
and cross-sectional imaging. Seven objectives were formulated. The objectives are discussed 
in this summary, which is divided into two sections that discuss the ‘clinical results’ and the 
difficulties that are encountered when screening for ‘Adverse Reactions to Metal Debris’ 
(ARMD)’ respectively.
Clinical results 
1. Determination of the effect of preference bias for a specific implant on 
satisfaction and short-term clinical outcomes. 
In the early years of the 2000s, the global demand for RHA rose, which led to the accelerated 
introduction of several brands of RHA on the market and a rise in their use.1 However, long-
term clinical results on many of the implants were lacking. The potential disadvantages, such 
as a more technically demanding procedure, the occurrence of excessive metal ion release 
and ARMD were less widely specified.2-4 In order to evaluate the clinical results of the RHA, 
a randomised clinical trial was set up, in which the RHA was compared to a MoM THA. 
A randomised trial is the ideal instrument for an objective comparison between two different 
implant types. As in this thesis, a new implant, such as a resurfacing implant, is compared 
to a ‘golden standard’ - a conventional type of MoM THA. By randomisation, the effects 
of potential confounding factors are minimalised, such as preference bias. Nevertheless, 
at time of the study start-up, it proved to be extremely difficult to include patients due to 
the randomisation between RHA and MoM THA. At that time, the RHA was marketed as 
a ‘sports’ hip, and an ideal solution for young and active patients. Young patients, who 
visited the orthopaedic outpatient clinic and were candidates for a total hip arthroplasty 
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were invited to participate in the randomised clinical trial. Even after being informed of the 
absence of any evidence in literature about the benefits of RHA over a conventional THA, 
patients tended to have a profound preference for RHA and often declined participation in 
the randomised trial. Patients with a profound preference for RHA, who declined inclusion 
in the study, were invited to participate in a cohort of patients with an identical follow-up 
to the randomised clinical trial. It is questionable if the patients included in the cohort were 
biased for subjective clinical scores due to their profound preference. The presence of a 
cohort of patients with a clear preference for RHA and a group of patients allocated to RHA 
after randomisation with an identical study set-up, provided the opportunity to gain some 
insight into the possible role of ‘preference biases’ on the outcome of the same surgical 
procedure. 
Chapter 2 presents the results of the prospective comparative study. Results on patient 
satisfaction and early clinical outcome in ‘biased’ patients with a high preference for RHA 
(the ‘Preference’ Group) did not differ with any statistically significance from the results 
obtained from ‘unbiased’ patients, who were simply allocated to a RHA after randomisation 
(‘Randomised’ Group). Nevertheless, there was a trend toward a better satisfaction in 
the ‘Preference’ Group. A statistically significant difference between groups was only 
encountered specifically for the preoperative Short Form-12 values, for the mental subscale 
in particular, with this in favour of the ‘Randomised’ Group. 
Despite the fact that the potential bias from treatment preferences is a well-recognised 
phenomenon in orthopaedic practice, there have only been a few studies dealing with 
this clinical dilemma. The results of this study contradict with a meta-analysis, in which 
preference for a specific treatment among patients in musculoskeletal trials was associated 
with treatment effects.5 The difference between this study and the meta-analysis might be 
caused by a slightly different situation, in which the decision to operate is already satisfactory 
for many patients. This may differ for trials that compare operative- with conservative 
therapies, in which compliance with a therapy is another factor. This is supported by the 
fact that in this study, both ‘Preference’ and ’Randomised’ Groups showed high satisfaction 
scores.
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2. Obtaining an objective comparison between the clinical results of 
a metal-on-metal resurfacing hip arthroplasty and a small-diameter 
head metal-on-metal total hip arthroplasty at mid-term follow-up. 
The clinical results of the randomised clinical trial that compared RHA and a MoM small-
diameter head THA (MoM THA) after a three- to five-year follow-up are given in Chapter 3. 
From June 2007 until January 2010, 71 patients under the age of 65 years were randomly 
assigned to receive either a Conserve® Plus RHA (Wright Medical Technology, Arlington, 
Tennessee, USA) (n=38) or a 28-mm metal head Zweymuller® Classic Metasul® THA 
(Zimmer Orthopaedics, Warsaw, Indiana, USA) (n=33). All patients reached the 36 month 
follow-up point, and approximately 50% of the patient participated in a five-year follow-
up. As expected, the functional results showed a highly significant improvement in the 
postoperative five years for both RHA and MoM THA. The Visual Analogue Scale (VAS) for 
satisfaction, Oxford Hip Score (OHS) and University of California Los Angeles activity score 
(UCLA), revealed a significant difference in favour of the RHA Group at some short term 
time intervals, but this difference resolved at further follow-up. In general, it seems that the 
RHA patients performed slightly better than the MoM THA patients in the first two years after 
surgery, but after three years, no major clinical significant differences in functional outcome 
could be demonstrated. These findings correspond with earlier studies that also found some 
significant differences in favour of the RHA at short term, but no significant differences at 
mid- or long-term follow-up.6,7 
Concerning the survival of both implants, at five year follow-up, six patients were re-
operated; three in the RHA group (8%) and three in the MoM THA group (9%). At two 
year follow-up, two MoM THA patients underwent a relatively simple insert exchange for 
recurrent dislocation, and one RHA patient had a femoral component revision, because of 
early aseptic loosening from avascular necrosis. The other three re-operations were related 
to adverse reactions to metal debris (ARMD).
Until a two year follow-up, no revisions for ARMD, or pseudotumours, as they are generally 
referred to, had occurred. Various serious adverse reactions to MoM bearings have been 
reported in literature in the years after reintroduction. These have included implant-
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induced hypersensitivity reactions, osteolysis, soft tissue necrosis and solid or fluid-filled 
pseudotumours.8-11. The reported prevalence of the pseudotumours range from 0.1% to 
67% and seems to increase latterly.12-14 Due to these reports, a peak of revisions due to 
pseudotumour formation was feared in the randomised clinical trial in the period after 
two-year follow-up. However, this turned out to not to be the case (Chapter 3). At three-
year follow-up, three patients, one MoM THA and two RHA patients had a symptomatic 
pseudotumour that mandated revision to an alternative bearing. Interestingly, one of these 
pseudotumours was encountered in the conventional MoM THA group. The occurrence of 
pseudotumours in this group is rather remarkable, since pseudotumours in patients with a 
28-mm MoM THA are not commonly described in literature. Two studies reported a 0.5–
1.8% revision rate, because of ARMD after a 28-mm diameter head MoM THA in a period of 
up to ten-year follow-up.15,16 In this study, one pseudotumour out of 33 patients implicated 
a prevalence of 3% in a period of up to five-year follow-up, which is rather high, when 
compared to the numbers given in literature. 
 
In contrast, the prevalence of pseudotumours in patients with a RHA (5%) encountered in the 
randomised clinical trial is relatively low compared to the prevalence given in literature that 
rose up to 67%.12,14 However, it has to be noted that cross-sectional imaging was not a part 
of in this study. This may explain the relative low number of encountered pseudotumours. 
Cross-sectional imaging was performed in a subsequent study, and is presented in Chapter 6.
The true incidence, pathogenesis and clinical significance of adverse reactions registered 
as ARMD remains indistinct. This is influenced by the fact that the pathogenesis is affected 
by a variety of factors, such as wear, implant design, size, positioning and patient specific 
characteristics that differ between reports. Moreover, there is still no clear definition of 
clinical relevant pseudotumours or ARMD. As a result, the prevalence of pseudotumours 
given in literature is rather widespread. 
Screening methods for Adverse reactions to metal debris
Due to the occurrence of ARMD, several guidelines were developed to for the screening of 
patients with a MoM bearing. These guidelines generally recommend: clinical evaluation; 
metal ion analysis; and cross-sectional imaging. The analysis of metal ions was included 
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in the guidelines driven by studies that related the evolution of ARMD to elevated metal 
ion levels in patients with a MoM implant.8,9,17 Moreover, it is proposed that cobalt and 
chromium levels correlate with linear and volumetric wear, and can function as an indicator 
of bearing performance and wear.18,19 The metal ions can be detected in various matrices, 
such as whole blood, serum and urine after implantation of a metal-on-metal bearing 
implant. Since urine sampling requires a 24-hour collection, and levels seem to be more 
variable due to variation in hydration of the patient, whole blood and serum are preferred. 
Patients enrolled in the randomised clinical trial were evaluated for metal ion concentrations 
in whole blood and serum at regular intervals.
3. Determination of the difference in metal ion release between a large-
diameter head resurfacing arthroplasty and a small-diameter head 
total hip arthroplasty. 
A prospective follow-up of cobalt- and chromium ion levels in whole blood and serum 
in a group of patients with an RHA versus a small-diameter head MoM THA is presented 
in Chapter 3. Both the RHA- and the MoM THA Groups revealed a chronological curve 
of cobalt and chromium blood levels, representing an increase during a running-in phase 
of one year and stabilising (cobalt) or decreasing (chromium) afterwards. Regardless, the 
implant group median metal ion levels remained well-below the safety cut-off level of 2.0 
μg/l for cobalt and chromium given by the Dutch Orthopaedic Association (NOV), and far 
below the limits given by the United Kingdom’s (UK’s) Medicines and Healthcare products 
Regulatory Agency (MHRA) (cobalt 119 nmol/l = 7.0 μg/l; chromium 134.5 nmol/l = 7.0 
μg/l).20,21 Within the safety zone of below 2.0 μg/l, overall cobalt and chromium levels were 
significantly higher for the RHA group. This difference tended to fade at five-year follow-
up, when RHA levels tended to decline. For chromium especially, a gradual decrease with 
longer follow-up in both groups was observed. Unlike some reports on a variety of RHA 
devices, the metal ion levels in both the RHA and MoM THA groups appeared to be rather 
low.22,23 Implant-related factors and component positioning are believed to play an essential 
factor in the metal ion levels encountered.
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4. Determining if metal ion concentrations in whole blood and serum 
can be used interchangeably, and if a formula can give a reliable con-
version from serum to whole blood.  
Metal ion level measurements were proposed as an indicator for wear and implant 
malfunctioning, and it was expected that orthopaedic surgeons would be able to interpret 
them. The interpretation was, however, obscured by an absence of a consensus in literature 
on the superiority of measurements in whole blood over serum or vice versa. Furthermore, 
cut off points are not always specified as levels in serum or whole blood. Since metal ion 
levels between both matrices differ, it is important to know if whole blood and serum can 
be used interchangeably.
In Chapter 4, an analysis into if metal ion concentrations in whole blood and serum could 
be used interchangeably was performed and if a formula could give a reliable conversion 
from serum to whole blood. Patients from the randomised clinical trial were combined 
with patients of the cohort with a high preference for RHA (Chapter 2), resulting in a group 
of 60 RHA and 32 MoM THA patients. A total of 343 serum- and whole blood samples 
were available for analysis. The mean cobalt serum levels were slightly lower or equivalent 
to whole blood represented by a mean difference of +0.13 μg/l (95%-CI:0.03;0.22). The 
opposite holds for chromium, in which serum levels were relatively higher compared to 
whole blood, indicated by a mean difference of -0.91 μg/l (95%-CI:-1.05;-0.77). Based on 
these differences and the wide limits-of-agreement of the Bland-Altman plot (Cobalt +1.5 
μg/l and -1.25 μg/l; Chromium +0.95 μg/L and -2.85 μg/l), it appears that the two blood 
fractions cannot be used interchangeably.
Formulae to convert whole blood values into serum values were generated from the available 
data (Chapter 4). 
Cobalt in whole blood = 0.34 + (0.88*cobalt in serum) 
Chromium in whole blood = 0.14 + (0.58*chromium in serum). 
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These formulas could not be validated from the study’s own data and an additional database 
was not available. To reach limits of agreement, a new formula was generated on half of 
the data and tested on the other half. This new formula provided limits of agreement of 
+0.77 μg/l and -0.84 μg/l for cobalt and +0.92 and -0.98 μg/l for chromium. However, the 
formula was obtained from testing only on a homogeneous group of patients and requires 
verification on external data and a more heterogeneous group before it can be used in 
practice. Nonetheless, the conversion formula could offer reassurance to the clinician in 
interpretation of metal ion levels if only serum levels are available and vice versa, accepting 
a prediction error of less than 1.0 μg/l. 
From the data used, whole blood cannot be recommended over serum or vice versa. From 
a practical perspective, the use of whole blood may be preferred, since whole blood can 
be sent to the laboratory without separation of serum. Obtaining an adequate and reliable 
measurement of ultra-low levels of metal ions is a delicate process and is susceptible 
to potential contamination. The separation of serum from whole blood can introduce 
contamination into the sample, which can result in an incorrect high metal ion test result. 
Alongside contamination and implant-related factors, metal ion levels may also be influenced 
by patient specific factors, such as renal excretion. Moreover, high levels can also be related 
to other sources of metal ion release, such as; mechanical heart valves, orthodontic implants, 
medical or nutritional supplements containing metal ion ‘equivalents’, or environmental or 
occupational sources of metal contamination. All of these confounding factors should be 
taken into consideration when confronted by high metal ion levels.
The potential toxic risk of high metal ion levels remains a point of debate. The carcinogenic 
potential, generalised hypersensitivity reactions, cardiomyopathy, neurological damage, 
hypothyroidism, renal impairment and a change in psychological status, have all been 
suggested to be associated with elevated metal ion levels, but others question the risks and 
state that solid epidemic studies are missing.24-28 
Despite the lack of evidence on the potential toxic effect of high metal ion levels, it is 
important for clinical practice to know if measured metal ion levels are within acceptable 
levels. A uniform international consensus on acceptable metal ion levels is, nevertheless, 
8Sum
m
ary and general discussion
143
lacking. Several national- and international regulatory bodies and orthopaedic societies 
have defined their own metal ion reference values. The MHRA has established its own 
acceptable limits at 7.0 μg/l (for cobalt and chromium), and the NOV has defined the 
safety cut-off at 2.0 μgl (for cobalt and chromium) and warrants close follow-up for values 
between 2.0-5.0 μg/l.20,21 These proposed limits are generally based upon available literature 
on metal ion levels and clinical results rather than on toxicity. As per the study of Van der 
Straeten et al. metal ion levels in patients with a well-functioning RHA were compared to 
malfunctioning RHA. In the well-functioning group, metal ions levels were lower than the 
poorly functioning group ion levels. Acceptable upper levels in serum were defined at 4.6 
μg/l and 4.0 μg/l for chromium and cobalt respectively, for unilateral RHA. Metal levels 
higher than these proposed safe upper limits were associated with failing RHA or ARMD. 
The specificity of these levels in predicting poor function was high (95%), but the sensitivity 
was low (25%), which is supported by other studies.29-31 This makes the follow-up of metal 
ion levels even more confusing. It implies that clinicians cannot solely rely on metal ion 
level measurements, as a screening measure for failing MoM prostheses or ARMD. A trend 
of metal ion levels may be more predictive in for the occurrence of ARMD.
The controversy on the role of metal ion levels in the occurrence of ARMD and failing 
implants is a result of the fact that the exact pathology of pseudotumour formation is far 
from fully understood. A toxic reaction to an abundant volume of metal particles, as well 
as a delayed hypersensitivity reaction to these particles has also been given as a causative 
factor.9 With a hypersensitivity reaction, metal ions do not have to be elevated beyond 
toxic levels in order to cause a soft-tissue reaction. As per the study (Chapter 3), two out 
of the three revisions for a pseudotumour had relatively low metal ion levels (<2.0 μg/L). 
The small number of encountered pseudotumours in this study made it impossible to 
draw any conclusion on an absence of possible correlation between metal ion levels and 
pseudotumour formation.
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5. Defining if concerns on metal ion release after MoM hip arthroplasty 
can be extrapolated to a metal-on-metal discus arthroplasty in the 
lumbar spine. 
The elevated metal ion levels and the adverse reactions to metal ion debris after a MoM hip 
arthroplasty raised concerns amongst hip surgeons and led to official alerts and guidelines 
of medical authorities. These concerns were not extrapolated to other orthopaedic metal-
on-metal arthroplasties elsewhere in the body, such as a MoM total disc arthroplasty used 
in the lumbar spine. A total disc arthroplasty (TDA) is a surgical procedure used to treat 
degenerative disc disease and some designs use two metal plates that articulate as a ball-
in-socket. As in MoM hip arthroplasty, it is conceivable that this MoM articulation can also 
elicit detectable metal ion concentrations in blood and can led to ARMD. By comparison, 
very little attention has been paid to this phenomenon in spinal surgery. Chapter 5 presents 
a study, in which it is questioned if concerns on elevated metal ion levels in MoM hip 
arthroplasty should be extended to a MoM TDA used in the lumbar spine.
Metal ion levels in whole blood and serum were analysed in four groups of patients; (1) 
patients with a TDA of the lumbar spine, (2) RHA, (3) 28-mm diameter MoM THA and (4) a 
control group without a MoM implant. Metal ion levels were measured in patients with a TDA 
at a median follow-up of 34.5 and at exactly 12 months for the both hip arthroplasty groups. 
Metal ion levels in the TDA group were significantly lower than those after resurfacing or 
MoM THA. Patients with a well-functioning single-level TDA appeared to have cobalt and 
chromium levels that were in most cases similar to those measured preoperatively in control 
patients without any form of MoM implant. Only cobalt levels in whole blood showed a 
significant median increase to 0.6 μg/l after a TDA, which is just above the detection limit 
of 0.5 μg/l. 
The fact that the metal ion levels were remarkably low may suggest that the amount of wear 
debris from a well-positioned TDA is relatively low. Earlier reports estimated the wear debris 
from a Maverick TDA to be between 0.38-0.44 mm3 per year, compared with 1-5 mm3 for a 
MoM hip replacement.32,33 This difference in wear is almost certainly due to the fact that the 
kinematics of a TDA, such as loading, shear forces, contact area and range of movement, 
8Sum
m
ary and general discussion
145
are profoundly different from those of any hip replacement. The range of movement in a 
TDA is relatively limited, and the shear forces are rather low, due to the contained position 
of the device. This will result in lower friction of the articulating surfaces and reduced wear. 
In conclusion, there is only limited cause for concern, as in this study the post-operative 
metal ion levels were significantly lower after TDA than after THA and RHA, and were 
generally comparable to those the general population. However, since the sensitivity of 
metal ion analysis in MoM hip arthroplasty is proven to be low and the exact pathology 
of pseudotumour formation is far from fully understood surgeons should be cautious and 
screen their patients at regular intervals or in case of complaints.
6. Determining if periprosthetic lesions, as seen on MRI, and classified 
as pseudotumours are exclusively seen around metal-on-metal hip 
implants. 
The complex interaction between implant and patient related factors makes it hard to find 
a sensitive and specific screening method for ARMD. Generally, the developed guidelines 
recommended clinical evaluation, metal ion level determination and cross-sectional 
imaging such as ultrasound, CT and MRI. Metal ion analysis seems to have high specificity, 
but low sensitivity.29-31 For cross-sectional imaging, this is less specified. Cross-sectional 
imaging of the hip frequently reveals soft-tissue and fluid collections, muscle atrophy and 
oedema, in relation to MoM joint arthroplasties, mostly classified as pseudotumours. The real 
significance of the lesions is, nevertheless, uncertain, because identical series on bearings 
other than metal-on-metal are scarce. It is questionable if all lesions seen on cross-sectional 
imaging of are actual, destructive pseudotumours, or if a part is actually physiological, and 
also seen in total hip arthroplasties other than MoM bearings.
Chapter 6 focuses on the prevalence of periprosthetic lesions diagnosed by metal-artefact-
reducing sequence-MRI (MARS-MRI) in patients with (1) a RHA, (2) small-diameter 
MoM THA and (3) an asymptomatic group of patients with a small-diameter ceramic-on-
polyethylene (CoP) THA. All depicted lesions were graded by three recognised classification 
systems for pseudotumours given in literature.
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The study presented in Chapter 6 illustrates that periprosthetic lesions seen on MARS-MRI 
and classified as pseudotumours by currently available scoring systems, are not exclusively 
seen in MoM hip arthroplasties. Surprisingly, the prevalence of periprosthetic lesions was 
equally distributed between the RHA (17%) and CoP THA (18%) groups, whereas these 
lesions were less commonly identified in the MoM THA group (4%). Solid periprosthetic 
lesions were exclusively seen in the RHA group, while all other lesions were bulging 
periprosthetic fluid collections. Nevertheless, the three classification systems graded most 
lesions as a ‘pseudotumour’ or ‘MoM disease’ with relatively high grading. 
Owing to the similar prevalence of periprosthetic lesions in the RHA and CoP groups, the 
question arises of whether all identified periprosthetic lesions are ‘real’ pseudotumours 
with clinical significance or not. Some fluid collection, in absence of any destructive 
characteristics, without signs of infection, in patients with good function and without pain, 
seems to be normal after any kind of THA. This is demonstrated by the fact that despite the 
high grading on the different MRI classification systems, nine of 13 periprosthetic lesions 
were small (< 25 ml) fluid collections, in the presence of good clinical results and low 
metal ion levels. Currently used classification systems seem to overestimate the prevalence 
of pseudotumours depicted by MARS-MRI. A better MRI classification system is required 
to reflect clinically relevant pseudotumours, in which a high grade actually corresponds 
with pathologically- and clinically relevant lesions. The presence of solid lesions, muscle 
damage and thickened capsule should be emphasised in seeking to define clinically relevant 
pseudotumours. Furthermore, the size of periprosthetic lesions changes over the course of 
time.34 Serial MRI may have an important role in differentiating benign from pathological 
lesions. 
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7. A case report of a patient with a destructive pseudotumour in the 
absence of a metal-on-metal bearing.
The occurrence of ARMD seems to be a multifactorial process. As in these studies, there is 
no clear relation between metal ion levels and pseudotumour formation (Chapters 3 and 6). 
These findings are supported by other studies, in which the extent of tissue destruction at 
revision surgery did not appear to be dose-related to the volumetric wear.19,35 There seems 
to be another factor that can be sought in patient-related immunological responses.11,36 In 
addition, it is not only the bearing surface that is prone to wear and the products of corrosion. 
Corrosion and wear can occur at any given MoM junction, when a passive protective oxide 
film on the metallic surfaces is constantly disrupted by fretting and micro-motion.37,38 The 
extent of the corrosion process is affected by a number of factors, including the amount and 
quality of metallic junctions and forces that are projected on the junctions.38-40
In Chapter 7, a case report is presented of a patient with a rapidly forming, large and 
destructive pseudotumour after a THA with a double-mobility metal-on-polyethylene 
bearing. Serum levels of chromium were below the detection level of 0.5μg/L, whereas 
cobalt serum levels were 5.7 μg/L. The pseudotumour could only have been triggered by 
metal ion release from the head-neck taper junction, since no other MoM articulating surface 
was used. This case report clearly demonstrates that the bearing surface is not the only 
source of ARMD. As components from different manufacturers were used, a subtle, angular 
mismatch between the trunnion and taper was created. Consequently, this incongruence 
may have led to increased wear and corrosion. 
Metal ion debris release from the head-neck taper junction is not exclusively seen in 
cases of mismatch. The release from the taper-head junction also seems to play a major 
role in the high incidence of ARMD in patients with a large-diameter head (LDH) MoM 
total hip arthroplasties. Numerous authors have reported higher metal ion levels and 
incidences of ARMD after LDH MoM THA, than after RHA using otherwise identical bearing 
characteristics.41,42 The latter lacks any modular MoM junctions, which may explain the 
difference encountered. In the presented case, the double-mobility system may have led to 
greater stresses on the taper junction according to the same principle that applies to LDH 
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MoM THAs. An increase in head-diameter causes an increased frictional force between 
the articulating surfaces and increases the length of arm, which may all induce a greater 
mechanical stress on the head-neck junction. Several reports are now available that explain 
the extent, to which the taper contributes to the release of corrosion products and ARMD.43-45
The reports on higher metal ion levels and incidences of ARMD after LDH MoM THA and the 
presented case report confirm that not all MoM hip arthroplasties can be ‘lumped together’ 
when analysing the incidence or ARMD. It is of great importance to define the brand and 
type of MoM implant. An RHA, LDH MoM THA (>36 mm diameter) and small-diameter 
head MoM THA of any given brand has its own characteristics. Prostheses vary in (1) the use 
of cast or forced material, (2) heat treatment, (3) radial clearance, (4) arc of coverage, and (5) 
angle of function of the femoral component, that all influence the wear, metal ion release 
and failure rates.19 Due to subtle differences of design, some implants seemed to have a very 
narrow arc of optimal component positioning.46,47 The acetabular positioning seems to be 
a particularly important determinant in implant failure rate. A high acetabular inclination 
is associated with edge-loading (contact between the femoral and acetabular components 
occurs at the edge/rim of the acetabular component wear) and the occurrence of adverse 
reactions.48-51 
Once again, it must be emphasised that all prostheses have their own successes and 
failures, and surgical technique is a key factor for success. The prostheses used in this study, 
together with the Birmingham Hip Resurfacing, turned out to be a prosthesis with a rather 
successful ten-year follow-up.1,52 The results of this study, therefore, cannot for that reason 
be extrapolated to all RHAs and small-diameter MoM THAs.
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GENERAL DISCUSSION
At the time of its reintroduction, the RHA was extensively promoted as a good alternative 
to the conventional type of THA for young and active patients due to its stability and wear 
characteristics. The RHA was assumed to be a new hip implant that would, in contrast to the 
conventional THA, last a lifetime. This thesis is based on a prospective randomised clinical 
trial of young patients with an RHA, who were compared to patients with a conventional 
type of MoM THA. 
In conclusion, it can be stated that both groups showed highly satisfied and well-functioning 
patients, with only some significant differences in clinical score in favour of the RHA group 
at short to mid-term follow-up. Moreover, the RHA seems to be a proven, mechanically 
stable concept, with no dislocations during follow-up. However, it can be discussed if these 
advantages are clinically relevant and if they are worth the risks of elevated metal ion levels 
and any form of ARMD. In addition, the thesis illustrates the difficulties in interpretation of 
metal ion analysis, cross-sectional imaging and its classification systems, and difficulties in 
determination of the source of ARMD.
Once again, it must be emphasised that this thesis focussed on a single brand of RHA 
(Conserve Plus®, Wright Medical), that appeared to have a relative low frequency of ARMD 
and rather satisfactory survival.1,52,53 In addition, operations were carried out by a limited 
number of experienced hip surgeons, who may have played a role in the relatively good 
outcome, as it is recognised that the surgical technique is important to obtain a good 
outcome in hip resurfacing. 
National- and international joint registries reveal a clear difference in survival between 
RHA, MoM LDH THA and THAs of any other bearing combination. The number of revisions 
of RHA is significantly higher compared to any other kind small-diameter head THA, with 
a profound difference between men and women. The Dutch Arthroplasty Register (LROI) 
reported a five-year RHA failure rate of 5.3% for men and 13.5% for women compared 
to an average of 3.5% and 3% for men and women respectively in any other type of 
bearing.1 However, there are several factors that must be taken into account in evaluating 
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these numbers. Firstly, the adverse reactions to metal-on-metal bearings caused a general, 
global fear of metal-on-metal implants. Moreover, there were recalls for specific implants. 
The fear of adverse reactions, and inevitably, the subsequent fear of possible lawsuits, may 
have resulted in revisions of asymptomatic patients without clinically significant ARMD. 
Additionally, all types of metal-on-metal implants are often bundled together in the 
registries. As is known from literature, there are RHAs from specific brands, such as the 
ASR, that functioned very badly and have a significantly higher reported failure rate.1,44 
Finally, it must be noted that, in general, the RHA was promoted as an alternative for THA 
in young patients. Consequently, the average age of the patients with an RHA is much 
lower, as presented in this thesis. Obviously, this patient group has a higher failure rate than 
compared to the older patient group. The mean age of patients allocated to an RHA in this 
randomised trial had a mean age of 57.5 years. The reported cumulative, five-years revision 
percentage was 4.5% for patients in the age category of 50-60 years, which approaches the 
average revision rate of RHA in men (5.3%) given in the registries.1 All these aforementioned 
factors must be taken into account when evaluating joint registries and revision rates of the 
RHA. Nevertheless, it cannot be denied that all RHA implants, irrespective of type or brand, 
have their specific reported serious adverse reactions, and the clinical benefit is marginal 
compared to a conventional type of THA. 
The uncertainty about the consequences of elevated metal ion levels, pseudotumour 
formation and its high failure rate, caused concerns worldwide, and diminished the use and 
acceptance of MoM bearings1,52,53 Various medical authorities, such as the UK’s Medicines 
and Healthcare products Regulatory Agency(MHRA), the United States’ (US’) Food and Drug 
Administration (FDA), and the Dutch Orthopaedic Association (NOV), have all published 
medical device alerts and produced guidelines regarding follow-up of patients.20,28,54 In the 
Netherlands in 2012, NOV even imposed a (temporary) ‘time-out’ for the use of all MoM 
hip implants with heads larger than 36mm, which was only recently postponed.54 Since the 
attention was drawn to the potential side-effects of RHA, the initial popularity of the RHA 
changed drastically, and worldwide, at that time, and turned into concern and disbelief on 
how these implants could have found their way onto the market. 
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The initial biomechanical- and clinical successes of the Birmingham Hip Resurfacing (BHR) 
drew the attention of other manufacturers that wanted to leverage the commercial success 
of the RHA. Subsequently, most implant manufacturers developed their own MoM implant, 
each with its own characteristic-based modifications of existing implants. When these 
MoM implants were introduced, the FDA considered the RHA as a new implant, which 
had to go through rigorous protocols that required clinical testing. Unlike in the US, the 
European regulatory bodies judged the implants as a category of device that only requires 
simulator testing, since the RHA was considered to be an extension of an existing implant 
design.55 Although the first reports on elevated metal ion levels and pseudotumours were 
already present, new RHA implants still found their way to the market. It would appear that 
regulatory authorities missed a chance to suspend the rapid introduction of RHA implants in 
the absence of any long term clinical studies. 
Illustrated by the failure of the introduction of the RHA, it would appear mandatory that 
the device regulation and implementation is in need of a change. In the Netherlands, NOV 
decided to act ahead of this change, and has implemented a plan for the introduction of 
innovative joint arthroplasties. Implants are now divided into three groups, based on the 
principles of the National Institute for health and Clinical Excellence (NICE) criteria of the 
National Health Service (NHS) in the UK; 1A, 1B and 2.56 Implants with less than a 10% 
revision rate at a ten-year follow-up are fully accepted and classified as 1A. Those with a 
revision rate of less than 5% at a five-year follow-up are classified as 1B, and new implants 
as 2. Use of these implants is only allowed in approved studies. In the UK the Beyond 
Compliance Service was founded for the latter group of implants.57 The Beyond Compliance 
Service consists of an independent panel of experts that works with implant manufacturers 
and clinicians and collects data about patients who receive a new or modified implants and 
about their recovery following surgery. This data is used to assess the relative risk of any new 
or modified product, and the rate at which it should be introduced to the market. Systems 
like these enhance the transparency towards patients and surgeons, and should prevent the 
introduction of new implants without a proven good long-term clinical result.
In the Netherlands, the ban of all MoM hip arthroplasties with a head diameter above 36 mm, 
including the RHA, is also an option, after a consideration of the advantages and potential 
disadvantages. This decision is a national one, and is rather exceptional worldwide. Despite 
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the potential disadvantages, the RHA remains an appealing concept for preserving patients’ 
own bone stock and anatomy with a minimal number of dislocations. The improved stability 
is particularly advantageous for young and active patients, but the risk of ARMD and its 
subsequent early revisions must be minimised. Perhaps in time, the RHA can be implanted 
in a controlled setting in designated, specialised hip centres, in the Netherlands, within a 
specific group of patients, such as men less than 55 years old, with a femoral head size 
larger than 50 mm, a BMI smaller than 35 kg/m2, and osteoarthritis as primary diagnosis.52,58 
Prerequisites should include that a specific RHA performs according to the NICE criteria and 
there should be a better understanding of implant design, patient characteristics that affect 
the chance of ARMD, and the value of screening methods, such as metal ion analysis and 
cross-sectional imaging. 
Lessons can be learned from the problems related to the current generations of RHA that 
will hopefully give rise to better innovations in hip arthroplasties and more regulated 
introductions of novel implants on the market. However, the bone- and natural anatomy 
preserving characteristics of resurfacing remains an appealing concept for hip replacement 
options for young and active patients, however, the optimal material from which this should 
be fabricated has yet to be invented.
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Nederlandse samenvatting en discussie
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SAMENVATTING EN DISCUSSIE
Artrose van de heup, coxartrose, is een veelvoorkomende aandoening welke het functioneren 
van mensen ernstig kan beperken. Een totale heupprothese (THP) is een succesvolle 
behandeling voor patiënten met een eindstadium van coxartrose. Jaarlijks worden er in 
Nederland ongeveer 28.000 primaire heupprotheses geplaatst en de verwachting is dat dit 
aantal in de aankomende jaren zal toenemen. Een nadeel van de conventionele metaal-op-
polyethyleen of ceramiek-op-polyethyleen articulerende prothese, is dat deze kan luxeren 
en dat het polyethyleen slijt, wat kan leiden tot loslating en instabiliteit. Met name bij 
relatief jonge patiënten kan de slijtage van het polyethyleen relatief snel optreden. In een 
zoektocht naar een duurzame prothese werd een oud concept, de metaal-op-metaal (MoM) 
heupprothese en in het bijzonder de resurfacing heupprothese (RHP) geherintroduceerd. 
Door nieuwe bewerkingstechnieken van het metaal, werd verondersteld dat de RHP slijtvast 
is. Bovendien resulteert de grote kop van de RHP in meer stabiliteit. Deze heupprothese 
werd derhalve aanbevolen voor jonge, actieve mensen en werd de ‘sportheup’ genoemd. 
Het doel van dit proefschrift is om een objectieve weergave te geven van de klinische 
resultaten van een metaal-op-metaal (MoM) articulerende RHP welke in een gerandomiseerd 
onderzoek werd vergeleken met een conventioneel type MoM THP met een 28 mm kop. 
Verder geeft het proefschrift een beter inzicht in de problematiek die gepaard gaat met 
MoM heupprothesiologie, waarbij in het bijzonder de verhoogde metaalionen in bloed en 
de beeldvorming van pseudotumoren op de voorgrond staan. Er zijn zeven doelstellingen 
geformuleerd. Deze zullen hieronder worden besproken, waarbij de discussie is verdeeld 
in een deel met klinische resultaten en een deel waarin de screening van verhoogde 
metaalionen en pseudotumoren centraal staan. 
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Klinische resultaten 
1. Vaststellen of een uitgesproken voorkeur van een patiënt voor een 
bepaald type prothese effect heeft op de postoperatieve tevredenheid 
van een patiënt?
In het begin van de jaren 2000 nam de vraag naar RHP’s toe. Verschillende producenten 
van protheses wilden meeliften op de wereldwijde toegenomen vraag en introduceerden 
versneld een eigen type RHP. Echter, langetermijnresultaten van het overgrote deel van 
deze ‘nieuwe’ implantaten ontbrak. Mogelijke nadelen van de RHP’s, zoals een complexere 
operatietechniek, het voorkomen van verhoogde metaalionconcentraties in bloed en 
pseudotumoren, werden mogelijk niet op tijd erkend. Om de toegevoegde waarde van een 
RHP te onderzoeken, werd er een gerandomiseerd onderzoek opgezet, waarbij de RHP 
werd vergeleken met een conventioneel type MoM articulerende THP met een kleine kop 
(MoM THP).
Er werd voor een opzet van een gerandomiseerde klinische studie (RCT) gekozen om de RHP 
objectief te vergelijken met een ‘gouden standaard’. Echter, het includeren van patiënten 
voor de gerandomiseerde studie bleek moeizaam. Ten tijde van de inclusie werd de RHP 
gepromoot als ‘sportheup’ en een ideale heupprothese voor jonge en actieve mensen. Aan 
jonge patiënten, die in aanmerking kwamen voor een heupprothese én voldeden aan de 
inclusiecriteria, werd gevraagd om mee te doen aan de studie. Een groot deel weigerde 
echter deelname, vanwege een aanzienlijke voorkeur voor een RHP, ondanks dat benoemd 
werd dat de voorgestelde voordelen niet bewezen waren. Patiënten met een uitgesproken 
voorkeur voor een RHP, werden geïncludeerd in een cohort met een follow-up identiek 
aan de RCT. Hierdoor werden er twee studiegroepen gecreëerd, die zich in principe alleen 
onderscheidde door een aan- of afwezigheid van een expliciete voorkeur voor de RHP. Dit 
gaf de mogelijkheid om te onderzoeken in hoeverre een uitgesproken voorkeur voor een 
prothese effect heeft op de klinische resultaten, waaronder tevredenheid.
De resultaten van deze vergelijkende studie staan beschreven in Hoofdstuk 2. Zowel 
de voorkeursgroep als de gerandomiseerde groep scoorden beide postoperatief hoog op 
tevredenheid en de overige klinische scores. Er was een trend tot een hogere tevredenheid 
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onder de patiënten in de voorkeursgroep, maar dit verschil was niet statistisch significant. 
Het enige significante verschil dat kon worden aangetoond, had betrekking op de mentale 
score van de SF-12. De patiënten in de voorkeursgroep scoorden preoperatief lager dan de 
patiënten in de gerandomiseerde groep.
Ondanks het feit dat veel clinici te maken hebben met patiënten met een duidelijke 
voorkeur voor een bepaalde behandeling, is er relatief weinig wetenschappelijk onderzoek 
verricht naar het effect hiervan op klinische resultaten en patiënttevredenheid. In onze studie 
konden we geen invloed een uitgesproken voorkeur aantonen. Dit is in tegenspraak met een 
meta-analyse waarin verondersteld werd dat een voorkeur voor een behandeling een positief 
effect zou hebben op de resultaten van de behandeling. In dit onderzoek werden echter 
naast operatieve ook conservatieve behandelingen geïncludeerd, waarbij therapietrouw 
een rol speelt. Dit is niet van toepassing op de studie beschreven in Hoofdstuk 2, waarbij 
beide groepen een identieke nabehandeling kregen. Tevens is het besluit om überhaupt een 
heupprothese te plaatsen voor veel patiënten al bevredigend, wat zich kenmerkt door een 
hoge patiënttevredenheidscore bij zowel patiënten met zowel een RHP als met een THP.
2. Objectief vergelijken van de klinische resultaten van patiënten met 
een resurfacing heupprothese en met die van patiënten met een 
metaal-op-metaal heupprothese met een 28 mm diameter kop na een 
follow-up van drie tot vijf jaar.
De klinische resultaten van de gerandomiseerde klinische studie, waarin de RHP werd 
vergeleken met een 28 mm kop MoM THP (MoM THP) na een follow-up van drie tot vijf 
jaar, staan beschreven in Hoofdstuk 3. Eénenzeventig patiënten jonger dan 65 jaar werden 
geïncludeerd in een periode van juni 2007 tot januari 2010. Na randomisatie werd er bij 
38 patiënten een RHP (Conserve® Plus, Wright Medical Technology, Arlington, Tennessee, 
USA) geplaatst en bij 33 patiënten een MoM THP (Zweymuller® Classic Metasul®, Zimmer 
Orthopaedics, Warsaw, Indiana, USA). Alle patiënten hadden ten tijde van de analyse een 
follow-up van 36 maanden en ongeveer 50% had een follow-up van vijf jaar. 
De klinische scores verbeterden postoperatief significant in beide groepen ten opzichte 
van de preoperatieve scores. De Visueel Analoge Schaal (VAS) voor tevredenheid, de 
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Oxford Hip Score (OHS) en de University of Los Angeles Activity Score (UCLA) waren op 
verschillende momenten gedurende de follow-up statistisch significant hoger in de RHP 
groep. Deze significante verschillen verdwenen echter naarmate de follow-up periode 
langer werd. Over het algemeen kan geconcludeerd worden, dat patiënten in de RHP groep 
met name in de eerste twee jaar postoperatief het klinisch beter doen dan patiënten met een 
MoM THP. Na deze periode van twee jaar, kan er geen duidelijk significant verschil tussen 
de twee groepen meer worden aangetoond. Deze resultaten komen overeen met eerdere 
soortgelijke studies. Deze studies beschrijven een algemene tendens dat patiënten met een 
RHP het klinisch net wat beter doen dan patiënten met een conventionele heupprothese, 
maar dat de significante verschillen verdwijnen op lange termijn.
Wat betreft de overlevingsduur van de protheses, kan worden gesteld, dat na vijf jaar follow-
up er zes heupprotheses zijn gereviseerd; drie in de RHA groep (8%) en drie in de MoM 
THP groep (9%). Gedurende de eerste twee jaar van de follow-up waren er twee patiënten 
in de MoM THP groep, waarbij er een insert wissel had plaatsgevonden in verband 
met recidiverende luxaties. Bij één patiënt met een RHP werd de femorale component 
gereviseerd in verband met aseptische loslating bij avasculaire necrose. 
De overige drie revisies, na de eerste twee jaar follow-up, waren allen gerelateerd aan 
‘Adverse Reactions to Metal Debris’ (ARMD). Rond deze periode verschenen er meerdere 
publicaties over ARMD na plaatsing van MoM articulerende heupprotheses. ARMD is een 
overkoepelende term voor diverse reacties die kunnen optreden na MoM prothesiologie, 
zoals overgevoeligheid, osteolyse en vocht-bevattende of solide pseudotumoren. De 
prevalentie van pseudotumoren beschreven in de literatuur varieert van 0,1% tot 67%, met 
een tendens van een toenemende prevalentie in de loop der jaren. Vanwege de beschreven 
prevalentie werd er in onze studiepopulatie een hoge prevalentie van ARMD na de eerste 
twee jaar follow-up verwacht, maar dit bleek niet het geval (Hoofdstuk 3). Na drie jaar 
follow-up werden er drie pseudotumoren vastgesteld; twee in de RHP groep en één in de 
MoM THP groep. Deze pseudotumoren waren allen symptomatisch en de heupprotheses 
werden derhalve gereviseerd. Het optreden van een pseudotumor in de MoM THP groep is 
redelijk opmerkelijk te noemen. Pseudotumoren worden in de literatuur zelden beschreven 
bij patiënten met een kleine diameter kop MoM THP. Er zijn twee studies die een prevalentie 
van 0,5-1,8% beschrijven bij een 28 mm kop MoM THP in een periode van een 10-jaars 
follow-up. Dit getal ligt beduidend lager dan de 3% beschreven in Hoofdstuk 3. 
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De prevalentie van pseudotumoren in de RHP groep (5%) kan als relatief laag worden 
beschouwd, vergeleken met de prevalenties beschreven in de literatuur die tot wel 67% 
gaan. Echter, het moet wel opgemerkt worden dat een cross-sectioneel beeldvormend 
onderzoek geen onderdeel was van de studie beschreven in Hoofdstuk 3. Cross-sectioneel 
onderzoek werd wel in een latere fase verricht en staat beschreven in Hoofdstuk 6.
De werkelijke incidentie, pathogenese en klinische relevantie van ARMD blijft tot op de dag 
van vandaag tot op zekere hoogte onduidelijk. Deze onzekerheid wordt veroorzaakt door 
een breed scala aan factoren, welke worden geassocieerd met het optreden van ARMD, 
zoals slijtage, het ontwerp en formaat van het implantaat, de accurate plaatsing van de 
prothese, maar ook patiënt-specifieke factoren zoals overgevoeligheid. Bovendien ontbreekt 
er ook nog een éénduidige definitie van een pseudotumor. Dit alles te samen maakt dat de 
beschreven prevalentie van pseudotumoren sterk uiteen kan lopen.
Screening voor ‘Adverse Reactions to Metal Debris’
Nadat er verscheidene studies het optreden van AMRD na plaatsing van een MoM 
prothese rapporteerden, werden er wereldwijd verschillende richtlijnen ontwikkeld voor 
het opvolgen van patiënten met een dergelijke prothese. Deze richtlijnen adviseerden 
een regelmatige controle met daarbij gedegen lichamelijk onderzoek, het bepalen van 
metaalionconcentraties in bloed en aanvullende beeldvorming in de vorm van echo, 
CT of MRI. De metaalionconcentratie-bepalingen worden geadviseerd nadat er studies 
verschenen, waarin verhoogde metaalionconcentraties werden gecorreleerd met het 
ontstaan van pseudotumoren. Daarnaast werden er ook een relaties beschreven tussen 
verhoogde metaalionconcentraties en slijtage en de functie van een MoM heupprothese. 
Derhalve werden metaalionconcentraties gezien als een adequate manier om patiënten met 
een MoM prothese te vervolgen.
De metaalionconcentraties kunnen bepaald worden in urine, bloed en serum. 
Aangezien voor de bepaling in urine een 24-uurs collectie noodzakelijk is en dit mede 
afhankelijk is van hydratietoestand van de patiënt, is deze methode minder aantrekkelijk 
dan de bepalingen in bloed. Metaalionconcentraties in bloed en serum werden in het eerder 
beschreven gerandomiseerde onderzoek (Hoofdstuk 3) tijdens vaste tijdstippen bepaald bij 
alle geïncludeerde patiënten.
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3. Vaststellen van het verschil in metaalionconcentraties tussen patiën-
ten met een resurfacing heupprothese en patiënten met een 28 mm 
kop metaal-op-metaal totale heupprothese. 
De resultaten van een prospectief onderzoek, waarbij kobalt- en chroomionenspiegels in 
bloed en serum werden bepaald bij zowel patiënten met een RHP als een MoM THP, staan 
beschreven in Hoofdstuk 3. In beide groepen is er een duidelijke toename van kobalt en 
chroom ionenspiegels gedurende een ‘running-in’ fase van één jaar en stabilisatie (kobalt) of 
afname (chroom) nadien. Onafhankelijk van het type prothese bleven de mediane waardes 
onder de door de Nederlandse Orthopaeden Vereniging (NOV) gedefinieerde grenswaarde 
van 2,0 μg/l en ver beneden de grenswaarde gedefinieerd door de United Kingdom’s 
Medicines and Healthcare products Regulatory Agency (MHRA) (kobalt 119 nmol/l = 7,0 
μg/l; chromium 134,5 nmol/l = 7,0 μg/l). De metaalionconcentraties in bloed en serum 
in patiënten met een RHP, zijn over het geheel gezien hoger dan die van patiënten met 
een MoM THP. Dit verschil werd kleiner gedurende de follow-up door een daling van 
de metaalionconcentraties in de RHP groep. De beschreven metaalionconcentraties zijn 
relatief laag in vergelijking met andere studies. Dit kan het beste verklaard worden door 
het type prothese dat in de studie werd gebruikt in combinatie met een adequate plaatsing.
4. Bepalen of metaalionconcentraties in bloed en serum uitwisselbaar 
zijn, of dat een formule een betrouwbare conversie van serum naar 
bloed kan weergeven.
Daar waar metaalionconcentraties worden beschouwd als indicator voor slijtage en het 
functioneren van een prothese, is het van belang dat orthopedische chirurgen de concentraties 
ook kunnen interpreteren. Dit wordt echter bemoeilijkt door een gebrek aan consensus over 
de superioriteit van bepalingen in serum of bloed. Daarnaast wordt niet altijd benoemd of 
de gegeven grenswaarden in serum of bloed zijn. Aangezien de concentraties in bloed en 
serum van elkaar verschillen, is het van belang om te bepalen of deze waardes door elkaar 
heen gebruikt mogen worden.
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In Hoofdstuk 4 wordt er een analyse beschreven, waarbij bepaald is of metaalionconcentraties 
gemeten in bloed en serum uitwisselbaarheid zijn. Tevens is er gekeken of er een betrouwbare 
formule gegeven kan worden voor de conversie van serum- naar bloedconcentraties. 
Voor dit onderzoek werden de patiënten van het cohort met daarin de patiënten met een 
uitgesproken voorkeur voor een RHP (beschreven onder stelling 1) gecombineerd met de 
patiënten uit het gerandomiseerde onderzoek (eveneens onder stelling 1 beschreven). Door 
deze combinatie ontstonden er twee groepen van 60 patiënten met een RHP en 32 met een 
MoM THP. In totaal waren er van deze patiënten 343 serum- en bloedmonsters aanwezig 
voor analyse. De gemiddelde kobalt serumconcentraties waren minimaal lager of gelijk aan 
de bloedwaardes, wat wordt weergegeven door een gemiddeld verschil van +0,13 μg/l (95%-
CI: 0,03;0,22). Het tegenovergestelde geldt voor chroom, waarbij de serumconcentraties 
gemiddeld hoger waren dan die gemeten in bloed met een gemiddelde van -0,91 μg/l (95%-
CI: -1,05;-0,77). Een Bland-Altman plot werd gebruikt om de spreidingsgrenzen te bepalen. 
Deze grenzen lagen met +1,5 μg/l en -1,25 μg/l voor kobalt en +0,95 μg/L en -2,85 μg/l voor 
chroom ver uiteen. Hieruit kan geconcludeerd worden dat serum en bloedconcentraties niet 
uitwisselbaar zijn.
Formules voor de conversie van metaalionconcentraties in bloed naar serum werden 
gegenereerd vanuit de beschikbare data. 
Kobalt in bloed = 0,34 + (0,88*kobalt in serum) 
Chroom in bloed = 0,14 + (0,58*chroom in serum). 
De formules kunnen niet getest worden op de data waaruit deze gegenereerd zijn. Derhalve 
werd er een nieuwe formule gegenereerd vanuit één helft van de beschikbare data en getest 
op het andere deel van de data. De Bland-Altman plot werd wederom gebruikt om de 
foutmarge van de gegeven formules te berekenen. De foutmarge werd berekend op +0,77 
μg/l en -0,84 μg/l voor kobalt en +0,92 en -0,98 μg/l voor chroom. Hierbij kan worden 
aangenomen dat de foutmarge van de formule binnen de 1,0 μg/l valt. Hierbij moet wel 
de kanttekening worden geplaatst, dat ondanks het splitten van de data de formule vanuit 
een relatief homogene groep is verkregen. Verificatie op een meer heterogene groep is van 
belang.
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Op basis van onze data kan er geen goede aanbeveling worden gegeven of het gebruik 
van serum- of bloedbepalingen de voorkeur geniet. Praktisch gezien kan er gesteld worden 
dat de bepalingen in bloed de voorkeur geniet aangezien deze geen bewerking voor de 
analyse vereist, wat de kans op contaminatie en daarmee de kans op een foutief hoge uitslag 
reduceert. 
Naast contaminatie is het bij het beoordelen van metaalionconcentraties van belang om 
implantaat-gerelateerde en patiënt-specifieke factoren zoals nierfunctie, de aanwezigheid 
van andere metalen implantaten, voedingssupplementen, medicatie en omgevingsfactoren 
te evalueren. Al deze factoren moeten in ogenschouw genomen worden bij de beoordeling 
van hoge metaalionconcentraties.
Verhoogde metaalionconcentraties kunnen toxiciteit geven. Carcinogeniteit, 
overgevoeligheidsreacties, cardiomyopathie, neurologische schade, hypothyreoïdie, 
nierfunctiestoornissen en veranderingen in psychologische status worden allen genoemd 
als potentieel effect, maar solide epidemiologische studies die dit bevestigen ontbreken.
Ongeacht de nog aanwezige onzekerheden over verhoogde metaalionconcentraties 
en hun klinische invloed, is het voor de klinische praktijk van belang grenswaardes van 
metaalionconcentraties te definiëren. Er is echter geen internationale consensus over 
de bovengrens van te accepteren metaalionconcentraties. Verschillende nationale- en 
internationale instanties ontwikkelden elk een eigen richtlijn met grenswaardes. Zo stelde 
de MHRA voor zowel kobalt als chroom een bovengrens van 7,0 μg/l. De NOV stelt dat een 
serumwaarde tot 2,0 μg/l veilig is en adviseert een intensieve controles bij een waarde van 
tussen de 2,0-5,0 μg/l. Deze waardes zijn echter grotendeels gebaseerd op studies die de 
relatie tussen het functioneren van de prothese en metaalionconcentraties onderzochten, 
niet de toxiciteit. Een voorbeeld hiervan is de studie van Van der Straeten et al. waarbij er 
lagere metaalionconcentraties werden gemeten bij patiënten met een goed functionerende 
prothese, in tegenstelling tot patiënten met een disfunctionerende prothese. De grenswaarde 
voor het omslagpunt voor unilaterale protheses in serum werd bepaald op 4,6 μg/l en 4,0 
μg/l voor respectievelijk chroom en kobalt. Waardes boven deze grens werden geassocieerd 
met disfunctioneren van de prothese en ARMD met een hoge specificiteit van 95%, maar 
een zeer lage sensibiliteit (25%). Dit maakt de waarde van metaalionbepalingen in serum 
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en bloed discutabel. Een trend van metaalionconcentraties lijkt van grotere waarde bij het 
voorspellen van het optreden van ARMD.
De onduidelijke rol van metaalionconcentraties bij het ontstaan van ARMD en het falen 
van MoM protheses, is het resultaat van een tot nu toe nog onduidelijke pathologie van 
ARMD. Gesuggereerde causale factoren zijn een toxische reactie op een grote hoeveelheid 
metaalpartikels en een overgevoeligheidsreactie voor metaal. In het laatste geval kan een 
niet-toxische waarde van metaalionen of een kleine hoeveelheid metaalpartikels al ARMD 
initiëren. Dit komt overeen met een relatief lage metaalionconcentratie (<2,0 μg/L) bij twee 
van de drie patiënten met een pseudotumor beschreven in Hoofdstuk 3. Het lage aantal 
pseudotumoren in deze studie maakt het echter onmogelijk om te concluderen dat er geen 
relatie aanwezig is tussen het ontstaan van pseudotumoren en metaalionconcentraties.
5. Beoordelen of de zorgen om rondom verhoogde metaalionconcentra-
ties na MoM heupprothesiologie geëxtrapoleerd kunnen worden naar 
MoM discus prothesiologie van de rug.
 
De verhoogde metaalionconcentraties in bloed en het ontstaan van ARMD na plaatsing van 
de MoM heupprothese leidde tot veel onrust en zorgen onder heup-orthopeden. Wereldwijd 
werden er waarschuwingen afgekondigd en werden richtlijnen opgesteld door regelgevende 
instanties en beroepsverenigingen. Deze waren allen gericht op heupprothesiologie. Andere 
MoM protheses, zoals bijvoorbeeld een MoM totale discus prothese (TDP) werden hierin niet 
genoemd. Een TDP wordt gebruikt bij degeneratieve rugklachten en een aantal types TDP’s 
bestaan uit twee metalen plaatjes die als een ‘ball-in-socket’ articuleren. Het is denkbaar 
dat, bij een dergelijke prothese, metaalionconcentraties in het bloed ook verhoogd kunnen 
zijn en er eveneens ARMD kan optreden. Hoofdstuk 5 beschrijft een studie waarin wordt 
onderzocht of de zorg rondom MoM-problematiek bij heupprothesiologie uitgebreid moet 
worden naar andere MoM prothesiologie; in dit geval een MoM TDP. 
Kobalt- en chroomconcentraties in bloed en serum van patiënten met een TDP werden 
vergeleken met die van patiënten met een MoM heupprothese. De studie bestaat uit vier 
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groepen: (1) patiënten met een MoM TDP, (2) RHP, (3) een 28 mm MoM THA en (4) een 
controlegroep van patiënten zonder MoM prothese. De metaalionconcentraties in de TDP 
groep waren significant lager dan die in de twee groepen met heupprotheses. Patiënten met een 
goed functionerende TDP op één niveau hadden over het algemeen metaalionconcentraties 
overeenkomstig met die van de controlegroep. Alleen kobaltconcentraties in bloed in de 
groep met een TDP waren statistisch significant verhoogd met een mediaan van 0,6 μg/l, wat 
maar net boven de detectiegrens van 0,5 μg/l ligt. 
De lage metaalionconcentraties in bloed en serum van patiënten met een goed functionerende 
TDP suggereren dat de slijtage van een dergelijke prothese relatief laag is. Een eerdere 
studie schatte de slijtage van de TDP tussen de 0,38-0,44 mm3/jaar in, vergeleken met 1-5 
mm3 voor een MoM heupprothese. Het kan verondersteld worden dat dit gerelateerd is 
aan een andere biomechanica. Zo is de bewegingsuitslag van een TDP redelijk beperkt en 
staat een TDP minder bloot aan grote krachten vergeleken met een heupprothese. Hierdoor 
zal de slijtage van een TDP lager zijn, wat een aannemelijke verklaring is voor de lage 
metaalionconcentraties.
Concluderend kan er gesteld worden dat deze studie geen reden geeft voor het uitbreiden 
van de zorgen rondom de MoM heupprothesiologie problematiek naar andere MoM 
prothesiologie. Echter, zoals eerder gesteld, is de sensitiviteit van metaalionconcentratie 
bepalingen voor het voorspellen van ARMD laag. Tevens blijft de exacte pathologie van 
ARMD onduidelijk. Derhalve valt het aan te bevelen om alle patiënten met een MoM 
nauwlettend op te volgen en te screenen op ARMD.
6. Bepalen of periprosthetische laesies of pseudotumoren, zoals die 
op MRI gezien worden bij patiënten met een MoM heupprothese, ook 
gezien worden bij keramiek-op-polyethyleen heupprothesiologie.
De complexe interactie tussen prothese en patiënt-gerelateerde factoren bemoeilijkt de 
zoektocht naar een sensitieve en specifieke screeningsmethode voor ARMD. Over het 
algemeen adviseren de richtlijnen voor screening van patiënten met MoM heupprothese 
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een gedegen lichamelijk onderzoek, metaalionconcentratie-bepalingen en aanvullende 
beeldvorming zoals echo, CT of MRI. De sensitiviteit van deze aanvullende onderzoeken is 
minder goed gespecificeerd vergeleken met metaalionconcentratie-bepalingen. Meerdere 
onderzoeken beschrijven vocht- en weke delencollecties, spieratrofie en oedeem op MRI 
na een MoM heupprothese. De vocht- en weke delencollecties worden over het algemeen 
geclassificeerd als pseudotumor (vorm van ARMD). De werkelijke klinische relevantie van 
deze bevindingen is echter nog onbekend, aangezien studies naar materialen anders dan 
MoM erg schaars zijn. De vraag is of alle vocht- en weke delencollecties rondom MoM 
heupprotheses destructieve pseudotumoren zijn en of een deel niet past bij een normaal 
beloop na heupprothesiologie en dus ook bij heupprotheses voorkomen met andere 
articulerende materialen. Hoofdstuk 6 richt zich op deze vraagstelling. De beschreven 
studie onderzoekt de prevalentie van periprosthetische laesies, gediagnostiseerd middels 
metal-artefact-reducing-sequence-MRI (MARS-MRI), bij patiënten met: (1) een RHP, (2) een 
28 mm MoM THP en (3) een groep van asymptomatische patiënten met een keramiek-op-
polyethyleen articulerende THP (CoP THP). Alle gediagnosticeerde periprosthetische laesies 
werden gegradeerd volgens drie gepubliceerde classificatiesystemen. 
De studie laat zien dat periprosthetische laesies, gediagnosticeerd middels MRI en 
gegradeerd als pseudotumor middels de drie classificatiesystemen, niet exclusief bij MoM 
heupprothesiologie voorkomen. Verrassend genoeg was de prevalentie van periprosthetische 
laesies in de RHP groep (17%) identiek aan die van de CoP THP groep (18%). De prevalentie 
was het laagst in de groep met een MoM THP (4%). Hierbij moet wel worden opgemerkt 
dat solide periprosthetische laesies alleen in de RHP groep werden aangetoond. De 
overige laesies waren vochtcollecties. De gebruikte classificatiesystemen gradeerde deze 
vochtcollecties echter relatief hoog op de beschreven schaal als pseudotumor.
Gezien de vergelijkbare prevalentie van periprosthetische laesies in de RHP en de CoP THP 
groep, kan bediscussieerd worden of al deze gediagnosticeerde laesies wel ‘echte’ klinisch 
relevante pseudotumoren zijn. Het lijkt er op dat enig vocht rondom een heupprothese 
bij afwezigheid van klachten, tekenen van infectie en zonder destructief karakter op MRI, 
een ‘normaal’ verschijnsel is. Illustratief hiervoor is dat negen van de 13 patiënten met 
een periprosthetische laesie een kleine vochtcollectie (<25ml), een goede functie van de 
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prothese en lage metaalionconcentraties in bloed hadden. De huidige classificatiesystemen 
lijken de prevalentie van pseudotumoren te overschatten. Een beter classificatiesysteem 
is nodig om klinisch relevante pseudotumoren goed te graderen. De aanwezigheid van 
een solide laesie, spierschade en een verdikt kapsel moeten hierbij meer aandacht krijgen. 
Daarnaast lijkt de verandering van de omvang van periprosthetische laesies in verloop van 
tijd ook een grote rol te spelen bij de differentiatie tussen benigne en pathologische laesies.
7. Beschrijven van een casus van een patiënt met een destructieve 
pseudotumor in de afwezigheid van een MoM heupprothese. 
Het ontstaan van ARMD na een MoM heupprothese lijkt een multifactorieel proces. Zoals in 
Hoofdstuk 3 en 6 beschreven, is er geen sterke relatie tussen het ontstaan van pseudotumoren 
en slijtage van de articulerende oppervlaktes of metaalionconcentraties in bloed. Mogelijk is 
er nog een patiënt-gerelateerde factor, waarbij in de hoek van een immunologische respons 
gezocht kan worden. Daarnaast ligt de focus op de relatie tussen slijtage van de articulerende 
oppervlaktes en het ontstaan van pseudotumoren, maar in feite staat elke metalen verbinding 
bloot aan corrosie en slijtage indien de passieve beschermende oxidelaag beschadigd raakt 
door bijvoorbeeld microbewegingen. De mate van corrosie wordt daarbij beïnvloed door 
de kwaliteit van en de hoeveelheid verbindingen en de krachten waaraan de verbinding 
wordt blootgesteld.
Hoofdstuk 7 beschrijft een casus van een patiënt met een snel vormende, grote, destructieve, 
solide pseudotumor na een double-mobility metaal-op-polyethylene (MoP) THP. De 
metaalionconcentraties in serum waren voor chroom onder de detectiegrens van 0,5 μg/l, 
maar die van kobalt was verhoogd met een waarde van 5,7 μg/l. De pseudotumor werd 
naar alle waarschijnlijkheid getriggerd door een kleine hoeveelheid metaaldebris vanuit de 
kop-nek taper verbinding gezien de afwezigheid van een MoM articulerend oppervlak. Dit 
werd versterkt door een mismatch van kop en steel van verschillende fabrikanten. Echter, 
ARMD wordt ook beschreven vanuit een kop-nek taper in afwezigheid van een mismatch. 
De kop-nek taper verbinding lijkt een grotere rol spelen bij het ontstaan van ARMD dan lang 
werd aangenomen. De kop-nek taper verbinding lijkt namelijk ook een grote rol te spelen 
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bij de hoge incidentie van AMRD in patiënten met een grote-diameter-kop (LDH, > 36-
mm diameter) MoM THP. Verschillende studies tonen een hogere incidentie van ARMD aan 
bij LDH-MoM THP vergeleken met een RHP met identieke biomechanische kenmerken. 
Het enige verschil tussen deze protheses zit in de afwezigheid van een kop-nek taper 
verbinding. In de gepresenteerde casus is er een double-mobility systeem gebruikt, wat 
biomechanisch overeenkomt met een LDH-MoM THP. Door de grote kop ontstaat er een 
grotere momentarm en een grotere frictiekracht tussen de articulerende oppervlakten. Dit 
principe van het ontstaan van ARMD in patiënten met een LDH-MoM THP wordt inmiddels 
door meerdere studies ondersteund.
De gepresenteerde casus en de rapportages van een hogere incidentie van ARMD in patiënten 
met een MoM LDH THP, illustreren dat niet alle MoM protheses op één hoop gegooid 
kunnen worden bij de analyse naar ARMD. Het is hierbij van belang om het type prothese 
en de fabrikant te definiëren. Een RHP, LDH-MoM THP en een MoM THP met een kleine 
kop van elke gegeven fabrikant, heeft zijn eigen karakteristieken. De protheses verschillen in 
(1) gegoten of gesmeed materiaal, (2) wijze van hittebehandelingen, (3) de afstand tussen de 
articulerende oppervlakten (radial clearance), (4) de mate van overhuiving van het femorale 
component door het acetabulum en (5) de functionele hoek van de femorale component. 
Deze kenmerken beïnvloeden allen de mate van slijtage, metaalionconcentraties, incidentie 
van ARMD en falen van een prothese. Door subtiele verschillen in protheses bleken enkele 
protheses een zeer kleine marge van optimale implantaat positionering te hebben. Met 
name de acetabulaire component is hierbij van belang.
Het moet benadrukt worden dat elke protheses zijn eigen successen en beperkingen kent, 
en niet te vergeten, de chirurgische techniek is ook zeker van cruciaal belang. De protheses 
die in de onderzoeken voor dit proefschrift zijn gebruikt, bleken een relatief gunstige tien-
jaarsoverleving te hebben met een relatief lage incidentie van ARMD. De resultaten, zoals 
in de gepresenteerde studies, zijn daarom ook niet te extrapoleren naar alle RHP en MoM 
THPs.
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ALGEMENE DISCUSSIE
Ten tijde van zijn herintroductie werd de RHP sterk gepromoot als een goed alternatief voor 
de ‘klassieke’ heupprothese en aanbevolen aan jonge en actieve patiënten vanwege de 
stabiliteit. Tevens zou de RHP door nieuwe bewerkingstechnieken van het metaal slijtvast 
zijn. De prothese werd daarom, in tegenstelling tot de ‘klassieke’ heupprothese, gezien als 
een prothese welke levenslang mee zou kunnen gaan. Het doel van dit proefschrift is om een 
objectieve weergave te geven van de klinische resultaten van een MoM articulerende RHP 
welke in een gerandomiseerd onderzoek werd vergeleken met een 28 mm kop MoM THP. 
Verder geeft het proefschrift een beter inzicht in de problematiek welke gepaard gaat met 
MoM heupprothesiologie, waarbij in het bijzonder de verhoogde metaalionconcentraties 
gemeten in bloed en de beeldvorming van pseudotumoren op de voorgrond staan.
Concluderend kan men stellen dat zowel de patiënten met een MoM THP als de patiënten 
met een RHP zeer tevreden zijn en beide klinisch goed functioneren. Alleen op korte 
termijn scoren patiënten met een RHP significant beter op een aantal klinische scorelijsten. 
Daarnaast is de RHP bewezen stabieler met geen enkele luxatie gedurende de gehele 
studie. Het is echter discutabel of deze voordelen opwegen tegen het risico van ARMD. 
Dit proefschrift illustreert dat de interpretatie van screeningsmethoden voor ARMD, zoals 
metaalionbepalingen in bloed en aanvullende beeldvorming in de vorm van een MARS-
MRI, complex is. 
In de beschouwing van de resultaten, is het wel van belang om te beseffen dat de 
onderzoeken zijn gebaseerd op één type RHP (Conserve Plus®, Wright Medical). Op lange 
termijn bleek deze prothese, in tegenstelling tot enkele andere merken RHP’s, een relatief 
goede survival en een lage incidentie van ARMD te kennen. Daarnaast werden de operaties 
uitgevoerd door ervaren heupchirurgen, wat tevens een rol kan spelen bij de goede klinisch 
resultaten.
Nationale en internationale implantaten registers tonen een duidelijk verschil in survival 
tussen RHP, MoM LDH en THP’s die gebruik maken van andere articulerende materialen. 
Het aantal revisies van RHP’s is significant hoger dan die van een conventionele kleine-
diameter kop (SDH) THP, waarbij het revisiepercentage van RHP’s met name bij vrouwen 
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hoog is. De Nederlandse Landelijke Registratie Orthopedische Implantaten (LROI) 
rapporteerde voor alle RHP’s een gemiddeld vijf-jaars revisiepercentage van 5,3% voor 
mannen en 13,5% voor vrouwen, vergeleken met een gemiddelde van respectievelijk 3,5% 
en 3% voor alle conventionele heupprotheses. Het is echter wel van belang om een aantal 
punten in ogenschouw te nemen bij het beoordelen van deze getallen. Als eerste ligt het 
revisiepercentage van RHP mogelijk hoger door een algemene angst voor MoM protheses. 
De enorme negatieve aandacht en de dreiging van rechtszaken hebben mogelijk geleid 
tot vroege, onnodige revisies van MoM protheses. Daarnaast gaat het om een gemiddelde 
van alle merken RHPs. Zoals bekend zijn er specifieke merken RHP’s zoals de ASR 
heupprothese, die erg slecht functioneerden en een erg hoog revisiepercentage vertoonden. 
Deze getallen worden in veel registers geïncludeerd wat kan leiden tot een vertekend beeld. 
Als laatste is het ook van belang om naar de gemiddelde leeftijd van de patiënten te kijken. 
De RHP werd gepromoot als een goed alternatief voor met name jonge patiënten. Dit 
resulteerde in een lagere gemiddelde leeftijd voor deze populatie, zoals ook in de studies 
geïncludeerd in dit proefschrift (gemiddelde leeftijd 58 jaar). Een lagere leeftijd brengt een 
hoger revisiepercentage met zich mee. Het geregistreerde vijf-jaars revisiepercentage van 
THP voor patiënten in de categorie van 50-60 jaar is 4,5%, wat de eerder beschreven 5,3% 
voor mannen met een RHP nadert. Het algehele revisiepercentage van RHP blijft hoger 
dan het percentage van de ‘conventionele’ prothese, maar de genoemde punten nuanceren 
het enorme verschil. Desalniettemin kan het niet ontkent worden dat RHP ongeacht welke 
fabrikant dan ook, vervelende complicaties onder de noemer ARMD kan geven. Gegeven 
de marginaal betere vroege klinische resultaten, kan bediscussieerd worden of de RHP ten 
opzichte van een ‘conventionele’ THP een toegevoegde waarde heeft.
De onzekerheden omtrent de gevolgen van verhoogde metaalionconcentraties, 
pseudotumorformatie en hoge revisiepercentages, maken dat het gebruik van de RHP en 
de acceptatie van MoM heupprotheses wereldwijd afneemt. Verschillende regulerende 
instanties, zoals de UK’s Medicines and Healthcare products Regulatory Agency (MHRA), 
de Amerikaanse Food and Drug Administration (FDA) en de Nederlandse Orthopaedische 
Vereniging (NOV), hebben allen waarschuwingen gepubliceerd en richtlijnen voor follow-
up van patiënten met een MoM prothese opgesteld. In Nederland is er zelfs een tijdelijk 
time-out voor MoM heupprotheses met een kop groter dan 36 mm ingesteld, welke recent 
werd verlengd. 
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Het geloof in en de ongekende populariteit van de prothese is wereldwijd afgenomen 
en heeft plaats gemaakt voor ongeloof en zorgen over hoe een dergelijk implantaat zijn weg 
naar de markt vond.
Ten tijden van de herintroductie werd de aandacht getrokken door de goede 
biomechanische en klinische resultaten van de Birmingham Hip Resurfacing (BHR). 
Andere fabrikanten wilden meeliften op het commerciële effect, wat resulteerde in een 
wildgroei van RHP’s, welke waren gebaseerd op modificaties van bestaande implantaten. 
De FDA beschouwden deze prothese als een nieuw concept, maar de Europese regulerende 
autoriteiten zagen het nieuwe concept daarentegen als een kleine variatie op een bestaand 
product. Dit had als consequentie dat de protheses enkel werden blootgesteld aan een 
simulatietest. Dit proces, waarbij lange termijn klinische studies ontbreken, heeft een 
cruciale rol gespeeld in de introductie van verschillende disfunctionerende implantaten op 
de markt en continueerde ondanks het feit dat de eerste publicaties over ARMD al reeds 
verschenen.
De gebrekkige testen rondom de introductie van RHP en andere MoM implantaten, 
illustreert dat de regulatie van implantaten herzien moet worden. De NOV heeft hierop 
geanticipeerd en heeft een plan geïmplementeerd waarin protheses in drie groepen worden 
verdeeld. De indeling is gebaseerd op de principes van ‘The National Institute for Health and 
Clinical Excellence’ (NICE) criteria van de ‘National Health Service’ (NHS) in de UK; 1A, 1B 
en 2. Implantaten met een revisiepercentage lager dan 10% na 10 jaar follow-up worden 
geclassificeerd als 1A, bij een percentage van 5% na vijf jaar follow-up 1B en nieuwe 
implantaten worden geclassificeerd als 2. De laatste groep mag alleen in studieverband 
geïmplanteerd worden. In de UK bestaat er voor deze laatste groep de ‘Beyond Compliance 
Service’. Deze nationale service wordt aangestuurd door een groep onafhankelijke experts 
die met fabrikanten en orthopeden samenwerken en gegevens en resultaten verzamelen 
van nieuwe of aangepaste implantaten. Uit deze data kan een risicoanalyse gegenereerd 
worden en kunnen adviezen gegeven worden over de introductie op markt. Deze genoemde 
systemen vergroten de transparantie voor zowel patiënt als chirurg en moet voorkomen dat 
er implantaten worden gebruikt waarvan geen lange termijn gegevens bekend zijn. 
De ‘tijdelijke’ time-out in Nederland van alle MoM heupprothesiologie met een kop groter 
dan 36 mm is een nationale beslissing na het afwegen van voor- en nadelen. Het is echter 
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wel een rigoureuze beslissing en wereldwijd relatief uniek. De RHP blijft, ondanks zijn 
tekortkomingen, een goed concept waarbij zoveel mogelijk van de anatomie behouden 
blijft en de prothese bewezen stabiel is. De stabiliteit is zeker voor de jonge en actieve 
patiëntenpopulatie aantrekkelijk. Mogelijk zal er in de toekomst nog plaats komen voor het 
resurfacing concept. Patiëntenselectie zal hierbij van belang zijn, daar waar jonge mannen 
onder de 55 jaar, met een diameter kop groter dan 50 mm en een BMI lager dan 35 kg/m2 
en artrose als primaire diagnose relatief goede klinische resultaten laten zien. Voorwaardes 
hiervoor zijn dat de RHA voldoet aan de NICE criteria, er een betere pathofysiologische kennis 
over ARMD aanwezig is en de waarde van screeningsmethoden, zoals metaalionbepalingen 
en beeldvorming bekend zijn.
Er kan lering getrokken worden uit de problemen die gerelateerd zijn aan de invoering van de 
huidige generatie RHP, wat hopelijk zal leiden tot betere innovaties in de heupprothesiologie 
en meer gereguleerde introducties van nieuwe implantaten op de markt. Het concept van 
een RHP, met behoud van originele anatomie blijft een aantrekkelijk concept voor jonge 
patiënten, echter, het geschikte materiaal waarvan deze gefabriceerd moet worden zal 
waarschijnlijk nog ontwikkeld moeten worden. 
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DANKWOORD
Na velen jaren in de vrije uren werken is het proefschrift dan een feit. Er zijn vele 
mensen geweest die gedurende het hele traject een bijdrage hebben geleverd op zowel 
wetenschappelijk gebied als bij de morele ondersteuning. Die wil ik hier graag bedanken in 
mogelijk het meest gelezen hoofdstuk van een proefschrift. Allen hartelijke dank voor jullie 
bijdrage. Een aantal mensen wil ik in het bijzonder bedanken:
Co-promotor, dr. J.L.C. Van Susante: Beste Job, ik weet nog goed hoe ik tijdens mijn 
coassistentschap bij je op de operatiekamer stond en je aan me vroeg of ik misschien 
onderzoek wilde doen. Ik heb toen kort getwijfeld, maar heb er absoluut geen spijt van. 
Bedankt dat je me de mogelijkheid hebt geboden. Een betere begeleider en inspirator kon 
ik me niet wensen. Met je sterke ideeën, humor en je ongekend snelle reacties en correcties 
van de teksten was het een plezier om onderzoek met je te doen. Bedankt voor de mooie tijd 
en alle energie en tijd die je naast je werk in de onderzoeken hebt gestoken. Zonder jouw 
bijdrage lag dit boekje er nu niet. Naar mijn beste weten is dit het derde boekje onder jouw 
begeleiding wat ook een mooie prestatie is.
 
Promotor, prof. dr. A. Van Kampen: Beste Albert, bedankt voor het begeleiden van de 
afronding van het proefschrift en de rol die je als promotor op je wilde nemen. De afronding 
van het boekje heb ik dermate uitgesteld dat je middels met emiraat bent en je de coördinatie 
voor een groot deel vanuit je huisje in Frankrijk kon doen. Tevens wil ik je bedanken voor 
het vertrouwen in me tijdens de sollicitatie tot orthopedisch chirurg en de ontzettend leuke 
stage die ik bij je heb gelopen. Waarschijnlijk zal ik één van je laatste promovendi zijn. Ik 
hoop dat je van de dag geniet.
De manuscriptcommissie: Geachte prof. dr. C.G.J. Sweep, prof. dr. W.M. Prokop en prof. dr. 
R.G.H.H. Nelissen, hartelijk dank voor het beoordelen en goedkeuren van het manuscript. 
Het onbewust achterwegen laten van één van de artikelen was geen test om jullie scherpte 
te controleren en werd gelukkig feilloos opgemerkt. 
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Beste paranimfen Bas Staffhorst en Jelle Schühmacher, na een goede tijd op de middelbare 
school gingen we samen richting Nijmegen om te studeren. Daar bleven we elkaar regelmatig 
zien en hebben we de kas van menig kroeg goed gespekt. Tijdens ons (Bas) onvergetelijke 
bestuursjaar bij de roeivereniging werden we de twee mannen uit één stuk genoemd tussen 
de overige vijf vrouwelijke bestuursleden. Ik waardeer het enorm dat jullie nu, 20 jaar nadat 
we elkaar hebben leren kennen, mijn promotie als paranimf bijstaan. Bedankt!
Beste Annemiek Hol, als je als basisarts begint aan onderzoek, komt je er al snel achter 
dat je kennis van statistiek erg matig is. Dankzij jou wist ik binnen no time mijn statische 
kennis naar een acceptabel niveau te tillen. Je hield ons scherp tijdens het analyseren van 
de data en dankzij jou wist ik altijd zeker dat we de correcte statistische test gebruikte. Met 
jouw bijdrage in het coördineren van het begeleiden van patiënten en het bijhouden van de 
database heb je ontzettend veel werk uit handen genomen. Bedankt voor de begeleiding en 
alle (vrije) tijd die je in de onderzoeken hebt gestoken.
 
José Smolders, het duurde even voordat ik je kon opvolgen met het afronden van een 
boekje. Terugkijkend naar het dankwoord van jouw proefschrift kan ik hier eigenlijk de tekst 
kopiëren. Met jouw discipline en de snelheid waarmee je teksten op papier wist te zetten, 
was het erg fijn om samen met jouw artikelen te schrijven. Je hebt mij veel werk uit handen 
genomen waar ik je zeer dankbaar voor ben. De Bland-Altman test zal ik inderdaad niet zo 
snel vergeten.
Lian Roovers, als Annemiek en ik er niet uit kwamen met de statistiek stond je altijd voor ons 
klaar. Vooral de Bland-Altman heeft ons heel wat doen zweten. Bedankt voor je expertise.
Maarten van Gorp, Bart de Wit en de medewerkers van de afdeling radiologie in het 
Rijnstate Ziekenhuis, mede dankzij jullie input is hoofdstuk 6 een succes geworden met 
een voor ons allen onverwachte uitkomst. Jullie wisten te regelen dat de MRI’s op zaterdag 
konden draaien en dat we de patiënten konden zien. Het waren weken waarin ik in de 
weekenden de afdeling radiologie vaker zag dan mijn eigen huiskamer, maar het onderzoek 
verliep daardoor wel snel. Maarten en Bart, bedankt voor het objectief beoordelen van alle 
MRI-beelden.
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Mede-auteurs Wim Schreurs, Catherine van der Straeten, Dick Zeilstra, Timothy Tan, Zhen 
Lu, Pat Campbell, bedankt voor jullie medewerking bij het uitvoeren van de onderzoeken 
en het schrijven van de artikelen. 
En niet geheel onbelangrijk, de patiënten, die bereid waren om mee te werken met de 
onderzoeken. 
Miranda Dood bedankt voor het omzetten van de simpele Word teksten naar dit professioneel 
uitziende boekje. Als hoofdleverancier van proefschriften in de regio Oost heb je me veel 
werk uit handen genomen.
Stafleden van de ROGOO bedankt dat jullie me destijds hebben aangenomen voor de 
opleiding en de ontzettend leuke en leerzame tijd die ik nu als AIO heb. 
AIOS Orthopedie van de ROGOO. Met de vele humor is het elke dag weer leuk om naar 
het werk te gaan. Zonder jullie was het werken zeker niet zo leuk.
Bandleden van de leukste en gezelligste coverband de BAB: Met z’n tienen hebben jullie 
voor een geweldige afleiding van het werk en onderzoek gezorgd. Natuurlijk was al het 
werk en vrijetijds-onderzoek soms wat lastig te combineren met het repeteren en optreden, 
maar de energie die ik van jullie en de optredens kreeg hielpen me weer verder in het 
onderzoek. Laten we er aankomend jaar een mooi 2e lustrum van maken met nog grotere 
optredens. www.wijzijndebab.nl.
Beste Cilia, bedankt voor alle steun en interesse die je altijd in de onderzoeken hebt getoond 
en het begrip dat ik een enkele keer een schoonfamilieaangelegenheid moest overslaan, 
omdat ik weer aan het onderzoek moest werken. Joachim kan ik helaas niet meer persoonlijk 
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